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ABSTRACT 
Owing to its ability to capture a systemic and temporal metabolic description of an 
organism’s response to a treatment, metabonomics is a well-established and valuable 
approach in elucidating the effects and mechanisms of a given perturbation. However, 
to optimise information recovery from the complex datasets generated, chemometric 
methods are essential. 
The work presented in this thesis focuses on the development of novel 
methods, and the use of existing methods in new applications to ease data 
interpretation and enhance information recovery from 1H Nuclear Magnetic 
Resonance (NMR) metabonomic datasets using correlation based methods. Although 
the methods here are largely applied to toxicological data, they could be equally 
valuable in the analysis of any metabonomic dataset, and indeed potentially to other 
‘omics’ data presenting similar analytical challenges. 
The first two methodological approaches relate to novel extensions of 
Statistical Total Correlation Spectroscopy (STOCSY), a valuable tool in elucidation 
of both inter- and intra-metabolite spectral intensity correlations in NMR 
metabonomic datasets. In the first, STOCSY is utilised in STOCSY-editing, a method 
for the selective identification and downscaling of the peaks from unwanted 
metabolites such as those arising from xenobiotics. Structurally correlated peaks from 
drug metabolites are first identified using STOCSY, and the returned correlation 
information utilised to scale the spectra across these regions, producing a modified set 
of spectra in which drug metabolite contributions are reduced, endogenous peaks 
reconstructed and thus, analysis by pattern recognition methods without drug 
metabolite interferences facilitated. In the second, the STOCSY approach is extended 
in Iterative-STOCSY, where metabolic associations are followed over several rounds 
of STOCSY through calculation of correlation coefficients initially from a driver 
spectral peak of interest, and subsequently from all peaks identified as correlating 
above a set threshold to peaks picked in the previous round. The condensation of 
putatively structurally related peaks into single nodes, and representation of the 
otherwise complex network in a fully interactive plot of node-to-node connections 
and corresponding spectral data, allows the ready exploration of both inter- and intra-
metabolite relationships and a more directed approach to the identification of 
biomarkers of the studied perturbation. Finally various clustering methods are 
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investigated with the aim of providing improved structural (intra-metabolite) versus 
non-structural (inter-metabolite) assignment. Thus, this thesis presents a framework 
for the enhanced identification, recovery and characterisation of inter- and intra-
metabolite relationships and how these are affected by metabonomic perturbation. 
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1 INTRODUCTION 
Systems biology is the study of an organism viewed as an integrated and interacting 
network of genes, proteins and biochemical reactions. A major driver in both systems 
biology as a whole, and in its contributory omics approaches is the discovery and 
development of new treatments for human disease and personalised healthcare. To 
this end a key step in many biomedical settings is the identification of biomarkers or 
signatures specific to, for example, a certain mode of toxicity, disease state or 
treatment prognosis.  
While much effort has been put into transcriptomic and proteomic 
technologies, a major problem remains in relating gene-expression or protein level 
changes to disease and pharmaceutically relevant end points (Nebert et al., 2003). 
This is largely owing to the huge complexity of higher organisms, which can not only 
be considered as ‘super organisms’ – with diverse metabolically interacting symbiotic 
gut microflora, but also are subject to strong environmental influences (such as diet, 
drug therapy and life style) (Nicholson et al., 2004; Nicholson et al., 2005). In 
contrast to other omics technologies, metabonomics (defined as the quantitative 
measurement of the multiparametric metabolic response of living systems to 
pathophysiological stimuli or genetic modification, (Nicholson et al., 1999) provides 
a systemic and temporal metabolic description of the whole organism response to 
treatment and thus, reflects effects not only from extended genomes but also from the 
impact of other environmental factors. This ability to capture real end points has made 
metabonomics a well-established and powerful tool in the elucidation of the effects 
and mechanisms of physiological or pathological perturbations. 
One area in which metabonomics has been particularly valuable, and shows 
continuing potential, is that of toxicology (Coen, 2010). Attrition of drug compounds 
from the discovery/development pipeline is at an all time high (Kola and Landis, 
2004), not only representing a major economic problem for pharmaceutical 
companies, but also raising potential safety concerns. Toxicological screening 
typically involves in vivo rodent models, but conventional assessment methods (for 
example, histopathology) can be costly, time consuming and can miss important toxic 
effects. It is here that there is considerable scope for metabolic approaches, for 
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example, in the discovery of biomarkers specific to a disease or stage of disease 
progression (Holmes et al., 2006b; Odunsi et al., 2005), in the elucidation of disease 
mechanisms and thus potential drug targets, and in the identification of more general 
biomarkers of toxicity and the efficient early elimination of potentially toxic drugs 
from the pipeline (Nicholson et al., 2002). Therefore the methods in this thesis are 
largely applied to toxicological data, although they could be equally valuable in the 
analysis of any metabonomic dataset, and indeed potentially in general to other omics 
data presenting similar analytical challenges. 
1.1 The scope of the thesis 
To extract meaningful biological information from the complex datasets generated by 
metabonomic approaches, the application of computational and statistical methods is 
essential. The work presented in this thesis relates either to the development of novel 
methods, or the application of established methods to novel approaches, both with the 
aim of facilitating data interpretation and optimising information recovery from 
metabonomic datasets. Owing to the inherent correlations between both structurally 
(arising from the same metabolite) and non-structurally related spectral variables, the 
use of correlation-based methods in information recovery and analysis is a central 
theme throughout. As such, the hypothesis addressed is whether the development of 
more sophisticated correlation-based methods can further clarify structural and non-
structural metabolic relationships.  
While the first two results chapters relate to novel extensions of statistical total 
correlation spectroscopy (STOCSY, Cloarec et al., 2005a), a valuable tool in 
elucidation of both inter- and intra-metabolite correlations in NMR metabonomic 
datasets, in the third chapter the hierarchical clustering of variables is compared with 
STOCSY based methods for discrimination between inter- and intra-metabolite 
variables. 
The first part of the thesis addresses a problem particularly common in 
toxicology studies whereby the presence of strong signals from (in this case) 
xenobiotic compounds and their metabolites can confound subsequent analyses since 
classifiers recognise treatment specific signals above those of the endogenous 
consequences of interest. In this STOCSY-editing method, structurally correlated 
peaks from unwanted metabolites (and if required those from closely related 
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pathways) are first identified using STOCSY. Subsequently the recovered correlation 
information is utilised to scale the NMR spectra across those identified regions, 
producing a modified set of spectra in which contributions from unwanted metabolites 
are reduced and any underlying signal reconstructed. In this way, STOCSY-editing 
facilitates analysis and enhances information recovery by pattern recognition methods 
without interference from unwanted (e.g. drug related) signals. 
In the second part, the STOCSY approach is extended in Iterative-STOCSY 
(I-STOCSY), in which metabolic associations are followed over several rounds of 
STOCSY through calculation of correlation coefficients initially from a driver peak of 
interest, and subsequently from all peaks identified as correlating above a set 
threshold to peaks picked in the previous round. While the analysis of metabolic 
networks is becoming an increasingly popular approach, the conversion of the raw 
correlation data into comprehensible plots for interpretation presents a continuing 
challenge. In I-STOCSY interpretation is enhanced through presentation of the 
resulting correlations in a fully interactive plot of node-to-node connections (where 
each node is representative of a highly correlated putatively structurally related set of 
variables) and corresponding spectral data, allowing the easy exploration of both 
inter- and intra-metabolite relationships. Since I-STOCSY is driven from a single 
resonance of interest (for example, that of a drug related compound), and can be tuned 
to pick up correlations of different strengths, metabolic associations (in this case 
including both those of drug metabolism and any related endogenous consequences) 
can be followed intuitively, allowing amongst other things, a more directed approach 
to the identification of biomarkers of the given metabonomic perturbation. 
Finally, various clustering methods were investigated for structural (intra-
metabolite) versus non-structural (inter-metabolite) assignment, an essential part of 
metabonomic analysis, both in the identification of unknown compounds and more 
recently as a method for dimension reduction (in which the number of variables are 
reduced to a set where ideally each uniquely represents a single metabolite). In the 
vast majority of cases, STOCSY is the key method used to identify potentially 
structural related resonances, and indeed, methods for the partitioning of variables 
into structural sets commonly involve a similar approach, grouping variables that 
correlate above a pre-set threshold. In a small number of cases though, clustering 
methods (either hierarchical or partitional) have been applied with a similar aim, thus 
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in the final part of this thesis such methods were compared to STOCSY. Although for 
the one-dimensional identification of unknowns clustering offered no improvement 
over STOCSY, a marked improvement in the structural versus non-structural 
discrimination and formation of structural sets was demonstrated when using 
hierarchical clustering with complete linkage and a correlation proximity measure. 
This result indicates that clustering may provide a better partitioning of variables into 
putative structural sets than that provided by other STOCSY-based methods, an 
important first step for the further investigation of metabolic interactions in any 
metabonomic dataset. 
The thesis is structured as in Figure 1.1. After this general introduction, 
Chapter 2 gives an introduction to the concepts and methods applied. Following this, 
Chapters 3 to 5 each relate to a main body of work as introduced above (with each 
containing specific introduction and discussion sections) and finally Chapter 6 
contains a general conclusion and outline for future work. 
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Figure 1.1 : General overview of the thesis. 
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2 BACKGROUND AND METHODS 
This chapter provides an introduction to the concepts and methods applied or referred 
to in the following chapters. Starting with an introduction to metabolic profiling itself, 
subsequent sections follow relevant aspects of the metabonomic approach from data 
acquisition through pre-processing and finally to details of common multivariate data 
analysis methods including STOCSY and cluster analysis. This chapter concludes 
with the experimental details of the datasets used. 
2.1 Metabonomics 
Metabonomics, metabolomics and the more general term metabolic profiling, refer to 
aspects of the quantitative measurement of small molecule metabolites in biological 
samples. Although the terms metabonomics and metabolomics are often used 
interchangeably and the analytical procedures are the same (spectroscopic methods 
followed by multivariate statistical analysis), the defined distinction lies in the 
application. While metabolomics aims to provide complete characterisation of all the 
small molecules in a sample, metabonomics (our focus) seeks to capture the metabolic 
response of an organism to systemic perturbation (Nicholson and Lindon, 2008). 
Metabonomics is formally defined as the quantitative measurement of the 
multiparametric metabolic response of living systems to pathophysiological stimuli or 
genetic modification (Nicholson et al., 1999). What makes metabonomics particularly 
powerful is its ability to capture a systemic and temporal metabolic description of the 
whole organisms response to an intervention. This description therefore importantly 
includes inter-organism effects, for example, from diverse metabolically acting 
symbiotic gut bacteria, alongside environmental influences such as diet and drug 
therapy (Nicholson and Wilson, 2003). Owing to its ability to capture real end points, 
metabonomics is therefore not only a powerful top-down systems biology tool in its 
own right, but also valuable in providing a connection to other ‘omics’ platforms. 
Additionally, using metabonomics, temporal changes in metabolism can be followed 
over several time points pre- and post- systemic perturbation. This allows multiple 
effects to be observed, for example, after toxic insult these include both the initial 
endogenous toxic response and decline or recovery over time, and potential 
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mechanistic insight into drug metabolism. This all-encompassing quality has proven 
metabonomics to be a powerful approach in toxicology (Coen, 2010; Coen et al., 
2008; Nicholson et al., 2002) and more recently across diverse applications from 
molecular epidemiology (Bictash et al., 2010; Holmes et al., 2007) to the impact of 
the gut microbiome on mammalian metabolism (Claus et al., 2008). Finally 
metabonomics has also been successful in the prediction of pharmacological response 
based on pre-dose metabolic profiling (termed pharmacometabonomics, Clayton et 
al., 2009; Clayton et al., 2006), convincing evidence of potential future application in 
personalised medicine (Nicholson, 2006). 
Traditionally the most common biofluids profiled are those of urine and blood 
plasma/serum, both of which can be obtained relatively non-invasively, again a 
significant advantage in the clinic (Lindon et al., 2007). However, the metabonomic 
approach has been applied to many other biofluids including cerebrospinal fluid 
(Holmes et al., 2006b) and seminal fluid (Maher et al., 2009) and also, with the 
development of magic angle spinning (MAS) NMR spectroscopy, to intact tissue 
samples (Beckonert et al., 2010). 
As mentioned previously, metabolic profiling involves the spectroscopic 
analysis of biological fluids and tissues coupled to statistical interpretation of the 
complex spectral datasets produced. In terms of spectroscopy, the majority of 
approaches utilise nuclear magnetic resonance spectroscopy (NMR) and/or mass 
spectrometry (MS). These are highly complementary techniques, while NMR requires 
minimal sample preparation, is non-destructive, relatively fast and reproducible, MS 
is, in principle, several orders of magnitude more sensitive and thus able to detect an 
unprecedented number of metabolites provided they can be separated using 
chromatography and then ionise (Lindon and Nicholson, 2007). The complex 
biochemical datasets generated by both NMR and MS require intensive data mining to 
recover useful biological information (Holmes and Antti, 2002). Typically both 
unsupervised and supervised methods are applied, both of which provide a reduction 
in data dimensionality, the classification of spectra based on peak profile similarities 
and subsequent identification of those spectral regions important in separating 
different classes or identifying inherent structure in the data. In unsupervised methods 
no prior grouping information is used, whilst in supervised methods datasets are 
modelled so the class of each sample in a test set is predicted based on models built 
using a training set of samples with known class information. In metabonomic 
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analysis two commonly used methods (unsupervised and supervised respectively) are 
principal component analysis (PCA, Jackson, 1999) and partial least squares (or 
projection to latent structures, PLS, Wold, 1985; Wold et al., 2001). Following the 
identification of important or discriminatory variables by pattern recognition methods, 
if not known, these are assigned to specific metabolites via a combination of statistical 
and experimental methods. To that end, statistical total correlation spectroscopy 
(STOCSY) was developed, which, through calculation of the correlation statistics 
between all data points in a set of NMR spectra and a single peak of interest allows 
identification of highly correlated and thus peaks potentially corresponding to the 
same metabolite (Cloarec et al., 2005a). Additionally, while high correlations in 
STOCSY are typically seen between such structurally related peaks, lower 
correlations can allude to biological or mechanistic (non-structural) connectivities and 
thus the STOCSY approach has become a valuable part of the metabonomics tool kit. 
The STOCSY method is described in more detail in Section 2.4.1. 
2.2 Nuclear magnetic resonance (NMR) 
Since the methods presented in this thesis have only been applied to NMR generated 
profiles, a more detailed description of NMR is provided in the following section. The 
technique of NMR spectroscopy exploits the properties of a subset of nuclei (most 
commonly 1H and 13C), which owing to the number of protons and neutrons in their 
nuclei have an intrinsic magnetic moment, or non-zero spin. When these nuclei are 
exposed to an external magnetic field (B0), they give rise to a net magnetisation that 
causes them to precess about the axis of the external field at their characteristic 
Larmor frequency (dependent on the strength of B0 and the magnetogyric ration of the 
nucleus). A nucleus of spin i will have 2i+1 possible orientations with respect to B0, 
for example for spin ! nuclei such as 1H two possible orientations exist, one parallel 
and one anti-parallel to the applied field, the latter being of slightly higher energy 
(Figure 2.1). 
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Figure 2.1: Illustration of the NMR spectroscopy acquisition process for spin ! 
nuclei such as 1H. On exposure to an applied magnetic field (B0), nuclei align either 
with the applied field (low-energy state) or opposing it (high-energy state). 
Subsequent radiofrequency (RF) irradiation causes excitation of the nuclei in the low-
energy state to the high-energy state. When this RF signal is removed these nuclei 
relax back to their base energy state concurrently inducing the detected free induction 
decay (FID), Fourier transform of which generates the final NMR spectrum. Adapted 
from Claridge, 1999. 
Subsequent irradiation of the magnetised sample with a specific radio 
frequency (corresponding to the Larmor frequency and thus the energy gap between 
orientations – for many metabonomics applications this is 600 MHz for 1H) causes 
excitation of the nuclei from the lower to the higher spin state. When this signal is 
removed the nuclei relax back to their base energy state inducing an associated 
oscillating voltage (the free induction decay or FID) that is measured in a suitable 
receiver coil. Subsequent conversion of this time domain signal into the frequency 
domain spectrum by Fourier transform produces the NMR spectrum. The sensitivity 
of NMR spectroscopy increases with the proportion of nuclei in the lower energy 
level, which in turn increases with higher applied magnetic field, this has therefore 
driven the use of higher field magnets, with 1 GHz NMR spectrometers now 
commercially available. 
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The NMR spectrum of a biofluid sample is not a single resonance, but a series 
of peaks at different chemical shifts, with different multiplicities of splitting and of 
varying intensities The chemical shift in the detected NMR spectrum is different for 
each active nucleus of each different molecule since it depends directly on the local 
chemical environment of the nuclei, which varies according to a phenomenon known 
as chemical shielding. Chemical shielding is a perturbation consequence of the actual 
magnetic field strength experienced by each active nucleus as a result of the shielding 
effects of the electron clouds around the nuclei. As such, the more shielded a nucleus’ 
environment, the lower the resonance frequency required for excitation and the more 
its detected signal is shifted towards a lower chemical shift. Chemical shifts are 
measured relative to that of a reference substance and the frequency difference is 
converted to a ppm scale by diving by the absolute frequency of the spectrometer. 
Commonly for metabonomics, the reference compound is 3-trimethylsilyl[2,2,3,3-
2H4]propionate sodium salt, (TSP) whose chemical shift is set to 0 ppm, and shifts 
from TSP are denoted by the symbol !. This allows calibration and thus comparison 
of samples. Different multiplicities of peak splitting arise owing to indirect spin-spin 
coupling (given the symbol J and measured in Hertz), where each NMR signal is split 
dependent on the number of magnetically active nuclei close by. The effect is 
transmitted via the electrons of the intervening chemical bonds and for 1H-1H 
coupling is generally only seen over no more than 3 or 4 bonds. Finally, peak area is 
proportional to the number of active nuclei giving rise to a resonance, thus a 
quantitative measure of concentration for each compound can be determined through 
peak integration. These key features combined mean that different compounds present 
in the sample can be differentiated by their characteristic profiles. Further details on 
NMR spectroscopy principles and methods can be found in Claridge, 1999; Harwood 
and Claridge, 1997; and Hore, 1995. 
2.3 Data pre-processing 
For NMR spectra from metabonomic studies there are many factors that can introduce 
variation in the data, and which if ignored can confound subsequent analyses. The 
sources of such variation can be both technical (such as varying spectral baselines or 
incorrect phasing) and biological (for example, as a result of overall sample, pH or 
salt concentration). While technical variation can be largely corrected by standard 
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routines either included as part of the NMR acquisition software or post-acquisition, 
biologically induced effects require more detailed consideration and pre-processing 
methods may vary depending on the dataset or intended analysis. Pre-processing is 
therefore an essential step prior to the analysis of spectral data from biological 
samples, and some common pre-processing methods are described in the following 
sections. Typically a set of NMR spectra is represented in matrix form, with each row 
representing a given biological sample and each column a measured variable, for 
example, NMR signal intensity at a particular frequency value. 
2.3.1 Normalisation 
Normalisation is a row operation (performed on each sample), applied with the 
objective of reducing inter-sample concentration variability and thus making samples 
directly comparable with each other. For samples from biofluids under high 
homeostatic control (e.g. plasma) or of known weights (e.g. tissue extracts) variable 
sample dilution is not usually a problem. However, for urine samples, even in the 
absence of additional factors, concentration differences between subjects can span 
half an order of magnitude, and when subjects are dietarily or toxicologically 
challenged, differences can exceed a factor of 10 (Dieterle et al., 2006). Since this 
dilution effect causes a consistent change across all the variables for a given sample, 
biologically relevant differences between samples can be overwhelmed and thus 
normalisation is essential prior to analysis of NMR spectra from urine samples.  
Historically, the most common method of normalisation for NMR spectra is 
that of total area normalisation, but when using digitised spectra, normalisation to 
total sum is frequently used as a close approximation (Equation 2.1). 
 
! 
xn =
x
xi
i=1
j
"
 (2.1) 
where xn is the total sum normalised set of spectra for dataset x. To obtain xn, each 
sample in x is divided by its sum of intensities across all j variables. 
One major drawback with total sum normalisation however, is the assumption 
that the total excretion of metabolites (total intensity) is constant for each sample. 
This is termed closure, and means that a dependency between variables is introduced; 
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if one large variable is present the remaining variables must decrease in intensity 
because the total sum is fixed (Johansson et al., 1984). This is a risky assumption, and 
is clearly wrong for example, in cases where a large signal such as a drug compound 
has been introduced into the spectrum. In this case, when total sum normalisation is 
applied the non-drug variables will be uniformly reduced in intensity, and a degree of 
self-correlation introduced simply as a result of the presence of this large signal. 
Additionally if pre- and post-dose samples are then compared the analysis may be 
completely inaccurate, with metabolites becoming discriminatory as a direct result of 
this closure effect. Therefore it may be necessary to remove certain parts of the 
spectra (e.g. drug related peaks) prior to total sum normalisation. 
More recently the method of probabilistic quotient normalisation has been 
developed as a more robust alternative to that of total sum (Equation 2.2, Dieterle et 
al., 2006). This method is based on scaling the spectra by the most probable dilution 
factor to remove differences in concentration between samples. For each sample the 
dilution factor is derived from the median concentration quotient between each 
sample and a reference spectrum, therefore assuming that this is representative of the 
overall sample concentration and not a treatment affect. 
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 (2.2) 
where xqn is the probabilistic quotient normalised spectral set obtained by dividing 
each variable of each sample in the dataset set x by its median concentration value-to-
reference spectrum (xref) quotient. For any dataset, the reference spectrum can either 
be selected manually, or the median spectrum used (in which case the normalisation 
may also be referred to as median-fold-change). In either case, as long as the 
reference spectrum represents the rough shape of spectra without specific changes 
(i.e. control samples) the choice of reference spectra was not found to be particularly 
critical (Dieterle et al., 2006). 
Probabilistic quotient normalisation is not affected by closure, and thus when 
applied to toxicology data does not require the identification and elimination of major 
drug-related signals prior to normalisation, but simply the input of the median control 
sample as a reference spectrum.  
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Although any normalisation method may introduce spurious correlations (first 
suggested by Pearson, 1886-1887), in many cases (especially for example, as 
described in urine data) it is an absolutely essential pre-processing step. Throughout 
this thesis, since based largely on toxicological studies, probabilistic quotient 
normalisation was applied, with the median spectrum generated from only control 
samples as advised in (Dieterle et al., 2006). 
2.3.2 Centering and scaling 
In contrast to normalisation, centering and scaling are typically performed on the 
variables (columns) of the data (i.e. on the spectral intensity across all samples). 
The most common method of centering is means centering, where the column 
mean is subtracted from each value in the column (Equation 2.3). This relocates the 
swarm of data points to centre on the origin, and is applied prior to performing the 
majority of multivariate analysis methods (e.g. PCA or PLS) where the main interest 
is modelling variation in the data as opposed to the absolute values. 
 
 (2.3) 
where xmc is the means centered data, x is the original dataset and  is the mean of 
each variable across all samples. 
Scaling is applicable in situations where the variances of the variables are not 
directly linked to the information of interest, i.e. where variables with higher variance 
should not have higher influence on the model. This is the case in discriminant 
analysis for example, where applying unit variance (Equation 2.4) to give all variables 
the same influence on the model can improve its predictive power. 
 
 
(2.4) 
where xuv is the unit variance scaled data, x is the original dataset and "x is the 
standard deviation of each variable across all samples. 
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2.3.3 Alignment of spectra 
A further challenge in the analysis of metabonomic datasets (particularly urine) is 
variation in peak position because of changes in pH and salt concentration between 
samples or slight instabilities in the equipment (Dieterle et al., 2006; Forshed et al., 
2003). This peak positional variation is complicated since only a subset of peaks is 
affected and for each sample the degree to which shifting occurs can vary even 
between peaks of the same metabolite. Although it has been demonstrated that peak 
position data can be used to separate classes and retrieve biologically interesting 
information (Cloarec et al., 2005b), for the majority of applications this is not the 
case. Indeed peak shifting can complicate analysis and produce misleading results on 
statistical testing (Forshed et al., 2003; Torgrip et al., 2003). 
Broadly speaking, two approaches are used to reduce peak shifting affects; 
either the integration of signal within set spectral regions or bins (typically 
corresponding to 0.04 ppm) which therefore include the entire peak shifted region 
(Craig et al., 2006) or more recently, use of the full resolution data following peak 
alignment using a variety of approaches (Forshed et al., 2003; Stoyanova et al., 2004; 
Veselkov et al., 2009). 
One such peak alignment algorithm, (and the one applied throughout this 
thesis where necessary) is that of recursive segment-wise peak alignment (RSPA), in 
this, increasingly smaller segments of the spectra are aligned to a representative 
spectrum until the optimal alignment is produced (Veselkov et al., 2009).  
2.4 Data analysis 
Since metabolic datasets can contain hundreds to thousands of signals from diverse 
biochemical molecules, effective methods for the analysis of such complex datasets 
are critical for interpretation. In the following sections the most commonly used 
chemometric methods (PCA and PLS) and the STOCSY approach (central to this 
thesis) are introduced. Additionally, the general aspects of clustering for multivariate 
data analysis and various statistical measures for assessing classification performance 
are described as relating to methods utilised in Chapter 5. 
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2.4.1 Statistical total correlation spectroscopy (STOCSY) 
Many NMR data analysis methodologies utilise the inherent correlations in the data 
(Bruschweiler, 2004; Bruschweiler and Zhang, 2004; Eads and Noda, 2002; Snyder et 
al., 2007), and one commonly used technique in the analysis of NMR generated 
metabolic datasets is that of statistical total correlation spectroscopy (STOCSY, 
Cloarec et al., 2005a). STOCSY is based on computation of the correlation matrix C 
(Equation 2.5): 
 
 
(2.5) 
where X1 and X2 are the autoscaled experimental matrices of n # v1 and n # v2 
respectively; n is the number of samples and v1 and v2 the number of variables in the 
spectra for each matrix. C is therefore a matrix of v1 # v2 with values corresponding to 
the correlation coefficient between variables in the matrices and X1 and X2. 
STOCSY takes advantage of the multi-colinearity of the intensity variables in 
a set of spectra, and when driven from a single peak to all other spectral variables, the 
degree to which resonances co-vary across samples can provide insight into both 
intra- and inter-metabolite relationships. Such relationships are commonly visualised 
by back projection of the correlation coefficients onto the covariance spectrum, thus 
giving strength and direction of association and retaining the splitting patterns for 
peak identification. Since different resonances in the spectrum resulting from a single 
molecule (structurally related resonances) will always have the same intensity ratio, 
the relative intensities across all samples will, in theory, be totally correlated i.e. have 
correlation coefficient r = 1. Although in practice spectral noise and peak overlap 
reduce r, very high values are still seen for structural correlations and thus STOCSY 
is a powerful tool in aiding metabolite assignment. In addition, lower correlations can 
allude to biological relationships, for example, between molecules in the same 
biochemical pathway or reaction intermediates. Thus, although originally developed 
as a tool for structural assignment, STOCSY has subsequently been used in the 
extraction of biomarker, pathway, and reaction information (Coen et al., 2007b; 
Holmes et al., 2006a; Maher et al., 2009). Additional applications include the 
identification of drug metabolite signatures in molecular epidemiology studies 
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(Holmes et al., 2007), enhancing information recovery from LC-NMR, J-resolved and 
diffusion-edited NMR datasets (Cloarec et al., 2007; Fonville et al., 2010; Maher et 
al., 2009; Smith et al., 2007) and aiding biomarker identification and pathway 
elucidation through two-dimensional (2D) heteronuclear STOCSY (Coen et al., 
2007b; Keun et al., 2008; Wang et al., 2008). 2D STOCSY has also been coupled to 
hierarchical clustering in the method of cluster analysis statistical spectroscopy 
(CLASSY, Robinette et al., 2009) and perturbed metabolic networks explored via 
recoupled-STOCSY (R-STOCSY, Blaise et al., 2010). 
2.4.2 Chemometric methods 
Chemometric methods are commonly applied for the production of robust, reliable 
and easily interpretable models for analysis of spectroscopic datasets (Lindon and 
Nicholson, 2007). A key aim of these methods is data reduction, the classification of 
spectra based on peak profile similarities and the subsequent identification of those 
spectral regions important in separating the different classes seen. As briefly 
introduced previously, commonly used pattern recognition algorithms include 
principal component analysis (PCA, Jackson, 1999) and partial least squares (PLS, 
Wold, 1985). These projection-based methods classify samples and provide a means 
for the indirect observation of the small number of latent variables assumed to drive 
the process under study. 
An NMR or mass spectrum can be considered a point in multivariate space, 
where each axis corresponds to a different variable and coordinates along each axis 
are therefore given by the spectral intensity value for that sample at that point. In PCA 
the data are projected into a lower number of dimensions using principal components 
(PCs) as the new variables. The first PC describes the largest variation in the data, and 
each subsequent PC describes the next largest direction of variation in the data, 
orthogonal to and therefore independent of the previous PCs. In this way complexity 
can be reduced since the majority of variation is explained in the initial PCs with later 
components simply describing noise variation in the data. PCA results in the 
generation of two matrices, those of scores and loadings. Scores provide a summary 
where each sample is mapped to new coordinates defined by the PCs. When plotted, 
this reduced dimensionality illuminates grouping trends and strong outliers, since 
samples found close together share a similar multivariate profile while those far apart 
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have dissimilar features. PC loadings define how the old variables form the new and 
therefore explain the underlying patterns in the data, interpreting the scores by 
identifying the variables (corresponding to metabolites) most important in separating 
the different classes seen. 
The supervised method PLS aims to fit a linear model and as such to define 
the relationship between two blocks of variables, for example, relating a data matrix 
(X) containing independent variables such as spectral data to a matrix of dependent 
variables e.g. toxicity scores (Y). PLS can also be used in discriminant analysis (PLS-
DA) to separate classes, in which case Y contains a dummy matrix of class 
membership information. Recent modifications of PLS include OPLS (orthogonal 
PLS) which enables the separation of systemic variation into that which is related to 
and therefore predictive of Y, that which is orthogonal (unrelated) to Y, the exclusion 
of which eases interpretation since confounding factors are removed, and finally that 
which contains the non systemic or residual variation (Trygg and Wold, 2002). 
Relevant models are those which provide a good fit to the data without over 
fitting (i.e. building in random error or noise variation), thus in all these methods it is 
important to have a means of judging model quality. This is provided by the statistical 
parameters R2 and Q2, calculated through model cross-validation. In cross-validation 
the X matrix is randomly divided into subsets (typically seven), subsequently for each 
of seven rounds six subsets (the training set) are used to build the model, and the 
remaining subset (the test set) to validate it. This process allows calculation of both 
the percentage of the variance in X that is explained by the model (R2X) and the 
percentage of the Y variance that is predicted by the model (Q2Y) and thus a measure 
of how robust the model is.  
2.4.3 Cluster analysis  
Cluster analysis is the umbrella term for a range of methods that aim to classify data 
into a smaller number of more closely related groups, and with the growing wealth of 
information generated by multivariate methods, has become an increasingly widely 
used and popular data analysis technique across the sciences. Generally speaking 
clustering algorithms partition data objects into a certain number of clusters based on 
some measure of distance between them. Owing to the vast number of different 
distance measures, clustering algorithms and associated parameters available, cluster 
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analysis is only discussed here in brief and in relation to methods applied in Chapter 
5; for a more comprehensive guide the reader is referred to the following texts (Everitt 
et al., 2001; Xu and Wunsch, 2008). 
Milligan (Milligan, 1996) has identified seven steps that make up a typical 
cluster analysis; objects to cluster, features to be used, feature standardisation, 
proximity measure, clustering method, number of clusters and replication, testing and 
interpretation. The relationship between these closely inter-related stages is 
summarised in Figure 2.2. 
 
 
Figure 2.2: The typical stages of cluster analysis. These stages are closely related, 
and any changes can explicitly affect the clusters produced. 
While the selection of objects to cluster and features to be used is fairly self-
explanatory (comprising those objects which are non-outlying and features which are 
potentially useful in describing variation between objects), choices at virtually all of 
the other steps can be contentious, and the results of clustering highly variable 
dependent on those choices made.  
Of central importance in any clustering method is a measure of how similar or 
dissimilar objects are to each other, and many clustering algorithms have as their 
starting point a matrix of values reflecting a quantitative measure of proximity 
between objects. Many measures have been proposed for deriving such a proximity 
matrix from a set of continuous multivariate observations, however, although 
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properties of many of these have been reviewed (Everitt et al., 2001; Gower and 
Legendre, 1986) and despite a number of comparative studies (Boyce, 1969; 
Cheetham and Hazel, 1969) selection of the ‘optimal’ measure for a given dataset 
remains inconclusive. Properties of the data and choice of clustering method can 
guide the choice of proximity measure, and it has been suggested that the simplest 
relevant coefficient should be chosen to ease interpretation of the final results (Sneath 
and Sokal, 1973). The most commonly used distance measure is that of Euclidean 
distance (Equation 2.6): 
 
 
(2.6) 
where dij represents the Euclidean distance between the two objects i and j, and xik and 
xjk are the kth values of the p-dimensional feature observations for these objects. 
The Euclidean distance is appealing in that the distances produced can be 
interpreted as physical distances between p-dimensional points, however, features 
with large values and variances will tend to dominate over other features (Xu and 
Wunsch, 2008). This is a situation where data standardisation (commonly mean 
centering and scaling to unit variance) may be appropriate in transforming feature 
measurements to a common scale and thus removing the influence of any unit 
variation. 
Alternatively, the proximity measure can be derived from correlation 
coefficients, for example, that of the Pearson correlation coefficient. Here, values fall 
in the range [-1,1] where -1 and +1 indicate the strongest negative and positive 
correlations respectively, thus the distance matrix can be defined as in Equation 2.7: 
 
! 
dij =
(1" rij )
2  
(2.7) 
where dij represents the correlation distance between the two objects i and j, and rij 
represents the Pearson correlation coefficient between these objects. Distance values 
now fall within the range [0,1].  
In contrast to the majority of distance measures (including Euclidean), 
correlation distances record similarities in the shape of profiles rather than absolute 
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sizes. Although their use is often contentious (Everitt et al., 2001) it can be justified in 
cases where all features have been measured on the same scale, and the absolute 
values are unimportant except to define the objects relative profile. 
In terms of the choice of clustering algorithm itself, although there are a wide 
range available, they can generally be classified either as hierarchical or partitional 
methods. In hierarchical clustering data objects are grouped successively into a series 
of either more (divisive) or less (agglomerative) closely related subsets, and the 
results typically displayed by a dendrogram (Figure 2.3).  
 
 
Figure 2.3: An example dendrogram from the hierarchical clustering of 30 objects. 
While in divisive methods clusters are successively split during the clustering process, 
in agglomerative methods clusters become grouped. Final cluster memberships are 
obtained by cutting the dendrogram horizontally at an appropriate level (producing 
the number of clusters required). 
Hierarchical clustering has been widely used in biology and zoology, since its 
structure is frequently complementary to that of the relationships under study (Everitt, 
1980). In addition to the choice of proximity measure, the formation of a new cluster, 
or joining of two existing clusters is dependent on a measure of distance between 
potential elements to be joined. Similar to proximity measures, there are many 
distance functions, for example, single linkage (nearest neighbour), complete linkage 
(farthest neighbour) or group average linkage (also known as unweighted pair group 
method with arithmetic mean, UPGMA). In a similar respect to that of choice of 
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proximity measure, the selection of an appropriate distance function is not fixed and 
thus in this case it is recommended to try a variety, and select that which performs 
optimally for the dataset under study. 
In contrast to hierarchical methods, in partitional methods data objects are 
divided directly into a pre-set number of clusters, usually through the optimisation of 
some criterion function. One of the most popular partitional methods is that of K-
means which seeks an optimal partition of the data by minimising the within-cluster 
sum-of-squared-error criterion through an iterative optimisation procedure 
(Macqueen, 1967). 
One of the major challenges in cluster analysis, and pre-requisite for many 
methods, is the selection of an appropriate number of clusters into which the data 
should be partitioned. To address this problem, many validation indices (or stopping 
rules in the case of hierarchical clustering) have been developed. The basic general 
strategy for which is to run the clustering algorithm several times from the minimum 
to maximum possible number of clusters, compute the validation index for the 
clustering structure obtained at each, then select that value which yields the best 
validation index. 
Finally, various goodness-of-fit statistics and quality assessments can be 
applied to assess the fit of the clusters to the original data. Additionally repeating 
clustering on subsets or bootstrapped samples (resamples of the original data selected 
by random sampling with replacement of the original data) can help to elucidate the 
stability and thus reliability of the clusters formed. Both the selection of an 
appropriate number of clusters and assessment of clustering performance are 
discussed in detail in Chapter 5 itself, although an introduction to some common 
classification performance statistics is included in the next section.  
2.4.4 Classification performance statistics: sensitivity, specificity, 
positive predictive value and the receiver-operator 
characteristic 
A number of measures are long established in assessing the performance of a binary 
classifier (in this thesis applied to the assessment of structural versus non-structural 
assignment by various clustering protocols). Given the actual result and the result as 
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determined by the classifier, test outcomes can be described as true positive, false 
positive, true negative or false negative, the relation between which is given in Figure 
2.4. 
 
  Actual condition 
 
  
  Positive 
 
Negative Total Statistic 
Positive True positive 
(TP) 
False positive 
(FP) 
 
Type I error 
Positive (P) PPV (positive 
predictive value) 
 
(2.10) 
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Negative False negative 
(FN) 
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True negative 
(TN) 
Negative (N) NPV (negative 
predictive value 
 
(2.11) 
 Total Positive (P) Negative (N) 
 
  
 Statistic Sensitivity or 
true positive rate 
(TPR) 
 
(2.8) 
Specificity or 
true negative 
rate (TNR) 
 
(2.9) 
  
Figure 2.4: The relationship between terms, and related statistics in binary 
classification. 
One approach is simply to determine the proportions of test outcomes that are 
correctly classified either as positive or negative results, defined respectively as the 
sensitivity (Equation 2.8) and specificity (Equation 2.9) (Altman and Bland, 1994a). It 
is also worth noting here that specificity is equal to 1 – false positive rate (FPR), 
where FPR = #FP/#P. In practice however, in many situations (such as with 
diagnostic tests in the clinic), it is more useful is to know the proportion of test results 
that correctly classify the actual condition. This is provided by the positive and 
negative predictive values (PPV and NPV), which, respectively, provide the 
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proportion of positive (Equation 2.10) or negative (Equation 2.11) test outcomes that 
are correctly classified (Altman and Bland, 1994b). 
For any given dataset, while some classifiers produce only single discrete 
classification results (and thus a single set of sensitivity, specificity and PPV values), 
others produce a measure of the degree to which results could represent a positive or 
negative result, and thus require a threshold value to define where this 
positive/negative separation occurs (Figure 2.5). 
 
 
Figure 2.5: Illustration of the dependence of classification results on the selection of 
an appropriate classification threshold. Changing this threshold implicitly results in 
altered numbers of each classification result, dependant on the distributions of the 
positive (red bounded) and negative (blue bounded) populations. 
In this case, classification performance can be compared between different 
methods through plotting the sensitivity versus the FPR (1 – specificity) attained 
across the full range of possible threshold values, in the Receiver-Operating 
Characteristic (ROC) curve (Metz, 1978). While a ROC curve that follows the 
diagonal represents random classification, the closer the curve runs to the upper left of 
the plot, the better the classification achieved (Figure 2.6). In addition to the ROC 
curve itself, a number of associated statistics can be used to summarise the results, 
and thus give a measure of classification accuracy in a single value. Perhaps the most 
common of these is that of the area under the ROC curve (AUC, Hanley and Mcneil, 
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1982), interpreted as an average sensitivity across all possible false positive rates and 
with values ranging from 0 to 1, the higher the AUC value the better the overall 
method performance. Although different classification methods can be compared 
through their AUC values, identical values between different methods do not 
necessarily mean identical ROC curves, where, for example, one method could 
outperform at low false positive rates and the other at high false positive rates (Figure 
2.6). This has resulted in the suggestion that in some settings, analysing a portion of 
the ROC curve, or computing a partial AUC, either between two false positive rates 
(Mcclish, 1989) or two sensitivities (Jiang et al., 1996), may be more relevant. Since 
the magnitude of the partial AUC is dependent on the bounding values, 
standardisation is commonly applied, dividing the partial AUC by the width of the 
interval as to obtain values (as in the full AUC) in the range [0 1]. 
 
 
Figure 2.6: Five ROC curves (true positive rate (TPR) versus false positive rate 
(FPR)) with different AUC (area under curve) values. (A) The perfect method has an 
AUC = 1, and (E) the ROC of random chance has AUC = 0.5. Other methods (B – D) 
have different abilities to discriminate between positive and negative results. While C 
and D have very different ROC curves (with D performing better at low false positive 
rates and C performing better at high false positive rates) their AUC values are 
identical. The hatched area shows the AUC region for a partial ROC curve of curve B 
with FPR < 0.1. 
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2.5 Datasets 
2.5.1 Flucloxacillin: a model antibiotic 
The experimental details have been published previously (Keun et al., 2008). In brief, 
urine samples were collected from six healthy adult volunteers over 10 h after oral 
dosing with 500 mg of flucloxacillin (total number of samples n = 26). On collection 
samples were immediately frozen and stored at -40°C before being thawed and 
vortex-mixed prior to preparation for NMR. 300 µL urine was added to 300 µL of 
phosphate buffer (0.2 M, pH 7.4) containing 1 mM sodium 3-(trimethylsilyl) 
propionate-2,2,3,3-d4 (TSP), 3 mM sodium azide and 20% (v/v) D2O. Samples were 
then vortex-mixed and centrifuged at 16 000 g for 10 min and 550 µL of the resulting 
supernatant placed in an NMR tube for analysis. 
One-dimensional (1D) 1H NMR spectra were acquired using a Bruker Avance 
II NMR spectrometer (Bruker Biospin, Rheinstetten, Germany) operating at a 1H 
frequency of 800.32 MHz. A standard solvent suppressed 1D pulse sequence (recycle 
delay-90°-t1-90°-tm-90°-acquisition) was used with an acquisition time of 3.36 s and a 
t1 of 3 µs. Presaturation of the water signal was applied during the recycle-delay of 2 s 
and the mixing time (tm) of 100 ms. For each sample, 64 scans and 8 dummy scans 
were collected into 64k data-points with a spectral width of 12.2 ppm. An exponential 
line broadening function of 0.3 Hz and automatic zero-filling of a factor of two was 
applied to each free induction decay (FID) prior to Fourier transformation (FT). 
Spectra were manually phased and baseline corrected using TOPSPIN (version 2.0.1, 
Bruker BioSpin) and referenced to the TSP resonance (!1H = 0.00).  
Data were imported into the MATLAB computing environment (R2009a, The 
MathWorks, Inc., MA) using Metaspectra 4.0 (in-house MATLAB routine written by 
Dr. O. Cloarec) with spectra reconfigured to a common ppm scale by cubic spline 
interpolation to 11 000 data points (!H = -1 to 10) resulting in a final spectral 
resolution of 0.8 Hz/pt.  Of the 26 samples, 5 were rejected from subsequent analysis 
owing to the presence of significant water suppression artefacts (as in (Keun et al., 
2008).  
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2.5.2 Bromoethanamine: a model renal papillary toxin 
Twenty seven male 6-7 week old SD rats (Crl:CD(SD) IGS BR, Charles River, 
Wilmington, MA) were housed in metabolism cages with a 12 h light, 12 h dark cycle 
and water and standard food was made available ad libitum throughout the study. A 
pre-dose urine collection was made for all rats 24 h prior to dosing. On day 0, rats 
were administered an intraperitoneal (ip) injection of vehicle (0.9% saline, n = 9), or 
250 mg/kg 2-bromoethanamine hydrobromide (n = 18). Urine was collected at 0-2, 2-
4, 4-8, 8-24 and 24-48 h after dosing and stored at -70°C until analysis. 
Samples were prepared for NMR as for the flucloxacillin study and similarly 
1D 1H NMR spectra obtained using a Bruker Avance NMR spectrometer operating at 
600 MHz 1H frequency, with solvent suppression using the standard 1D pulse 
sequence with water suppression. For each sample, 64 scans and 8 dummy scans were 
collected into 64k data-points with recycle-delay = 4 s, tm = 100 ms and a spectral 
width of 20 ppm. Prior to Fourier transformation an exponential line broadening 
function of 0.3 Hz and automatic zero-filling of a factor of two was applied to each 
FID. Spectra were manually phased, baseline corrected and referenced to the TSP 
resonance (!H = 0.00) using NMRproc (in house software developed by Drs T. 
Ebbels and H. Keun). Similarly to the flucloxacillin data, data were imported into 
MATLAB using Metaspectra 4.0 with spectra reconfigured to a common ppm scale 
by cubic spline interpolation to 22 000 data points (!1H = -1 to 10).  
2.5.3 Galactosamine – a model hepatotoxin 
1H NMR exemplar spectroscopic datasets representing aqueous liver tissue extracts of 
male Spraque-Dawley rats treated with the model hepatotoxin galactosamine (galN) 
were analysed. This study formed part of the second COnsortium on MEtabonomic 
Toxicology (COMET-2) project in mechanistic toxicology, and conventional 
biomarker analysis has been published in detail previously (Coen et al., 2007a; Coen 
et al., 2007b; Coen et al., 2009). In brief, following a 6 day acclimatisation period, 
male Spraque-Dawley rats (n = 48) were administered a single intraperitoneal 
injection of vehicle (0.9% saline) with 0 (n = 8) or 415 mg/kg (n = 40) galN and were 
euthanized 24 h post dose. Aqueous liver tissue extracts were prepared by 
homogenising 80 mg liver tissue sample in 1.5 mL of cold acetonitrile/water (50:50), 
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then spinning the homogenised samples at 9447 # g for 10 min, removing and 
lyophilizing the supernatant and finally reconstituting in 600 µL of D2O/H2O (90:10) 
containing 3-trimethylsilyl[2,2,3,3-2H4]propionate sodium salt (TSP) (1.3 mM) and 
sodium azide (1.4 mM).  
 1H NMR spectra were acquired using a standard solvent suppressed one-
dimensional pulse sequence (relaxation delay - 90° pulse – delay (4 µs) - 90° pulse - 
mixing time - 90° pulse - acquisition) with an acquisition time of 2.7 s and 
presaturation of the water signal applied during the relaxation delay of 4 s and the 
mixing time of 100 ms. For each sample 128 scans were collected into 64 K data 
points with a spectral width of 12 000 Hz, and an exponential line broadening 
function corresponding to 0.3 Hz was applied to all spectra prior to Fourier 
transformation. Data were imported into the MATLAB computing environment 
(R2009b, The MathWorks, Inc., MA) for subsequent analysis.  
2.5.4 COMET datasets: control, caloric restriction, ammonium 
chloride and hydrazine 
These datasets formed part of the Consortium on Metabonomic Toxicology (COMET) 
project in which 1H NMR spectra were collected from urine samples of male Sprague-
Dawley rats at -16 and 0 h pre dose and 8, 24, 48, 72, 96, 120, 144 and 168 h post 
exposure to one of 147 different treatments (Lindon et al., 2005). The four datasets 
selected were chosen as representative of a variety of pathophysiological conditions 
(number of samples after outlier removal in brackets); controls at 48 h (n = 1043), 
caloric restriction (50% of normal intake) at 48-168 h (n = 34 from nine animals), 
ammonium chloride treatment (0.28 M in drinking water) at 48-96 h (n = 49 from 10 
animals) and hydrazine treatment (90 mg/kg) at 48 h (n = 39).  
Urine samples were prepared and 1D 1H NMR spectra acquired using standard 
metabonomic procedures as previously described (Ebbels et al., 2007). In brief, 400 
µL of each urine sample was added to 200 µL phosphate buffer (0.2 M Na2HPO4, 
0.04 M NaH2PO4, 20% (v/v) D2O, pH 7.4, 1mM TSP and 9 mM sodium azide) and 
1H spectra obtained on a Bruker Avance NMR spectrometer operating at 600 MHz 
and 300 K using a robotic flow injection system and the standard 1D pulse sequence 
with water suppression (as previously described). For each sample, 64 scans were 
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collected into 64 K data points using a spectral width of 20 ppm. Prior to Fourier 
transformation an exponential line broadening function of 1 Hz was applied to each 
FID and following FT the resultant spectra phased, baseline corrected and referenced 
using NMRproc and imported into MATLAB (as for other datasets). 
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3 Statistical total correlation spectroscopy editing 
(STOCSY-E) – application to drug metabolite 
profile identification and enhanced information 
recovery 
This chapter describes a novel method for the selective downscaling of unwanted 
metabolites and thus enhanced information recovery from NMR spectral datasets. In 
this method, STOCSY is first used to identify the putative full set of peaks which 
structurally correlate to unwanted metabolite/s. Subsequently, this correlation 
information is utilised to scale the spectra across the identified regions, producing a 
modified set of spectra with reduced signal contributions from unwanted metabolite/s 
and thus facilitating analysis by pattern recognition methods without interference 
from those metabolites. In this chapter, following an introduction for the motivation 
for this work, the method, termed STOCSY-E (including developmental aspects) is 
described and then applied to several datasets. Here the majority of the work relates to 
the application of STOCSY-E to the identification and removal of drug metabolite 
peaks and has been previously published in Sands et al., 2009 (Appendix A.1). 
3.1 Introduction 
NMR-based metabolic profiling provides a powerful technique in elucidating the 
metabolic consequences of many scenarios. Frequently, however, analysis of such 
datasets can be confounded by the presence of strong signals not directly related to the 
condition under study. A major example of this is in the field of toxicology, where the 
presence of signals from the administered compound and its metabolites can 
overwhelm the resulting endogenous metabolic consequences of treatment. Although 
these drug-related compounds (DRCs) convey valuable information in their own 
right, it is crucial that they are identified and removed from the spectra, so any 
subsequent classification exercises recognise endogenous patterns of toxicity and not 
signals specific to a particular treatment (Ebbels et al., 2007). Unfortunately the 
identification of drug metabolite spectral resonances is often both difficult and time-
consuming. Furthermore, the removal of drug metabolite resonances from spectral 
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data can lead to the loss of (potentially biologically interesting) information since if 
signals from drugs obscure and overlap endogenous signals, these will also be 
removed when the drug peaks are cut from the spectra. In some cases (where all 
confounding compounds present in the dataset are known and standard spectra have 
been prepared and acquired under identical conditions) curve fitting (for example, 
using the method LCModel (Provencher, 1993), and subtraction can be an effective 
method of selective peak removal. However, not only can this method be problematic, 
for example, leading to the loss of a large amount of information in datasets where 
multiple spectral regions are excluded, but also, for the vast majority of studies the 
standard spectra required (e.g. of drugs and their metabolic products) are simply not 
available. 
STOCSY-E was therefore developed as a rapid means of drug metabolite peak 
identification and editing for facilitated data analysis and enhanced information 
recovery from complex NMR spectral datasets. In this method, following STOCSY 
(Section 2.4.1) driven from a chosen drug-related resonance, a correlation threshold is 
used to identify highly correlating signals, which are likely to arise from the driver 
DRC. Subsequently, the returned correlation values are used to scale the original 
spectral data across these DRC regions. Since the presence of unrelated overlapping 
signals results in reduced correlation values, where such peak overlap occurs there is a 
concurrent reduction in scaling of the original data and thus (following background 
correction) potential endogenous peaks in DRC regions can be reconstructed. In this 
way, this method simplifies the identification of potential DRCs, eliminates the need 
to identify and cut individual drug metabolite signals and provides a set of spectra 
where DRC contributions are removed, enhancing subsequent chemometric analysis 
to avoid an otherwise unavoidable loss of sensitivity. Here, the STOCSY-E method 
development and application are described and illustrated with two 1H NMR 
spectroscopic datasets from toxicology studies, however, this method could be 
valuable in many other settings. Some potential applications include the removal of 
signals corresponding to alcohol or analgesics from epidemiology study data (these 
signals are common but largely not related to the condition of interest) (Dumas et al., 
2006; Holmes et al., 2007) or the removal of solvent or excipient signals prior to 
analysis. Indeed, STOCSY-E can be applied to any dataset where any unwanted 
metabolite/s (drug or otherwise) overwhelm the spectral data.  
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3.2 Datasets  
In this chapter the flucloxacillin and bromoethanamine datasets were utilised (see 
Sections 2.5.1 and 2.5.2). The flucloxacillin dataset was selected since its metabolism 
is well established, and the concurrent collection of 19F NMR data has facilitated the 
unambiguous identification of the parent flucloxacillin resonances in the 1H NMR 
spectral data. Different analytical challenges were presented by the more 
comprehensive yet more complicated bromoethanamine (BEA) dataset, in which the 
identification and removal of a series of BEA-related metabolites which appear 
sequentially in post-dose urine samples was required. 
3.2.1 Data pre-processing 
Following removal of those spectral regions corresponding to water (! 4.7 – 4.9), urea 
(! 5.6 – 6.0), and TSP (! -0.2 – 0.2), NMR spectral data were aligned (Veselkov et 
al., 2009) and the alignment individually optimised in regions displaying significant 
chemical shift variation. Subsequently probabilistic quotient area normalisation was 
applied using the method described by (Dieterle et al., 2006). 
3.3 Method development 
In this section the development of STOCSY-E is described using the flucloxacillin 
dataset. 
3.3.1 Method outline:  
STOCSY-E consists of four sequential steps,  
1. Identification of unwanted peaks: The full set of peaks corresponding to the 
unwanted metabolite is identified as those peaks with high STOCSY 
correlations to a known unwanted metabolite peak. 
2. Production of a set of spectra scaled across the unwanted peak regions: The 
original data are scaled across the unwanted metabolite peak regions to 
produce a set of spectra in which the contribution from unwanted metabolites 
is reduced. 
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3. Production of a set of spectra corresponding to unwanted peaks: By removing 
the scaled dataset from the original spectral data, unwanted metabolites peaks 
are quickly identified. 
4. Production of the final STOCSY-edited spectra: The set of scaled spectra 
produced are corrected across the scaled regions, to remove scaling artefacts 
whilst retaining any potential overlapping endogenous signal. 
3.3.2 Identification of unwanted peaks 
Driving STOCSY from a particular peak (in this case a known flucloxacilin resonance 
at !1H = 5.53) returns a set of correlation coefficients (r) that vary in strength across 
the spectrum (Figure 3.1 A). As mentioned previously while highly correlated points 
are likely to be structural (signals resulting from the same molecule) points with lower 
correlations may highlight metabolic relationships, for example, in toxicology studies, 
the product of temporal metabolism of the administered toxin or changes in 
endogenous metabolites as a result of the toxic insult. The selection of spectral points 
to scale is achieved through selecting only those data points that correlate with the 
driver peak with an r2 value greater than a set threshold ! using Equation 3.1: 
 
! 
D = i : ri2 > "{ } (3.1) 
where D is the set of indices (i) corresponding to those spectral data points with 
intensities that correlate to those of the driver peak with a correlation coefficient r2 > 
!.  
Here, the use of r2 rather than r emphasises high correlations more than 
moderate correlations, beneficial for the STOCSY-E method. In addition the use of r2 
means both positive and negative correlations above the threshold are detected, 
essential for the detection of drug metabolism products, where high negative 
correlations can arise when one compound is formed from metabolism of another. 
The selection of an appropriate ! value is critical and depends both on the 
dataset and on the aim of the research. In terms of the toxicology application 
presented here, the requirement was the exclusive identification of drug metabolite 
peaks. A value ! = 0.9 was selected based on the outcome of recent research in which 
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it was shown that a STOCSY correlation threshold of r > 0.95 (corresponding to an r2 
close to 0.9) was required to assign resonances as resulting from the same metabolite 
with high probability in a variety of datasets (Couto Alves et al., 2009). Comparison 
of the indices identified with different correlation thresholds supported the choice of 
this value (Figure 3.1 B-D), while ! = 0.9 exclusively identified structural resonances; 
at lower thresholds increasing numbers of additional endogenous peaks were selected.  
 
 
Figure 3.1: Selection of an appropriate correlation threshold ! for drug peak selection 
from the flucloxacillin dataset. (A) STOCSY on the 1H NMR data driven from the 
peak at !1H = 5.53* (a known flucloxacillin resonance) highlighting correlations to all 
flucloxacillin resonances (a-e). The correlation coefficient (r2) is superimposed onto 
the covariance at each data point using the colour scheme indicated. (B-D) Indices 
picked out as correlating to the driver peak with decreasing thresholds !  (B) !  = 0.9; 
(C) !  = 0.5; (D) !  = 0.2. 
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3.3.3 Production of a set of spectra scaled across the unwanted peak 
regions 
Following the identification of drug related peaks, STOCSY assisted scaling is used 
to reduce the influence of each drug metabolite in the spectral data to the overall 
variation between control and treated classes. For each sample spectrum x, a 
STOCSY edited spectrum xsc is generated through scaling the original data only in the 
drug metabolite peak regions D using the correlation coefficient r as below (Equation 
3.2): 
! 
xsci =
xi 1" ri2( ) i # D
xi i $ D
% 
& 
' 
( 
) 
* 
(3.2) 
 
A key property of this equation is that the scaled value (Xsc) approaches 0 as r 
approaches 1 and vice versa. Although potentially any equation having this property 
could be used to scale the spectral data, it was found that for this application, this 
equation gave good results for spectral interpretability. Here again, the use of r2 rather 
than r emphasises high correlations more than moderate correlations, again beneficial 
for the STOCSY-E method. This stage of STOCSY-E therefore results in a set of 
scaled spectra with intensities across drug peak regions reduced based on the 
corresponding correlation coefficients (Figure 3.2). Initially spectra were scaled just 
across the original drug metabolite regions (i.e. those with r2 > !), however, this 
resulted in production of artifactual peaks either side of each region where the 
correlation dropped below ! and thus spectral data remained completely unscaled 
(Figure 3.2 C and D, green bounded area). To overcome this, prior to scaling, each 
identified drug peak region was extended at either end until signal intensity attained a 
local minimum, and thus the whole peak included (Figure 3.2 C and D, red bounded 
area). Although the default is the extension of each drug peak region until the local 
minimum in signal intensity for each sample individually, the extension of each drug 
peak region until the mean local minimum intensity across all samples could also be 
considered, and may improve results in some circumstances. 
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Figure 3.2: Production of scaled spectra in STOCSY-E illustrated for an expansion of 
the ! 5.45 - ! 5.67 region (A) Original data, mean spectrum, (B) correlation 
coefficients returned from STOCSY driven from !1H = 5.53, line shows correlation 
threshold ! = 0.9, (C) mean spectrum, with lines indicating unwanted peak regions 
from r2 > 0.9 (between green lines), and these region extended either side to the local 
minimum to incorporate the full peak (between red lines), (D) original data, mean 
spectrum (blue), initial mean scaled spectrum, scaled just for regions where 
correlation r2 > 0.9 (green) and final mean scaled spectrum, scaled across extended 
drug peak regions until spectral intensity is minimised (red). 
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3.3.4 Production of a set of spectra corresponding to unwanted 
peaks 
Following initial scaling a set of ‘spectra’ corresponding to the drug metabolite peaks 
xdrug can be quickly generated though subtracting the scaled spectrum (xsc) from the 
original spectrum (x) for each sample (Equation 3.3, Figure 3.3):  
 
! 
xdrug = x " xsc  (3.3) 
 
 
 
Figure 3.3: Spectra corresponding to the unwanted peak regions, i.e. ‘pure drug 
spectra’ 
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3.3.5 Production of the final STOCSY-edited spectra 
The scaling step produces spectra where drug signals are reduced, however, both in 
terms of data interpretation and pattern recognition, using the unmodified scaled data 
in subsequent analysis is suboptimal. Firstly, where signal intensity approaches 
background noise level (at the edge of and occasionally, particularly for multiplets, 
within drug peak regions), decreased correlation coefficients result in reduced scaling 
compared to bordering regions and thus the production of spurious peaks (Figure 3.4 
C). These peaks create misleading signals in the STOCSY-edited spectra, not only 
potentially for peak identification, but also in terms of pattern recognition. Across the 
entire scaled region, since r rarely has a value of 1 and as at each index point all 
samples are scaled by the same coefficient, some small amount of signal frequently 
remains after scaling and this continues to be picked up as important when pattern 
recognition methods are applied. For example, when pre-dose and 2 h post-dose 
flucloxacillin-treated samples are compared using OPLS-DA (Section 2.4.2) after 
spectral scaling (Figure 3.4 D) the result is similar to when OPLS-DA is run on the 
original data (Figure 3.4 A and B). Background correction is thus a crucial part of the 
algorithm, since it allows the correction of spurious peaks and randomisation of any 
correlations that remain owing to the scaling method, thus removing the contribution 
of these signals in the discrimination between control and treated samples (Figure 3.4 
E and F) whilst importantly, leaving any endogenous signal present across the scaled 
regions.  
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Figure 3.4: The importance of the background correction step in STOCSY-E, 
illustrated for an expansion of the ! 5.51 - ! 5.62 region, with doublets at ! = 5.528 
and ! = 5.597 corresponding to flucloxacillin. (A) Original spectral data coloured by 
time-point (0 h black, 2 h red, 4 h orange, 6 h yellow, 8 h green, 9 h blue, 10 h 
purple), (B) OPLS-DA coefficient loadings comparing 0 and 2 h samples for the 
original data. Plotted is the covariance across the chemical shift scale coloured by 
correlation to the discriminant variable (correlation coefficient) on the scale shown. 
(C) Scaled spectral data (before the background correction step) coloured by time-
point with superimposed representative original sample (cyan) illustrating where drug 
metabolite peaks have been removed, (D) OPLS-DA coefficient loadings as in B but 
from OPLS-DA run on the scaled data. (E) Scaled spectral data (green) and the final 
STOCSY-edited (scaled and background corrected, red), (F) OPLS-DA coefficient 
loadings as in B but from OPLS-DA run on the final scaled and background corrected 
data, here no significant discriminatory peaks or artifactual peaks remain. 
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The background correction method is based on the theory that where 
endogenous signal is present in a drug region, the data points will correlate less 
strongly with the drug metabolite driver peak, and therefore after scaling, higher 
signal levels will remain in the scaled spectra. At this point, peaks in the scaled 
spectra could be either owing to true endogenous signal or spurious peaks (as 
discussed above). However, since true drug signal will correlate more strongly to the 
driver peak than endogenous signal, the drug signal will be scaled to a greater degree 
producing smaller peaks in the scaled spectra. Thus, signal intensity across the scaled 
regions can be used in determining whether points should be replaced or remain in the 
final spectrum. This is achieved by first identifying set (B) of indices (i) within the 
drug metabolite peak regions (D) in the scaled data (xsc), which fall below the limit of 
detection as defined by Equation 3.4: 
 
 (3.4) 
where 
! 
x baseline  and 
! 
snoise  are estimates of the local baseline and noise respectively (see 
text below).  
Here the right hand side of the formula represents the limit of detection – the 
minimum signal that can be distinguished from the background spectral noise (Long 
and Winefordner, 1983). Subsequently, the identified set of variables falling below 
the LOD (B) is replaced with a random set taken from a normal distribution with 
mean 
! 
x baseline  and variance 2noises to generate xfinal, the final STOCSY edited spectral 
data (Equation 3.5): 
 
! 
x finali =
~ N x baseline,snoise( ) i " B
xsci i # B
$ 
% 
& 
' 
( 
) 
 
(3.5) 
 
At this step, anything in the scaled data greater than the limit of detection 
remains in the spectra as valid signal, while anything less is replaced. Throughout this 
stage in the algorithm, the standard deviation of the noise (snoise) is calculated from 
intensity levels for all samples in a chemical shift region known to be devoid of 
signals (default noise region between 9.5 and 10 ppm, but region can be user inputted 
if for a given sample set signals are present across this range). However, the local 
! 
B = i : i " D, xsci < x baseline + 3snoise{ }
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baseline level frequently varies across the spectrum owing to broad protein envelope 
signals. Therefore, the mean baseline level 
! 
x baseline( )  is estimated separately for each 
drug replacement section. For each drug region and each sample the baseline is 
estimated as the minimum intensity value across an extended area (0.02 ppm either 
side of each drug peak region), then the mean is subsequently calculated across all 
samples. Since each extended region covers multiple peaks, it is reasonable to assume 
that the minimum level is an accurate estimation of the baseline level for that specific 
region.  
It is crucial that the replacement background intensities be randomly 
distributed to ensure that no patterns are present which could subsequently be picked 
up as important discriminators by pattern recognition tools. For pattern recognition, as 
long as the intensities are randomly distributed and signals in the STOCSY-edited 
spectra remain above the level of noise, the actual values of replaced regions are 
unimportant. However, from a visual point of view and ease of spectral interpretation, 
it is important that the replaced sections resemble typical spectral baselines to provide 
optimal visualisation of signals remaining above the limit of detection. Sampling the 
replacement section from a normal distribution with mean and variance as described 
proved the optimal method to satisfy these criteria. 
3.3.6 Final algorithm 
The final algorithm for STOCSY-E for the identification and removal of drug 
metabolite peaks is shown below (Algorithm 3.1). 
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Algorithm 3.1: The STOCSY-E algorithm  
Let x = [x1…xn] denote intensity values of real spectrum at each ppm. 
1.1 Select a peak corresponding to a drug metabolite. 
1.2 Run STOCSY on the original spectral data driven from the selected peak. 
1.3 Use the correlation coefficient (r) values returned by STOCSY to identify the 
set (D) of indices (i) corresponding to those spectral data points with 
intensities that correlate to those of the drug driver peak with r2 > !  
! 
D = i : ri2 > "{ } 
1.4 For each sample spectrum extend D at either end of each identified region to 
include spectral data points until the signal intensity reaches a local minimum. 
This new set D’ corresponds to putative drug related compound (DRC) peak 
regions. 
2 For each sample spectrum x generate a STOCSY edited spectrum xsc by 
scaling the original data only in the drug metabolite peak regions 
! 
" D using 
! 
xsci =
xi(1" ri2) i#D'
xi i$D'
% 
& 
' 
( 
) 
* 
3 For each sample generate a drug metabolite spectral profile xdrug calculated as  
! 
xdrug = x " xsc  
4.1 Identify regions in the scaled data within 
! 
" D which fall below the limit of 
detection as defined by 
! 
B = i : i" # D , xsci < x baseline + 3snoise{ } 
where 
! 
x baseline  and 
! 
snoise  are estimates of the local baseline and noise 
respectively (see text below)  
4.2 Replace signal intensities over B to yield the final edited spectra xfinal such that  
! 
x finali =
~ N(x baseline,snoise ) i"B
xsci i"B
# 
$ 
% 
& 
' 
(  
where ),(~ 2noisebaseline sxN  denotes sampling from a normal distribution with 
mean 
! 
x baseline  and 
! 
snoise  
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3.3.7 Running STOCSY-E 
The STOCSY-E code and user guide are given in the appendix (Appendix A.2 and 
A.3 respectively). 
 
Required user defined input arguments: 
Running STOCSY-E requires only the pre-processed set of spectra, a vector of 
corresponding ppm values and a vector of one or more index values each 
corresponding to a peak of a metabolite whose removal is required (driver peaks). 
When just these arguments are imputed, STOCSY-E will be run with a threshold of 
0.90, the noise region will be defined as between 9.5 and 10 ppm, and the local 
background defined as 0.02 ppm either side of each region to be scaled. 
 
Optional input arguments: 
If required, in addition to those required arguments as defined above, a number of 
other running parameters can be individually set so as to optimise STOCSY-E for a 
particular dataset or application. These optional user defined parameters include the 
threshold value (which can also be set to a different value for each driver peak 
selected), the boundaries for definition of the noise region, and the range over which 
the local background region should be defined for generation of the background 
replacement sections. Furthermore, as mentioned in Section 3.3.3, it is also possible to 
specify whether each drug peak region should be scaled until the local minimum in 
signal intensity for each sample (default), or until the mean local minimum across all 
samples. Finally, it can also be stipulated whether all peaks with correlations greater 
than the threshold should be scaled, or only those with positive correlations (i.e. 
structurally related, default). 
For application to the flucloxacillin and bromoethanamine datasets as presented 
here, the default settings were used unless otherwise stated. 
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3.4 Results: Application of STOCSY-E to toxicological 
metabolic data 
Running STOCSY-E on the flucloxacillin dataset illustrates the quick and effective 
identification of the parent flucloxacillin resonances in the spectrum. Additionally the 
background correction method effectively removes drug metabolite signals whilst 
retaining endogenous signal where endogenous peaks overlap (Figure 3.5). Finally in 
OPLS-DA the resultant final spectra (with contributions from parent drug resonances 
removed), provides clearer observation of the endogenous resonances important in 
discriminating between data sampled at different time-points and thus, a more easily 
interpretable model for characterising the biochemical effect of treatment. However, 
the number of samples in each group for this dataset was small (n = 4), thus (as for the 
original data), the OPLS-DA model quality was low and no additional endogenous 
discriminators were identified between the time-points investigated when OPLS-DA 
models generated for the STOCSY edited and original data were compared. 
Therefore, a more comprehensive spectral dataset, representing administration of the 
renal papillary toxin, 2-bromoethanamine (BEA), allowed further testing of the 
STOCSY-edited scaling method and the generation of more robust discriminant 
models. 
 
 
Figure 3.5: Expansion of ! 1.47 - ! 1.53 region for STOCSY-E results. (A) Original 
spectral data, blue and final STOCSY edited, red, (B) original data coloured by time 
point (as before). In this region no signals remain in the STOCSY edited spectra for 
the peak at 1.52 ppm, whilst some signal above the LOD is present in the edited peak 
at 1.48 ppm, this result can be validated since endogenous signal is present in the 0 h 
samples for the peak at 1.48 ppm but not for the peak at 1.52 ppm. 
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BEA treatment results in many BEA-related metabolites appearing in the 
urine, with the largest contributions from aziridine (AZ), 2-oxazolidone (OX) and 5-
hydroxy-2-oxazolidone (HOX) (Anthony et al., 1995; Holmes et al., 1995). AZ is the 
cyclic intermediate formed from BEA through elimination of hydrogen bromide 
(HBr), while OX is formed from the reaction of BEA with endogenous bicarbonate 
followed by a cyclisation reaction in which HBr is eliminated. HOX is subsequently 
formed from the hydroxylation of OX (see schematic of BEA metabolism, Figure 
3.6). BEA and its metabolites appear sequentially in the urine spectra (collected at 0-
2, 2-4, 4-8, 8-24 and 24-48 h post-dosing with BEA) with BEA and AZ appearing in 
the early time-point spectra and OX and HOX appearing at later time-points, 
reflecting the metabolic time-course. 
 
 
Figure 3.6: Schematic of bromoethanamine (BEA) metabolism adapted from Holmes 
et al., 1995. 
Owing to the time-course of BEA metabolism, it was necessary to drive 
STOCSY-E from one resonance relating to each of the four major metabolites (BEA, 
OX, HOX and AZ). Again, a correlation cut-off of r2>0.9 identified the resonances 
relating to the four compounds (Figure 3.7 A) and resultant drug peak edited spectra 
were produced for each sample, in this case, using the editing method to remove 
peaks from all four compounds simultaneously (Figure 3.7 B). Driving STOCSY-E 
from different resonances relating to each of BEA, OX and HOX (AZ only has one 
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singlet resonance), did not significantly affect the correlation coefficients and thus the 
results of the algorithm in terms of drug metabolite peaks identified and final 
STOCSY edited spectra. 
In addition, the higher number of samples available at each time-point for this 
dataset, allowed the generation of robust OPLS-DA models for both the original and 
the newly generated STOCSY-edited data comparing control (n = 8) and dosed (n = 
17) samples at each time-point. The results of an OPLS-DA model discriminating 
between control and treated animals at the 8 h time-point (representing urine 
collection from 4-8 h) are shown in Figure 3.8. The statistical parameter Q2 , 
calculated for each model represents the predicted proportion of variance in the data 
following 7-fold cross-validation, thus providing a measure of model robustness 
(Trygg and Wold, 2003). The similar Q2  values obtained for the OPLS-DA models 
for original and STOCSY-edited data (0.776 and 0.771 respectively) indicate no 
significant loss of model quality for models generated from the edited spectral data. 
 
 
Figure 3.7: Bromoethanamine (BEA) administration study. (A) Mean drug 
metabolite spectral profiles (
! 
x drug) for each of the major BEA drug metabolites 
generated from running STOCSY from one peak corresponding to each of the drug 
metabolites, HOX (5-hydroxy-2-oxazolidone), OX (2-oxazolidone), AZ (aziridine), 
and BEA. (B) Results of STOCSY-editing for all samples across all time-points 
showing the original spectra (blue) and final STOCSY-edited spectra (red) with BEA-
related metabolites highlighted.  
! 
ˆ " 
! 
ˆ " 
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Figure 3.8: OPLS-DA coefficient loadings from the BEA administration study. Each 
loadings plot is the covariance across the chemical shift scale coloured by correlation 
coefficient (scale shown) comparing control and dosed 8 h urine samples for (A) the 
original spectral data (Q2
! 
ˆ "  = 0.776), (B) the final STOCSY-edited spectra (Q2
! 
ˆ "  = 
0.771). Key: HOX, 5-hydroxy-2-oxazolidone; OX, 2-oxazolidone; C, creatinine; H, 
hippurate; 2-OG, 2-oxoglutarate; GTA, glutaric acid. 
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At this time-point in the edited data, resonances of HOX and OX (the main 
xenobiotic-derived resonances present in the 8 h urinary data) were no longer picked 
up in discriminatory analysis, allowing clearer observation of the major known 
endogenous changes between control and treated animals (glutaric acid, 2-
oxoglutarate, creatinine and hippurate) (Holmes et al., 1995). However, in addition to 
these previously identified metabolites, a new significant peak at 3.68 ppm was also 
picked up in the STOCSY-edited data, which was not seen in analysis of the original 
data (Figure 3.9 A and B). This peak is present in control samples but it overlaps 
significantly with the OX triplet at 3.67 ppm (Figure 3.9 C) and is therefore only 
resolved in the final spectra following removal of the drug metabolite resonances, 
scaling and background correction (Figure 3.9 D). 
Based on inter-peak correlations using STOCSY (Figure 3.9 E) and 
assignments in the literature, this peak has been identified as arising from the gut 
bacterial-mammalian co-metabolite phenylacetylglycine (PAG, Li et al., 2008). The 
negative covariance at 3.68 ppm in the OPLS-DA coefficient loadings plot (Figure 3.9 
B) indicates a reduction in levels of PAG between control and dosed 8 h samples, a 
result that is verified by examination of changes in the original NMR spectral data. 
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Figure 3.9: Identification and assignment of the novel discriminatory peak recovered 
after STOCSY-editing of the BEA data. (A) and (B) OPLS-DA coefficient loadings 
from the BEA administration study. As before, each loadings plot is the covariance 
across the chemical shift scale coloured by correlation coefficient (scale shown) 
comparing control and dosed 8 h urine samples for (A) the original spectral data and 
(B) the STOCSY-edited spectra. (C) Original spectral data coloured by time-point 
(pre-dose, black; 0-2 h, red; 2-4 h, pink; 4-8 h, green; 8-24 h, cyan; 24-48 h, blue), (D) 
original spectral data, blue; and final STOCSY-edited spectra, green (arrow indicates 
newly discriminatory peak). (E) Peak identification; STOCSY plot driven from the 
identified peak (*). Similarly to parts A and B, this plot is the covariance across the 
chemical shift scale coloured by correlation coefficient (scale as shown for A and B). 
Key: P, phenylacetylglycine (PAG). 
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3.5 Discussion 
The STOCSY-E method has been shown to be effective at quickly identifying drug 
metabolite peaks and also at providing enhanced endogenous information recovery 
from spectral regions containing drug metabolite resonances, through the selective 
scaling and background correction of the original spectra. Thus, this method 
represents a useful semi-automatic tool to aid drug metabolite peak identification and 
subsequent data analysis of the associated toxic consequences on the endogenous 
metabolic profile. 
For this application (the selective identification and removal of only structural 
correlations i.e. resonances resulting from the same molecule), selecting only those 
resonances that correlate with each driver (a known drug peak) with a cut-off r2>0.9 
proved appropriate. In this case (for proof of principle) the principal drug-related 
metabolites were known a priori, however, even if drug resonances were unknown 
prior to dosing, in the majority of cases, comparison of pre- and post-dose spectra 
would yield putative drug candidates that could then be investigated by application of 
the STOCSY-E algorithm. The correlation coefficients obtained through STOCSY are 
obviously dependent on the choice of driver peak. In theory therefore, correlation 
coefficients resulting from STOCSY driven from different peaks of the same 
compound may be affected by peak overlap and baseline fluctuations and this could 
affect the results of STOCSY-E in a way similar to the affects caused by mis-
alignment (discussed in detail below). However, despite some serious peak overlap in 
the data, the correlation values and thus overall results were not significantly affected 
when STOCSY-E was driven from different drug peaks for both the flucloxacillin and 
bromoethanamine datasets. 
Although r2 > 0.9 was found to be an appropriate cut-off value for both 
datasets investigated (and agrees with related literature, Couto Alves et al., 2009), it is 
certainly possible that for different datasets, and depending on the specific goal of 
performing STOCSY-E, a different value may be more appropriate. One approach to 
select an appropriate cut-off value could be the iterative process of running the 
algorithm with different cut-off values and selecting the value generating the most 
reasonable resultant drug metabolite spectral profiles with respect to the structure of 
the compound. Additionally (even if the drug metabolite is unknown), running the 
extracted putative drug metabolite spectral profiles against NMR spectral databases 
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(such as the Biological Magnetic Resonance Data Bank (BMRB, Ulrich et al., 2008) 
or the Human Metabolome Database (Wishart et al., 2007)), in an approach analogous 
to that utilised by the Brüschweiler laboratory (Robinette et al., 2008), could prove 
useful in the identification of endogenous resonances. This information could then be 
used to update the cut-off value so as not to include resonances relating to endogenous 
molecules. 
The challenge remains, that it may be the case that (for biological reasons), an 
endogenous peak correlates highly to the driver drug peak. This has serious 
implications: not only would this produce a false positive peak in the identified drug 
metabolite spectral profiles, but also this peak would be scaled and removed from the 
edited spectra and thus lost from any subsequent analysis. It is worth noting that a 
major endogenous consequence of treatment with BEA results in marked increases in 
urinary excretion of glutaric acid. However, this metabolite is not picked up as a drug 
metabolite, despite following a time course similar to OX, possibly owing to subtle 
timescale differences and inter-animal variation in response to the treatment. It is 
therefore perhaps unlikely that an endogenous metabolite would correlate wholly with 
a parent drug metabolite, and so, with selection of a stringent enough cut-off this 
should not prove to be a problem. On the other hand, owing, for example, to peak 
overlap, it is possible that certain drug metabolites resonances may fall below the set 
correlation cut-off and thus remain in the final edited spectra. However, even if these 
resonances were picked up as important (for example in discriminant analysis of pre 
and post dose samples), it is likely that in the subsequent process of metabolite 
identification they would be identified as drug related and thus disregarded.  
This method could also be used to elucidate subtle metabolic pathway 
connections, for example, from STOCSY-E derived connectivities between a drug 
metabolite and toxic metabolic products or metabolites produced in detoxification 
processes. In this case, the selection of an appropriate cut-off is more complicated 
since different drug metabolites correlate with different degrees to the drug driver 
peak. If this were required, the approach suggested above of systematically 
decreasing/increasing the cut-off could be employed to optimise selection of an 
appropriate cut-off value. 
In terms of data pre-processing for STOCSY-E, specifically normalisation, the 
important factor to consider is that any normalisation procedure preserves both the 
structural and non-structural correlations between spectral points. Although total area 
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normalisation is most common in metabolic analysis it has been shown that this 
method can introduce correlation artefacts (Craig et al., 2006), which may affect the 
results of STOCSY-E. Therefore, probabilistic quotient normalisation was applied, 
although other normalisation methods could be equally suitable. 
Understandably, since STOCSY relies on the multi-colinearity of variables in a 
set of spectra, it is important that peaks across the spectrum are well aligned. Any 
peak shifting will directly change the order of sample intensities, affecting the 
apparent multi-colinearity and thus potentially significantly impacting the correlation 
coefficient at affected points. In STOCSY-E, the presence of shifted peaks has several 
implications; firstly true drug metabolite peaks may be missed if shifting results in 
correlation coefficients falling below the cut-off. Secondly, even if correlation 
coefficient levels remained above the cut-off they may still be reduced compared to 
their true value (i.e. if peaks were properly aligned). This may mean such peaks are 
significantly less scaled than they should be and thus the remaining signal may meet 
the criteria for remaining in the STOCSY-E spectrum as ‘endogenous’ signal.  
Finally, this method has shown to be effective in the recovery of novel 
information, for example, in the identification of the PAG peak in the BEA dataset. 
PAG is a microbial-mammalian co-metabolite and has previously been identified as a 
surrogate biomarker of phospholipidosis when present in urine at high levels (Espina 
et al., 2001; Nicholls et al., 2000). In this case however, the alteration in PAG levels 
are more subtle and decrease following BEA treatment, thus these changes are more 
likely to indicate minor disruptions to gut microbial activities rather than overt 
phospholipidosis (Yap et al., 2008). It is worth noting that the intensity values of these 
resonances are modified from their original values, thus, if novel peaks are resolved in 
the regions where drug peaks are removed, it is necessary (as for all biomarkers 
identified in chemometric models) to go back to the original data to identify whether 
these changes are indeed valid.  
In conclusion, this semi-automatic algorithm provides a rapid method for the 
identification of potential spectral drug metabolite resonances. Additionally the 
removal of these drug related peaks, together with reconstruction of the surrounding 
regions, facilitates improved statistical analysis and ultimately enhanced biomarker 
recovery and discovery. As such, STOCSY-E assisted scaling could provide a 
valuable tool in the analysis of any NMR spectral dataset containing resonances 
resulting from a set of interfering metabolites. 
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4  Iterative statistical total correlation spectroscopy 
(I-STOCSY) – a data-driven approach for 
metabolite relationship recovery 
In this chapter a new approach for the elucidation of inter- and intra-metabolite 
relationships in 1H NMR data is developed and applied to an exemplar metabonomic 
dataset. In this method, termed Iterative-STOCSY (I-STOCSY), metabolic 
associations are followed over several rounds of STOCSY through calculation of 
correlation coefficients initially from a driver peak of interest, and subsequently from 
all peaks identified as correlating above a set threshold to peaks picked in the previous 
round. The resultant metabolic associations are presented in a fully interactive plot 
showing node-to-node connections alongside their corresponding spectral data. This 
allows the easy exploration of both inter- and intra-metabolite relationships stemming 
from a specific endogenous and/or treatment related peak of interest and thus a more 
directed approach to the identification of biomarkers of the studied perturbation. 
Following an introduction the development of the I-STOCSY approach is followed 
from initial concept, through method improvement to the final algorithm, and 
subsequently applied to an exemplar toxicological dataset. 
4.1 Introduction 
Owing to the complex nature of spectral datasets produced by metabonomic analytical 
techniques the development of effective and accurate tools for data interpretation 
presents a continuing challenge. As previously described (Section 2.4.2), a typical 
approach to address this challenge includes the identification of important or 
discriminatory variables by pattern recognition methods, followed by their assignment 
as specific metabolites using a combination of statistical and experimental methods. 
Consequently data analysis can be time-consuming, the identification of biomarkers 
difficult, and the visualisation and interpretation of results complicated by the 
multivariate nature of the data. 
 As introduced in Section 2.4.1, correlation analysis of metabolic datasets is 
well established, and STOCSY provides one example of the power of such techniques 
in the analysis of NMR metabonomic datasets. An increasingly popular approach in 
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the analysis of metabolic datasets is the production of a metabolic map or network 
based on inter-peak (intensity or area) or inter-metabolite (concentration) correlation 
coefficients (Blaise et al., 2010; Clish et al., 2004; Kose et al., 2001; Robinette et al., 
2009; Steuer et al., 2003; Weckwerth et al., 2004; Zhang et al., 2008). Aside from the 
computational time involved, interpreting the pairwise correlations between all 
variables in a metabonomic dataset (tens of thousands of points in 1H NMR) can be 
overwhelming, and though cherry-picking a small number of metabolites of interest 
may ease analysis, important interactions may be overlooked. A common approach is 
therefore to reduce the full variable set into a smaller number of clusters, each of 
which is, in theory, representative of a single metabolite. This is the approach used in 
both CLASSY (Robinette et al., 2009), and the recently published R-STOCSY (Blaise 
et al., 2010), both of which aim to provide a snapshot of metabolic relationships 
following a perturbation of interest. In CLASSY peaks are grouped into putative 
structural sets by evaluation of an overlap matrix on the inter-variable correlations 
thresholded at increasing correlation coefficients to identify unambiguous local 
clusters. Subsequently the most highly correlated member of each local cluster is 
taken to represent the cluster, and this representative set is subject to correlation 
analysis (2D STOCSY). A correlation map presented after hierarchical clustering of 
the resultant correlation matrix reveals inter-variable relationships. Similarly, a 2D 
STOCSY approach is applied in R-STOCSY, this time on mean cluster intensities 
following the clustering of consecutive variables based on their correlation/covariance 
profile (statistical recoupling of variables, SRV, Blaise et al., 2009). Here results are 
presented both in a correlation map and, for improved interpretation, super-imposed 
onto a subset of the global KEGG metabolic network. However, in both cases, 
considerable time is required both in the assignment of metabolites to clusters and in 
the subsequent relation of metabolites to the correlation data produced. Additionally 
the representation of each putative structural group by a single value may lead to true 
associations being overlooked. 
 Here Iterative-STOCSY (I-STOCSY) is presented, a novel data-driven 
approach for the elucidation of intra- and inter-metabolite relationships in 1H NMR 
metabolic datasets. In this method, STOCSY is recursively performed, initially from a 
selected driver peak of interest, and subsequently for all peaks identified as 
correlating to the previous driver peak with a correlation coefficient greater than a 
pre-set threshold. Additionally putatively structurally related peaks are grouped and 
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represented as single nodes in a fully interactive plot, which not only shows node-to-
node I-STOCSY connections, but also relates the nodes directly to the spectral data 
they represent, thus allowing the easy exploration of inter- and intra-metabolite 
relationships. In comparison to other correlation-based methods, this allows a more 
directed and logical approach to the identification of metabolites that are biomarkers 
of the studied perturbation and the generation of hypotheses for inter-metabolite 
associations. Additionally the flexibility afforded by the user-defined choice of both 
initial driver peak and correlation threshold allow specific endogenous and/or 
treatment related associations of interest to be followed with respect to both the effect 
under study and strength of association. 
4.2 Datasets 
The I-STOCSY approach was tested on a 1H NMR dataset of 24 h post-dose aqueous 
liver extracts from rats treated with the model hepatotoxin galactosamine (galN). 
Although galN has been widely used as a model for hepatotoxicity for many years, 
the mechanism of its toxicity is still unclear, particularly with respect to inter-animal 
variability in toxic response. Thus, following treatment of a group of animals with 
galN, individual animals can either be classified as responders, presenting with a 
differing degree of liver pathology, or as non-responders, displaying no toxic 
response. This variability in response has been consistently observed across a variety 
of studies (Coen et al., 2009), and presents a particular challenge in the elucidation of 
the mechanism of galN toxicity. However, it is known that following the initial 
conversion of galN to galactosamine-1-phosphate (galN-1-P), UDP-galN is formed 
from reaction of galN-1-P with UDP-glucose (UDP-glc). The subsequent 
epimerisation of UDP-galN to UDP-glcN and formation of glcN-1-P links subsequent 
metabolism into the glucosamine pathway and thus results in the formation of 
glcNAc-1-P, glcNAc-6-P and the UDP-N-acetylhexosamines UDP-galNAc and UDP-
glcNAc. The critical point in galN toxicity is the formation of the UDP-hexosamines 
(UDP-galN and UDP-glcN); these cannot serve as uridylate donors in the 
uridylyltransferase reaction, resulting in depletion of the uridine nucleotide pool, 
inhibition of RNA and protein synthesis and ultimately liver pathology (Coen, 2010; 
Coen et al., 2009; Decker and Keppler, 1972). The experimental details of the 
galactosamine dataset are described in Section 2.5.3. 
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4.2.1 Data pre-processing 
Following removal of the regions corresponding to water/HDO (! 4.7 - 4.9) and TSP 
(! -0.2 - 0.2), spectra were subsequently probabilistic quotient normalised (Dieterle et 
al., 2006). To reduce dimensionality the variable set was peak-picked to consist of 
only those variables representing peak apexes. Peaks were detected at zero crossings 
of a smoothed spectral derivative calculated using a Savitzky-Golay third order 
polynomial filter (Savizky and Golay, 1964) of the mean spectrum with window size 
0.005 ppm. In this way the full variable set after removal of water and TSP (19 272 
variables) was reduced to 514 variables (Figure 4.1). 
 
 
Figure 4.1: Mean 1H NMR spectrum of 24 h post galN-dose liver aqueous extracts (n 
= 48). Stars indicate variables corresponding to peak-picked apexes and the box insert 
shows a focus on the spectral region ! 5.5 - ! 6 to illustrate picked peaks in detail. 
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4.3 Method development 
In this section development of the I-STOCSY approach is described from initial 
concept through to the final algorithm. 
4.3.1 I-STOCSY concept 
In contrast to other correlation-based approaches that involve the outright 
computation of the full correlation matrix of a reduced set of representative variables 
(an example of which is given in Figure 4.2), the idea behind I-STOCSY was to 
provide a more focused analysis stemming from a specific metabolite of interest and a 
real improvement in visualisation for the ease of subsequent interpretation. 
 
 
Figure 4.2: Correlation matrix generated between all spectral variables corresponding 
to the 514 peak-picked variables coloured according to the scale shown. The values 
on the diagonal represent autocorrelation (and are therefore equal to one), and off-
diagonal values show the correlation between variables. 
Consequently, in the original I-STOCSY algorithm, from a set of spectra, a set 
of indices corresponding to peak apexes, a user defined peak of interest and 
correlation cut-off value !, STOCSY was repeatedly performed, initially driven from 
the defined peak, but for subsequent rounds driven from all peak apexes identified as 
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correlating to the driver with a correlation coefficient (r) with absolute value greater 
than !. The resulting network therefore highlights all inter-peak connectivities (with | 
r | > !) originally stemming from the driver peak of interest, but expanding to 
encompass connections from the peaks picked up in previous rounds as the number of 
rounds increases. This initial method is summarised in Algorithm 4.1 and the resultant 
plot shown Figure 4.3. 
 
Algorithm 4.1: Original I-STOCSY pseudocode 
1. Select peak of interest and define correlation threshold (!) 
2. Run STOCSY from driver peak on spectral data corresponding to peak-picked 
variables to recover correlation coefficient (r) values 
3. Obtain set (D) of indices with absolute correlation coefficient | r | > !   
4. Remove those indices in D that have been previously identified and therefore 
already run as STOCSY driver peaks in previous rounds. Each member of this 
new set D’ will become a driver peak in the next round of I-STOCSY 
5. Repeat steps 2 to 5 for each member of D’ until no new peaks identified or 
user defined/default number of rounds exceeded 
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Figure 4.3: Inter-peak connectivity map for the basic I-STOCSY method driven from 
a UDP-galNAc peak (!1H = 5.52) in the galN spectral dataset with peak-picked 
variables. Peaks are represented by uniquely coloured nodes with adjacent ppm values 
showing peak location, and positioned in columns corresponding to the round in 
which they were identified. Peaks with correlation coefficient r > threshold (!) are 
connected by lines coloured by the strength of connection (correlation coefficient r, 
on scale shown). For illustrative purposes only the first three rounds are shown. 
Although this mode of display gives some idea of the complexity of metabolic 
associations captured in the spectroscopic datasets (as does the correlation map in 
Figure 4.2), the interpretation of such networks is non-trivial even if associations just 
corresponding to one peak of interest are highlighted (Figure 4.4). Modification of the 
basic method was therefore critical to improve visualisation and interpretability of 
results. This was achieved through two important developments; firstly, the addition 
of a step whereby putative structurally related peaks are grouped and thus can be 
represented by just one node in the resulting network, and secondly, in the 
development of a fully interactive tool for the visualisation of I-STOCSY node-to-
node connections alongside the spectroscopic data each connection represents. These 
steps are described in the context of the full I-STOCSY approach in the following 
sections. 
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Figure 4.4: Subset of the full I-STOCSY network (Figure 4.3) highlighting only 
associations to and from the peak at !1H = 4.37 in Round 2. As in Figure 4.3 peaks 
are represented by uniquely coloured nodes with adjacent ppm values showing peak 
location, and peaks with correlation coefficient r > threshold (!) are connected by 
lines coloured by the strength of connection (correlation coefficient r, on scale 
shown). Even when just a subset of the full set of connections is shown, interpretation 
is not straightforward. 
4.3.2 Method description 
Consisting of five sequential steps, performed recursively for each driver peak in each 
round, the complete I-STOCSY method along with a simple worked example is 
shown in Figure 4.5 A. Here I-STOCSY was applied to a set of simulated spectra 
generated using MetAssimulo (n = 30 simulated 1H NMR urine spectra, signal-to-
noise ratio = 10 000 and peak shifting simulation switched off) with pre-specified 
inter-metabolite concentration correlations selected as to best exemplify the method 
(Muncey et al., 2010). 
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Figure 4.5: (A) I-STOCSY method and (B) results as illustrated on a simple 
simulated dataset. 
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In the first step of the first round of I-STOCSY, the STOCSY calculation is driven 
from the user defined driver peak of interest and the returned set of correlation 
coefficients used to determine those peaks (set D) that correlate to the driver with | r | 
greater than the pre-set correlation threshold ! (Step 2). Following this, at Step 3, the 
subset of D not picked up in previous rounds (D’) is selected and condensed into 
putative structurally related subsets (in Round 1, the set D’ is identical to the set D 
since this is the first occasion at which correlating peaks are detected). It has been 
established that a STOCSY correlation threshold of r > 0.95 is necessary to assign 
peaks to the same metabolite with high probability (mean threshold value for a 
positive predictive value of 0.9 across a variety of datasets, (Couto Alves et al., 2009; 
Sands et al., 2009). Therefore, at this stage the inter-peak correlation coefficients 
between all members of D’ are calculated and any peaks found to share a correlation 
greater than 0.95 are assigned to the same structural set. Subsequently each newly 
defined putative structural set is added as a new row to a matrix in which all such sets 
are defined. In the next step (Step 4), this matrix of structural sets is searched for the 
row locations of all peaks found originally to correlate with the driver above the given 
threshold (all peaks in set D). Thus the number of driver-to-peak connections is 
reduced, since connections to multiple peaks in the same structural set are represented 
by reference to one index value (the row in which the peaks are found) instead of one 
value per peak. At this stage the corresponding correlation between driver and each 
identified set is also determined, and where structural sets contains multiple peaks, 
correlations are calculated simply as the mean correlation between the driver peak and 
all set members. Finally, in Step 5, any newly identified peaks (i.e. the set D’) are 
added to the list of peaks to be carried forward and become driver peaks in the next 
round (Dround). Again in Round 1 the set Dround is equivalent to the set D’ since there is 
only one driver peak (the initial user defined peak), and therefore only one iteration of 
Steps 1 to 5. However, in subsequent rounds, if more than one new peak is picked up 
in the previous round then the steps must be repeated for every newly identified peak 
(each member of Dround), thus the set D’ will be different for each driver peak and as 
such (as long as new peaks are picked up) membership of Dround for the next round 
will increase with every iteration of the 5 steps. I-STOCSY continues until either no 
new peaks are identified or the maximum number of rounds (preset by the user) is 
exceeded. 
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The condensation of peaks into putative structural sets (Step 3) is key in 
reducing the complexity of interpretation, and although as a result of this multiple 
peaks are represented by one node, no information is lost. This is because in the 
subsequent round, all of the newly identified peaks, not just one per structural set, are 
run as drivers, and thus all the resulting correlations with | r | > ! are saved as 
connecting to that given structural set. If the chosen threshold causes some intra-
molecular correlations to be treated as intermolecular, this means that the desired 
reduced complexity is only compromised marginally, and the true connectivities are 
easily deduced in the subsequent interpretation stage. 
4.3.3 I-STOCSY interactive plot 
Representing the I-STOCSY results as a diagram of inter-connected nodes (Figure 
4.3) is useful in that it highlights both connections and the order in which peaks are 
picked up. However, the complexity of such a diagram and the necessity to link each 
node to its real spectral data for interpretation, as in other correlation based methods, 
remains both time consuming and tedious. Therefore, an interactive plot was 
developed in which the nodes are plotted alongside complementary spectral data 
(Figure 4.5 B). Selecting a node or spectral peak of interest highlights all connecting 
nodes in a map of connectivities and their corresponding peaks in the spectral data. 
Node-peak relationships are shown by node colour-coordinated stars underneath the 
spectral data, and the strength of connection (correlation) given by the colour of the 
peak above. 
4.4 Running I-STOCSY 
The I-STOCSY code and user guide are given in the appendix (Appendix B.1 and B.2 
respectively). 
4.4.1 Required user defined input arguments 
I-STOCSY requires just two user defined parameters; firstly, the initial driver peak 
from which the first round of STOCSY should be run, and secondly, the threshold 
value corresponding to the minimum correlation coefficient required to define peak to 
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peak connections (!). In principle any peak index can be selected as the driver, 
although choice may be guided by user knowledge of the system under study and the 
required outcome of I-STOCSY application. For example, previous studies or 
comparison of pre- and post- treatment samples may yield a set of metabolites whose 
levels are perturbed by treatment and thus whose metabolic associations may be of 
interest. Or, if, for example, in toxicology studies, drug metabolism is of interest, 
selecting a xenobiotic peak as the driver could help to elucidate other drug related 
compounds alongside any associated endogenous metabolic perturbations. 
In contrast, selection of an appropriate correlation cut-off may require 
investigation of different values to optimise information recovery. While high 
threshold values will result in less complex association networks (since only strong 
associations will be shown) as the threshold value is reduced, more and more 
metabolic associations will be recovered. Threshold selection is also dataset 
dependent, since depending on the perturbation under study the distribution of inter-
metabolite associations can be very different (see Chapter 6). Although in theory any 
cut-off can be selected, one factor that may influence choice at lower correlations is 
the lowest threshold at which correlations are meaningful. A measure of the 
significance of a correlation can be determined through the concurrent calculation of 
the associated p-value, which gives the probability of getting a correlation as large as 
that observed by random chance when the true correlation is zero, the smaller the p-
value the more significant the correlation. In significance testing, although choosing a 
significance level is arbitrary, by convention in many applications a level of 5% 
(maximum p-value = 0.05) is chosen. The relationship between correlation coefficient 
value and p-value is illustrated in Figure 4.6 for correlation coefficients calculated 
between peak-picked variables in the 24 h post-dose galactosamine liver aqueous 
extract 1H NMR dataset. Here it can be seen that p-values are extremely low for 
absolute correlations greater than approximately 0.4, but increase exponentially as the 
absolute correlation decreases below this value, with a maximum p-value of 1 at r = 0. 
For this dataset correlation coefficients with r > 0.285 are significant at the 5% level, 
and thus in practise any I-STOCSY correlation threshold above ~ 0.3 would yield 
significant correlations at the 5% level. To determine the general applicability of this 
minimum threshold value, this process was repeated for four additional datasets (the 
COMET datasets, see Section 2.5.4 for details). In general the minimum correlation 
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for significance at the 5% level was around 0.3 across all datasets (Table 4.1), 
although increasing to a maximum of 0.34 in the dataset with the fewest samples and 
reducing significantly in the control data owing to the huge sample size. In practice 
therefore, these results suggest that as long as the correlation threshold exceeds 0.35 
correlations will be significant at the 5% level. In reality though, for most datasets 
selecting a threshold this low would not be worthwhile owing to the vast number of 
connections recovered at this level. 
 
 
Figure 4.6: The relationship between correlation coefficient and p-value as calculated 
for correlation coefficients between the 514 peak-picked variables of 24 h post galN 
dose liver aqueous extract 1H NMR dataset (n = 48). 
 
Dataset Number of samples Minimum correlation significant at p = 0.05 
Control 1043 0.0607 
Control (50 randomly 
selected samples) 50 0.2787 
Ammonium chloride 49 0.2816 
Galactosamine 48 0.2845 
Hydrazine 39 0.3160 
Caloric restriction 34 0.3388 
Table 4.1: Minimum correlation coefficient value significant at a 5% level across a 
range of datasets. On average correlations greater than 0.3 are significant at this level. 
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Finally of potential interest in terms of correlation threshold selection is the 
distribution of correlation values for correlations coefficients calculated between all 
peak-picked variables (Figure 4.7). This is interesting since it could be used to give a 
rough indication of the number of correlations that will be detected at a particular cut-
off. Although the reduction in the number of I-STOCSY associations owing to the 
grouping of structurally related peaks is not taken into account here, this will only 
affect the number of correlations with r > 0.95. Therefore pre-calculation of the 
correlation matrix with associated matrix of p-values and plotting the distribution of 
significant and insignificant correlation values obtained could help guide suitable 
threshold selection. 
 
 
Figure 4.7: Bar chart showing the distribution of significant (p-value " 0.05) 
correlations (blue bars) and insignificant (p-value > 0.05) correlations (red bars) for 
correlations calculated between the 514 peak-picked variables in the galN 1H NMR 
dataset. 
 
 78 
4.4.2 Additional optional user defined input parameters 
In terms of practical usage of the I-STOCSY program, simply inputting the full 
spectral data along with the initial driver peak and correlation threshold is sufficient 
for running I-STOCSY, and the remaining parameters will be set to their default 
values. However, these can also be user defined if required, and as such are discussed 
below (for full details of running I-STOCSY please see the users guide Appendix 
B.2): 
 
Maximum number of rounds 
By default I-STOCSY runs until either no new peaks are identified or the number of 
rounds exceeds 10. This default value was selected from experimentation with 
different thresholds as a value where the number of rounds does not become limiting 
in terms of information recovery. However, the lower the threshold selected, the 
higher the number of associations recovered, and thus it may be desirable to reduce 
the maximum number of rounds to ease interpretation and minimise computational 
time. 
 
Variable dimension reduction - peak-picking 
If the full spectral data are inputted, then peaks will be picked through detection at 
zero crossings of a smoothed spectral derivative calculated using a Savitzky-Golay 
third order polynomial filter of the mean spectrum (as described in the data pre-
processing Section, 5.2.2). However, if the dataset contains more than one class (for 
example, pre- and post- dose samples), then using the mean spectrum may result in 
peaks that are only present in one class not being detected. Thus, if class information 
is included, the peak-picking algorithm will be run on the mean spectrum of each 
class and the results combined. Additionally if required, the output of the peak 
picking can be plotted and the user can add any peaks that have been omitted.  
Additionally, once calculated, the peak-picked variables can simply be added 
as an input argument for any subsequent runs with different thresholds or initial driver 
peaks, thus saving computational time. Finally, if required, dimension reduction can 
also be carried out by another means (for example SRV, Blaise et al., 2009) and the 
reduced dataset imputed directly into the I-STOCSY algorithm. 
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Structural sets 
By default variables are classified into structural sets that are determined as the 
algorithm runs, however, there are several situations where imputation of variables 
pre-clustered into structural sets may be advantageous. Firstly if the user is interested 
in the differences in metabolic connections within and between metabolites in 
different subgroups or classes, the peak-picking and structural sets can be generated 
once (for example, on the full dataset) and then these pre-defined variables used in I-
STOCSY with different data subsets to compare differences like-for-like. 
Additionally, as with peak picking, if the structural sets are pre-defined, 
computational time is saved on subsequent runs. Also here, again if required, an 
alternative method of choice (e.g. the local clustering algorithm of CLASSY, 
Robinette et al., 2009) can be used to define structural membership. 
4.5 Results 
The I-STOCSY method was applied to the spectral dataset representing aqueous liver 
extracts 24 h post galactosamine administration, driven from the UDP-galNAc 
anomeric proton resonance (!1H = 5.52) with a correlation threshold ! of 0.85. UPD-
galNAc was selected as a major galN-related metabolite in post-dose samples, and the 
threshold of 0.85 as best to exemplify the method. As the value of the threshold 
decreases, more peaks are picked up as correlating to each driver peak, thus this 
relatively high threshold keeps the number of connections to a minimum so results 
can be presented in full. 
 Previous investigation of this dataset has shown increased hepatic levels of the 
galN related metabolites UDP-galN/UDP-glcN, glcNAc-6-P, UDP-galNAc and UDP-
glcNAc in galN treated rats (Coen et al., 2009); all of which are detected here in the 
first three rounds of I-STOCSY (Figure 4.8), with Round 1 nodes corresponding to 
the remaining resonances of UDP-galNAc and UDP-glcNAc. Owing to the stringent 
threshold for defining structural sets (r > 0.95) and the inherent signal overlap and 
peak shifting present in NMR data, the majority of nodes represent only a subset of 
peaks for any given metabolite. Therefore most metabolites are represented by a 
number of nodes each containing peaks with similar overlap or shifting profiles. 
However, in Round 1 each of the three nodes corresponds to resonances of both UDP-
galNAc and UDP-glcNAc (Figure 4.8 A and B).  Not only is this because the majority 
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of resonances for these metabolites overlap, but also, owing to the presence of an 
epimerase (UDP-acetylglucosamine 4'-epimerase, (Jacobson and Davidson, 1963) 
these compounds are in fast metabolic equilibrium and therefore even the fully 
resolved resonances corresponding to the anomeric (UDP-galNAc !1H ~= 5.55, UDP-
glcNAc !1H ~= 5.52) and N-acetyl (UDP-galNAc !1H = 2.09(s), UDP-glcNAc !1H = 
2.085(s)) peaks correlate extremely highly. In Round 2, nodes corresponding to 
uridine and the previously unassigned glcNAc-1-P (assigned by comparison to a 
standard spectrum of authentic material) are detected (Figure 4.8 C). From analysis of 
the corresponding spectral data however (Figure 4.8 D), it can be seen that the uridine 
peaks picked are those that overlap with UDP-gal/glcNAc (!1H = 4.365 and 4.24) and 
therefore are not meaningful connections at this point. In the final round shown in this 
figure (Round 3, Figure 4.8 E), nodes connected to glcNAc-1-P are revealed, 
representing the metabolites glcNAc-6-P, UDP-galN/UDP-glcN, glucose and 
glycogen, all of which corroborate previous findings (Coen et al., 2007b). 
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Figure 4.8: Interactive plot views of the first three rounds of I-STOCSY on the 24 h 
post galN dose liver aqueous extract 1H NMR dataset showing associations to (A) 
Round 1, the original driver peak, UDP-galNAc (!1H = 5.52), (C) Round 2, a UDP-
galNAc/UDP-glcNAc peak, (E) Round 3, a GlcNAc-1-P peak. In each case all nodes 
connecting above the selected threshold are coloured and indicated by arrows from 
the driver peak, and $ indicates that the node represents a subset of peaks for that 
given metabolite. (B, D and F) Corresponding spectral data for each of (A, C and E). 
Coloured markers show the resonances corresponding to each node (coloured as for 
A, C or E) and peaks are coloured by the strength of the connection (correlation 
coefficient r, on scale shown). Arrows indicate driver peak. 
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 As well as indicating which peaks are part of, and connected to, any given set, 
the spectral plot view of I-STOCSY also shows the strength and direction of 
correlation of each connected node to the node from which it was picked up (Figure 
4.8 B, D and F). With the exception of glucose and glycogen the metabolites all 
correlate positively with their drivers and thus with the original driver peak UDP-
glcNAc. These metabolites therefore all increase in abundance in 24 h post-dose liver 
samples, fitting in with findings from established methods and the metabolism as 
discussed above. Glucose and glycogen on the other hand, are negatively correlated to 
their driver (glcNAc-1-P). The depletion of hepatic glycogen and glucose has been 
previously shown (Coen et al., 2009), and explained as a direct result of galN-induced 
UDP-glc depletion, one consequence of which is a concurrent inability to maintain 
hepatic glucose levels (Coen et al., 2009; Keppler et al., 1970) 
 Parts A and B, C and D, and E and F of Figure 4.8 represent three views of the 
I-STOCSY iterative plot, with a peak of interest selected from Round 1, 2 and 3 
respectively. In each case selecting a node in the node-to-node plot (parts A, C and E) 
or a peak in the spectral view plot (parts B, D and F) produce the same result; 
highlighting all connecting nodes in the node-to-node view, and their corresponding 
peaks coloured by the strength of connection in the spectral data. Since on the right, 
the markers beneath putatively structurally related peaks (represented by one node on 
the node-to-node plot) are uniformly coloured, this allows the intuitive exploration of 
intra- and inter-metabolite correlations and easy selection of peaks of interest from the 
otherwise complex spectral data. 
The full node connectivity map for I-STOCSY driven from galNAc is shown 
in Figure 4.9. In this figure, metabolites have been highlighted along with the 
direction of their change in concentration relative to that of the original driver UDP-
galNAc. It is worth noting that although initially picked up as a result of overlap with 
UDP-galNAc and UDP-glcNAc resonances, non-overlapped uridine peaks also 
positively correlate to GlcNAc-6-P, and thus uridine remains a valid I-STOCSY 
derived metabolite. All the additional metabolites (in Rounds 4 to 8) are negatively 
correlated to UDP-galNAc, i.e. their levels decrease following galN administration. 
Although uridine levels would be expected to decrease in post-dose samples, the 
increasing levels of this metabolite have been attributed to a compensatory increase in 
synthesis in response to GalN-induced depletion (Coen et al., 2008; Keppler et al., 
1970). The decrease in the hepatic levels of the remaining metabolites can be largely 
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be explained as resulting from the galN induced depletion of hepatic glucose and 
consequently of ATP generation. 
With the exception of glutathione, the majority of metabolites and their 
relative change in abundance on galN treatment have been previously described 
following metabonomic investigation (Coen et al., 2007b; Coen et al., 2009). In terms 
of glutathione and inosine, inosine is closely metabolically related to the previously 
reported metabolite adenosine, and although not previously found from metabonomic 
investigation of galN treatment, a reduction in glutathione levels following galN 
treatment has been experimentally well established in both in vivo and in vitro 
hepatocytes (Mcmillan and Jollow, 1992; Mcmillan and Mcmillan, 2006; Seckin et 
al., 1995). 
 
 
Figure 4.9: Full network of nodes for I-STOCSY on GalN driven from UDP-galNAc 
(over the total eight rounds). Nodes of each known metabolite are highlighted in the 
same colour, and the metabolite names outlined based on their relative correlation to 
the original UDP-galNAc driver peak; red – positively correlated; blue – negatively 
correlated. 
 Thus in a single automated run the I-STOCSY approach can not only 
reproduce previously deduced information on the complex response following 
metabolic perturbation, but also generate new hypotheses even on this well-studied 
model system. In addition, the above demonstration of the I-STOCSY method could 
have been driven from any of the endogenous metabolite peaks in the 1H NMR 
spectral dataset to further expose metabolic connectivities within the data. 
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4.6 Discussion 
The I-STOCSY method represents a semi-automatic, data-driven approach for the 
investigation of inter- and intra-metabolite relationships. This method has been shown 
to recover both previously known and novel metabolic consequences of systemic 
perturbation quickly, effectively, and with minimum user input. The interactive plot 
allows the user to quickly visualise peak associations either by following a series of 
connections node to node, or by selecting peaks of interest directly from the plotted 
spectral data. Since each node represents a highly correlated set of peaks, not only 
does this method present inter-metabolite connectivities clearly, but also it gives an 
idea of putatively structurally related intra-metabolite peaks all linked directly to the 
spectral data. Thus, I-STOCSY represents a comprehensive tool for correlation based 
analysis of 1H NMR datasets, providing improved visualisation and interpretation of 
the key metabolic changes and thus the underlying biology of metabolically 
challenged organisms or individuals. Additionally, the user specification of initial 
driver peak and correlation threshold allows the information presented to be tailored 
to metabolic associations of interest with depth of information given by the set 
correlation cut-off. 
 STOCSY is a well-established method in identification of both structurally 
and non-structurally correlated metabolites related to a peak of interest. Here 
STOCSY analysis is extended and interpretation enhanced since essentially selecting 
a given peak in the interactive I-STOCSY plot is equivalent to running a STOCSY 
analysis from that peak (and viewing all peak correlations with | r | > !. Thus a single 
run of I-STOCSY (depending on the threshold selected) can represent the majority of 
meaningful information contained in multiple STOCSY calculations from all peaks 
recursively correlated to the original user defined driver peak of interest.   
I-STOCSY requires two crucial user defined parameters; firstly, the initial 
driver peak from which the first round of STOCSY should be run, and secondly, a 
threshold value corresponding to the minimum correlation coefficient required to 
define peak to peak connections (!). The initial driver peak exemplified here was 
selected as a major drug metabolite, but in principle any peak could be used. While 
different initial driver peaks will select different connecting peaks dependent on their 
inter-peak correlations, it is worth mentioning that once a peak is selected, for a given 
I-STOCSY threshold its set of peak connections will be identical regardless of the 
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round in which it appears. Therefore, in terms of driver peak selection, for maximum 
information recovery, multiple runs of I-STOCSY should be driven from peaks 
undetected in previous applications of I-STOCSY. 
The I-STOCSY threshold defines the absolute value of correlation coefficient 
that must be exceeded between two peaks before they are defined as connected, and 
as such threshold choice has a significant impact on I-STOCSY results. At high 
thresholds, only a few node-to-node connections will be detected between highly 
correlated peaks; indeed for thresholds approaching | r | > 0.95, in the majority of 
cases only structural correlations will be detected. As the threshold value is reduced 
however, more and more connections will be detected from each driver peak, alluding 
to inter- as well as intra-metabolite relationships. In this example a correlation value 
of | r | > 0.85 was selected, since the resulting plot could be shown in its entirety and 
explained comprehensively. At this threshold, not only were a significant number of 
metabolites as previously identified as affected by galN administration detected, but 
also connections to the previously undetected metabolite glutathione were recovered, 
illustrating the capacity of this method, in a single run, to both reproduce previous 
results and generate new hypotheses. In a practical sense, repeating I-STOCSY with a 
reduced threshold would yield yet more connectivities and thus certainly be useful in 
further analysis.  
 Within I-STOCSY, the condensation of detected peaks into sets where each 
represents a highly correlated putative structurally related group is key in simplifying 
visualisation and thus improving interpretability. In principle, the ideal situation 
would be for all peaks corresponding to a given metabolite to correlate above a certain 
threshold, and thus for each metabolite to be represented by a single node. In practice 
however, the peak overlap and shifting inherent in NMR data mean no one threshold 
is applicable for grouping together structural peaks across all metabolites. The choice 
of r > 0.95 as a threshold for placing two peaks into the same ‘structural’ set is 
therefore a highly conservative estimate derived from an extensive study into the 
behaviour of STOCSY in assigning structural vs. non-structural correlations (Couto 
Alves et al., 2009). Although truly structurally related peaks may well correlate with 
lower coefficients, in the definition of structural sets here, selection of such a high 
threshold is desirable. If the threshold were reduced, although there would be fewer 
nodes in the final interactive plot (each node would represent a greater number of less 
closely related peaks), since even a connection greater than the user set I-STOCSY 
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threshold to a single peak within a node leads to the all the peaks in that node being 
highlighted in the plot, results could be misleading. On the other hand, the grouping 
of very highly correlated peaks provides a distinct advantage in terms of visualisation 
and thus interpretation compared to if a node represented each individual peak. Even 
if grouped peaks are in fact non-structural (i.e. from two different metabolites), their 
correlation profiles to other peaks are inherently extremely similar and thus no 
information is lost. In fact the grouping of multiple metabolites into a single structural 
set can be informative, for example, indicating a strong metabolic relationship, such 
as that between UDP-galNAc and UDP-glcNAc. Multiple structural sets and therefore 
multiple nodes though represent the majority of metabolites, yet all the nodes 
corresponding to a given metabolite are picked up as connected over several I-
STOCSY rounds. It is worth mentioning that although alignment was not required for 
this dataset, if the dataset under study contains a high degree of peak shifting, prior 
peak alignment by appropriate algorithms for example, recursive peak-wise segment 
alignment (RPSA, Veselkov et al., 2009) may well be worthwhile. 
Other methods also utilise a correlation-based approach to group peak indices 
into highly correlated sets. For example, in CLASSY, this is an overlap matrix 
evaluated on the inter-variable correlations thresholded at increasing correlation 
coefficients to identify unambiguous local clusters (Robinette et al., 2009), and in R-
STOCSY a correlation/covariance landscape termed SRV with clusters then grouped 
into super-clusters by virtue of their inter-cluster correlation (Blaise et al., 2010). In 
subsequent steps however, only the most highly correlating member of each local 
cluster (CLASSY) or the mean signal intensity of variables in each super-cluster (R-
STOCSY) is chosen to represent the entire set in the correlation based cluster 
analysis, and thus novel inter-peak correlation information could be lost at this stage. 
In contrast, in I-STOCSY, even after the formation of structural sets, since each newly 
detected peak in each set becomes a driver peak in the next round, there is no loss of 
information even if different peaks are picked up as connecting above the I-STOCSY 
threshold for different members of the same structural set. However, the option to 
include structural clusters or peak-picked variables as an input variable means that if 
the user required to define the sets via another method such as CLASSY (Robinette et 
al., 2009), or to utilise a different method of dimension reduction such as SRV (Blaise 
et al., 2009), then this is easily achieved. 
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Finally, development of the interactive I-STOCSY plot represents a significant 
advantage in visualisation and interpretation over other correlation based methods, 
since intra- and inter-metabolite relationships can be explored simultaneously, both 
through the node-to-node network map and the spectral data itself. Although other 
correlation-based approaches (e.g. CLASSY and R-STOCSY) provide 2D inter-
cluster correlation maps, before the correlations can be interpreted the assignment of 
clusters to specific metabolites is still required, which can be a lengthy process 
whether carried out by hand or through database matching algorithms. This is 
overcome in I-STOCSY through the linking of node-to-node connectivities with 
corresponding spectral data, both of which can be selected to explore correlation 
connectivities. This is not only valuable as an intuitive exploration tool, but also since 
it allows relationships to be easily user-verified. For example, in this dataset, uridine 
is first identified as connecting (with a subset of its peaks) directly to UDP-galNAc 
and UDP-glcNAc, however, inspection of the spectral data reveals this to be as a 
result of peak overlap and therefore not a meaningful connection at this point. 
However, selecting a non-overlapped uridine peak in the spectral view plot reveals all 
connections at this threshold, including a connection to glcNAc-6-P at Round 3. The 
detection of glutathione at Round 4 illustrates the ability of this method to pick up 
novel and meaningful metabolic consequences of treatment, which may be 
overlooked in other broader correlation analyses. Finally, since the spectral data is 
coloured by the strength of correlation to the selected peak or node, the strength and 
direction of associations can be explored easily regardless of the threshold selected. 
Although here applied to an NMR spectroscopic dataset from a toxicological 
study, the I-STOCSY approach is of potential value in any metabonomic dataset. 
While when applied to full datasets of results following a metabolic challenge the 
major affects of treatment will be elucidated, this approach is putatively equally 
valuable in revealing connections within and between metabolites in single treatment 
groups. 
In summary, I-STOCSY represents a significant advance in terms of maximum 
information recovery from complex NMR spectral datasets, providing a 
comprehensive tool for exploring inter- and intra-metabolite relationships and 
elucidating novel mechanistic insight into metabolic perturbations. 
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5 Clustering of 1H NMR metabolic datasets for 
structural assignment 
In metabonomics the assignment of spectral variables to given metabolite structures is 
often key, both traditionally in the assignment of unknown metabolites, and more 
recently in the automated partitioning of putatively structurally related variables into 
groups prior to inter-metabolite global network analysis. In this chapter the 
application of clustering for discrimination between structural and non-structural 
variables is investigated, and its performance is compared to other methods used for 
both assignment and unambiguous clustering as described above. Applied across a 
variety of datasets representing a range of biological conditions, and explored in 
datasets with both different numbers of samples and different numbers of variables, a 
comprehensive investigation of clustering methodologies is presented alongside 
practical considerations for its use. 
5.1 Introduction 
The identification of spectral resonances arising from the same molecule (a key point 
of structural assignment) is frequently an important step in metabonomic data 
analysis. As introduced in previous chapters, in traditional analyses, structural 
assignment and metabolite identification is commonly necessary following the 
detection of important or discriminatory variables by pattern recognition methods. 
Conversely, an increasingly popular approach is the investigation of metabolic 
networks, and to increase efficiency and interpretability, this is typically carried out 
on a reduced set of variables, ideally where each variable corresponds to a separate 
metabolite (Blaise et al., 2010; Robinette et al., 2009; Weckwerth et al., 2004; Zhang 
et al., 2008). The correct assignment of structurally related peaks is thus desirable 
under two distinct conditions; firstly for the identification of compounds in biomarker 
discovery, and secondly in dimension reduction through the grouping of structurally 
related variables prior to extraction of a single measure characteristic of the whole, 
and therefore by which each group can be represented in subsequent analyses. While 
the former circumstance requires only some measure of how closely different 
variables are related, and thus relationships can be somewhat ambiguous (i.e. although 
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variables A and B, and variables A and C appear closely related, variables B and C 
may appear less so), in the latter case, variables must be grouped unequivocally i.e. 
each variable can only be a member of a single putatively structurally related group. 
 One method by which metabolites can be identified is through matching to one 
or more of the several publically available NMR spectral databases such as the 
Biological Magnetic Resonance Data Bank (BMRB, Ulrich et al., 2008) or the 
Human Metabolome Database (HMDB, Wishart et al., 2007). Although these contain 
an increasing number of compounds and therefore are increasingly useful for 
metabolite identification, frequently they either do not contain the molecule of 
interest, are erroneous, or the high degree of spectral overlap and peak shifting in 
NMR datasets precludes accurate matching. Furthermore, to search these databases, a 
list of chemical shift values thought to correspond to each unknown metabolite is 
required. Therefore, although a first port of call for the identification of unknown 
compounds, database searching cannot be directly coupled to metabolite identification 
from the inherently complex 1D NMR biofluids spectra unless putative structurally 
related sets of peaks are first extracted by some other means. 2D NMR techniques 
though provide separation along a second dimension thereby facilitating division of 
individual metabolites, and thus recently, several methods have been developed which 
illustrate the potential of direct metabolite identification from such spectral data 
(Robinette et al., 2008; Xi et al., 2006; Zhang et al., 2009). In such methods, 
following decomposition of the 2D spectra into component 1D spectra (where each 
corresponds to a single compound), for example, by multivariate curve resolution 
analysis (Rey Castellanos and Wist, 2010) or a method developed in the Bruschweiler 
laboratory termed DemixC (Zhang and Bruschweiler, 2007), each component 
characteristic trace is screened against a spectral database for metabolite 
identification. This has been implemented on a publically accessible web server, 
COLMAR (complex mixture analysis by NMR, Robinette et al., 2008; Zhang et al., 
2009). 
 Despite these advances however, owing to the current incomplete nature of 
metabonomic databases and since identification of compounds through database 
matching is unsuitable for 1D NMR spectra, statistical methods such as STOCSY 
(Cloarec et al., 2005a) remain paramount in structural assignment. In such techniques, 
the inherent correlations present in NMR data are exploited to identify highly 
correlated and thus potentially structurally related peaks. For assignment purposes, 
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computing the set of STOCSY correlations across the full number of variables from a 
single peak of interest is quick, and expert interpretation can suggest putative 
structural peaks even if inter-peak correlation values are comparatively low. Recently 
though, from study into information recovery in STOCSY, a correlation threshold of 
0.89 has been suggested, above which correlation peaks can be assigned to the same 
metabolite with high probability (positive predictive value, PPV = 0.9, Couto Alves et 
al., 2009). This threshold has subsequently been used to cluster points (selected 
following dimension reduction by SRV, (Blaise et al., 2009) into putative structural 
sets prior to metabolic network analysis (Blaise et al., 2010). An alternative method is 
employed in CLASSY analysis; termed local clustering, this method does not rely on 
input of a single value, but uses an overlap matrix evaluated on the inter-variable 
correlations thresholded at increasing correlation coefficients to identify unambiguous 
local clusters (Robinette et al., 2009).  
 All of these methods discussed so far though rely on strong correlations 
between peaks of the same metabolite. In NMR datasets however, peak overlap and 
shifting are common, both of which can result in a reduction in the strength of inter-
peak correlation and thus lead to true structural peak connectivities being missed. 
Indeed the threshold of 0.89 for a PPV = 0.9 in the COMET control data used by 
(Couto Alves et al., 2009) picks up less than half of the true structural peaks 
examined, and this low rate can no doubt be attributed to variation between samples 
as a result of chemical shift and peak overlap differences. Additionally, although there 
is not a significant difference in the threshold required to achieve this high PPV 
between datasets, at lower positive predictive value and indeed for any desired true 
positive rate (proportion of correctly assigned structural correlations) there is 
significant variation in the threshold needed across different datasets (Couto Alves et 
al., 2009). 
 An alterative means of structural assignment is that of clustering. Clustering, 
the umbrella term for a range of methods, which separate data into a smaller number 
of constituent groups, is a widely used and well established technique in multivariate 
analysis (as introduced in Section 2.4.3). In NMR indeed applications of clustering 
range from assessing similarity between metabolic profiles of different populations 
(Holmes et al., 2008) to classifying toxicity (Beckonert et al., 2003) or the metabolic 
characteristics of adverse clinical phenotypes (Makinen et al., 2008). Although the 
majority of applications cluster in the sample direction, the clustering of variables has 
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also been applied to metabonomic data, where both hierarchical and K-means 
clustering have been utilised to identify redundant sets of NMR variables with similar 
response profiles (Dumas et al., 2002; Ishihara et al., 2006; Ishihara et al., 2009; 
Robinette et al., 2009). Furthermore, hierarchical clustering applied to gas 
chromatography (GC)-mass spectroscopy (MS) data have been used to group peaks of 
the same metabolite by selecting those clusters in which variables correlate with 
greater than a set correlation threshold and share a similar retention time window 
(Tikunov et al., 2005; Ursem et al., 2008). Finally, a bagging (bootstrap aggregation) 
approach has been implemented with K-means clustering and shown to be effective in 
reducing the influence of noise and thus improving accuracy in the assessment of 
metabolic associations (Hageman et al., 2006). In this method, given the original 
dataset of N samples, m new training sets are generated, each of size N and with 
samples selected randomly and with replacement from the original data. Models are 
fitted (here in the form of cluster analysis) to each of the training sets and results 
obtained by averaging the output across all m resamples. 
Although a variety of clustering approaches have been used in assessing the 
relationships between variables, their relative performances specific to structural 
versus non-structural assignment and when compared to that of threshold-based 
approaches has not been established. Here the methods of hierarchical and K-means 
clustering as alternative means of structural assignment in 1H NMR datasets were 
investigated. In terms of the two conditions under which structural assignment is 
required (introduced at the beginning of this section), while identification of 
unknowns requires only some measure of how closely each variable is related to the 
variable of interest, the automated clustering of variables into putative structurally 
related sets requires ‘hard’ clustering approaches where each variable can only be 
present in one cluster. In terms of STOCSY, the basic method does not result in 
unambiguous clusters (i.e. if variables A and B, and variables A and C are associated, 
this does not mean that variables B and C need be associated), however, with 
selection of an appropriate threshold, variables can be unambiguously grouped so that 
each is present only in a single set. Clustering approaches were therefore compared on 
the one hand directly to basic STOCSY as would be used for assignment purposes, 
and on the other, to threshold-based methods in which unambiguous clusters are 
produced. These included the local clustering method applied as part of CLASSY 
(Robinette et al., 2009), and a method based on STOCSY but analogous to that used 
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in (Blaise et al., 2010) where each of a range of thresholds is used to group variables 
into unambiguous clusters, termed STOCSY clustering. Finally a method based on the 
bagging of K-means or hierarchical clustering or STOCSY results was applied to 
investigate whether this method affords any improvement in performance. 
5.2 Methods 
The overall methodology is outlined in Figure 5.1, each stage of which is described in 
the following sections. 
 
Figure 5.1: Schematic of the assessment of clustering for structural assignment as 
compared to STOCSY based methods. The comparison of structural versus non-
structural classification results obtained from clustering or STOCSY based methods 
(test outcomes) with the actual structural or non-structural condition (as known for the 
peaks corresponding to a pre-selected subset of metabolites) allows calculation of 
performance statistics as described in Figure 2.4 and thus assessment and comparison 
of the performance of different methods. 
5.2.1 Datasets and pre-processing 
For comparative purposes, clustering methodologies were assessed across four NMR 
datasets as previously used to investigate STOCSY based structural assignment in 
Couto Alves et al., 2009. Chosen to represent a variety of physiological and 
pathological conditions, these comprised control, caloric restriction, ammonium 
chloride and hydrazine, the experimental details of which are given in Section 2.5.4.  
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Spectra were reduced to the chemical shift ranges ! 0.2 - 4.5 and ! 6.2 -10.0 
(to exclude TSP, urea and water signals) and probabilistic quotient normalised 
(Dieterle et al., 2006). A typical full resolution NMR spectrum corresponds to tens of 
thousands of variables (here n = 14,726) and many analytical methods utilise this full 
variable set. However, clustering across the entire set of variables is extremely 
computationally intensive, and indeed unnecessary in this context since I am 
interested in identifying putative structural relationships between only the subset of 
variables that correspond to peaks. It has been shown that, in terms of STOCSY at 
least, when peaks are represented by single variables corresponding to peak apexes 
(resonance maximum representation), better discrimination between structural and 
non-structural correlations is provided than when peaks are represented by a range of 
variables spanning whole peak regions (Couto Alves et al., 2009). Thus variables 
were peak-picked from the full complementary set as zero crossings of a smoothed 
spectral derivative (Savitzky-Golay third order polynomial filter (Savizky and Golay, 
1964) with window size 0.005 ppm) on the mean spectrum for each dataset (as in 
Chapter 4). This results in an approximate 30-fold reduction in the number of 
variables, with each dataset represented by around 500 peak-picked variables. 
5.2.2 Data and performance assessment setup 
For assessment of the relative performance of each clustering method in structural 
versus non-structural assignments a strategy as described in Couto Alves et al., 2009 
was applied. For each dataset the peak-picked variables were divided into two subsets, 
one corresponding to target metabolites of known structural relationships and one 
containing the remaining complementary set of variables (where none was structurally 
related to peaks in the first set). Initially the target metabolites were chosen (again for 
comparative purposes) as in Couto Alves et al., 2009 as corresponding to a set of 52 
resonance apexes from nine metabolites selected to be representative of the diversity 
exhibited in NMR biofluid spectra (Table 5.1). However, on further investigation the 
two peaks assigned as the metabolite creatine were found in fact to correspond to 
creatinine and betaine (! = 3.045 and ! = 3.903 respectively), thus these peaks were 
removed from the target set, which consequently contained 50 apexes from eight 
metabolites. For consistency across datasets a total of 250 variables were selected 
from each, 50 from the target set and the remainder as the highest intensity peaks 
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picked from the complementary set. Target and complementary variables for the 
control dataset are shown in Figure 5.2 A. 
Since the structural relationships between variables in the target set are known, 
and the complementary variables are known not to correspond to any of the target 
metabolites, true positive and true negative relationships between all variables in the 
full set can be defined (Figure 5.2 B). Subsequently, this true relationship can be 
compared with the outcome following the clustering of variables into putative 
structural sets, and the number of true and false positives and related performance 
statistics calculated. 
 
Metabolite (common abbreviation) Standard ! 1H Multiplicity 
Hippurate 3.97 d 
 7.55 m 
 7.64 m 
 7.84 m 
Phenylacetylglycine (PAG) 3.68 s 
 3.76 m 
 7.37 m 
 7.42 m 
Citrate 2.54 d 
 2.66 d 
2-Oxoglutarate (2-OG) 2.45 t 
 3.01 t 
Creatinine 3.05 s 
 4.06 s 
Creatine 3.04* (3.05 - creatinine) s 
 3.93* (3.90 - betaine) s 
Lactate 1.33 d 
 4.11 q 
N-methylnicotinic acid (NMNA) 4.44 s 
 8.84 t 
 9.12 s 
N-methylnicotinamide (NMND) 4.48 s 
 8.18 m 
 8.90 d 
 8.96 d 
 9.28 s 
Table 5.1: Target metabolites for structural assignments adapted from Couto Alves et 
al., 2009. Standard ! 1H denotes the central chemical shift of each resonance, with 
associated multiplicity: s – singlet, d – doublet, t – triplet, q – quartet, m – multiplet. 
The creatine resonances (marked with a *) were wrongly assigned in Couto Alves et 
al., 2009 (correct assignments shown in parentheses) hence this metabolite was 
excluded from the target set in this analysis. 
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Figure 5.2: Target and complementary variables and set up for performance 
assessment. (A) Mean control data 1H NMR spectrum highlighting target (red stars) 
and complementary (blue stars) variables with target variables assignments 
individually coloured and annotated. (B) Target (upper left quadrant) and 
complementary (lower right quadrant) variable distribution for structural versus non-
structural assignment (not to scale). The lower triangle of each target variable is 
coloured corresponding to peak assignments as in (A), for example the peaks 
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corresponding to hippurate are indicated in black in part A, and a black triangle in part 
B. Classification results are indicated by the red, yellow and blue coloured sections in 
part B. Following classification by clustering or STOCSY, any points in a red region 
correspond to true positive structural correlations, and any falling in the yellow region 
to false positive results. Putative assignments between complementary variables (blue 
region) are excluded from analysis since the structural/non-structural relationship 
between these variables is not defined. Key: PAG, phenylacetylglycine; 2-OG, 2-
oxogluterate; NMNA, N-methylnicotinic acid; NMND, N- methylnicotinamide. 
5.2.3 Clustering and STOCSY for structural assignment 
As introduced in Section 2.4.3, seven steps that make up a typical cluster analysis 
have been defined (Everitt et al., 2001; Milligan, 1996): objects to cluster; features to 
be used; feature standardisation; proximity measure; clustering method; number of 
clusters and replication, testing and interpretation. In the following section these are 
discussed only in the context of clustering NMR variables for structural versus non-
structural assignment (as related to Figure 5.1), and the background section of Chapter 
2 (Section 2.4.3) should be referred to for a general introduction. In clustering, the 
majority of applications in the literature aim to cluster objects, individuals or samples 
based on a set of features or variables. However, here the aim is to investigate the 
clustering of NMR variables based on similarity between samples, thus, to avoid 
confusion, in terms of clustering, the terms object and feature will be used throughout, 
while the terms variable and sample will always refer to NMR variables and samples. 
 
Objects (NMR variables) and features (NMR samples) to be used: 
For each dataset, the objects to cluster comprised the 250 peak-picked target and 
complementary variables as described above (Section 5.2.2). In terms of feature 
selection, since, with the exception of outliers, all NMR samples are potentially 
valuable in determining clusters, all samples (excluding outliers) for each dataset were 
used in the analysis.  
 
Feature standardisation and proximity measure: 
Data standardisation, i.e. the normalisation and scaling of data such that each feature 
has zero mean and unit variance, is typically applied in cases where features are 
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measured in units that are quite different and thus, depending on the distance measure 
used, features with large values and variances could otherwise dominate in 
determining the similarity between objects. In relevance to NMR data when clustering 
variables however, it would be unusual for a sample (feature) to have particularly high 
values and variance across all variables, and indeed if this were the case it would 
likely be removed as an outlier. Additionally, since all the features are measured in 
the same way, and if necessary normalised specifically to minimise inter-sample 
concentration variability, standardisation was not deemed appropriate for this 
application.  
The most commonly used distance measure in clustering is that of Euclidean 
distance, where proximity is based on differences between the values of objects. Since 
in NMR, different peaks from the same metabolite do not necessarily share similar 
intensities, the Euclidean distance, and indeed any distance measure where proximity 
is based on the comparative size of objects, is not appropriate. In contrast, correlation 
distances record similarities in the shape of profiles rather than the absolute size. 
Although the use of correlation coefficients has been contentious in the clustering of 
samples (Everitt et al., 2001), correlation analysis, particularly utilising Pearson 
correlation distances, is well established in methods exploring the relationship 
between biological variables, be they metabolites, genes or proteins (Arkin et al., 
1997; Clish et al., 2004; Kose et al., 2001; Steuer et al., 2003). This is owing to the 
fact that correlation is ultimately suitable for situations where all features have been 
measured on the same scale, and the actual values are unimportant except to define 
each object’s relative profile. This is absolutely the case in the clustering of NMR 
variables, since as already mentioned, peak intensity is not conserved across peaks 
from the same metabolite, but (putting aside overlap and peak shifting affects) the 
ratio between different samples at each peak of the same metabolite is. Thus Pearson 
correlation has been overwhelmingly the proximity measure of choice in previously 
published variable clustering methods (Dumas et al., 2002; Hageman et al., 2006; 
Robinette et al., 2009; Tikunov et al., 2005; Ursem et al., 2008). In this study Pearson 
correlation was computed, alongside Spearman’s rank correlation (in the event that a 
somewhat non-linear relationship existed between variables) and Euclidean distance 
(although for this measure good performance was not expected).  
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Clustering and STOCSY methods: 
As described in the introduction, although STOCSY methods dominate in the putative 
structural/non-structural assignment of peaks, various hierarchical and K-means 
clustering methods have also been applied with the same aim, or at least in the 
clustering of variables with a similar metabonomic response (Dumas et al., 2002; 
Hageman et al., 2006; Ishihara et al., 2006; Ishihara et al., 2009; Tikunov et al., 2005; 
Ursem et al., 2008). Therefore both hierarchical and K-means methods were 
compared to the STOCSY approach. The performance of both STOCSY and 
clustering methods were compared by computing performance statistics across all 
correlation thresholds (STOCSY) and number of clusters (clustering) as described in 
the following section. 
 While the basic STOCSY approach is suitable for highlighting the degree to 
which variables correlate, owing to peak overlap and peak shifting effects, for any 
given threshold, unambiguous clusters of variables are not produced. Thus for the 
comparison of clustering with STOCSY for the automated clustering of variables into 
distinct putatively structurally related sets, a modification of the STOCSY method 
was developed. In this STOCSY clustering method, for any given correlation 
threshold, STOCSY is driven from the first variable and all variables correlating with 
a correlation coefficient greater than the set threshold are grouped. This set of 
variables is then removed from the full variable set and the process repeated until all 
the variables are grouped in sets with similar variables of similarity as defined by the 
cut-off value (Algorithm 5.1). This is distinct from the local clustering method 
described by Robinette et al., 2009 since the clusters formed are dependent on the 
correlation threshold used to define them. 
Finally in the case of hierarchical clustering, in addition to the selection of an 
appropriate proximity measure, the formation of a new cluster, or joining of two 
existing clusters is dependent on a measure of distance (linkage) between potential 
elements to be joined. Selection of an appropriate linkage function is largely based on 
trial and error, and as such a selection of measures appropriate for non-Euclidean 
distances (average, complete, single and weighted) were investigated. 
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Algorithm 5.1: Unambiguous clustering of variables using STOCSY clustering 
Let P denote the set of peak-picked variables. 
1. Run STOCSY on the spectral data driven from the first variable in P. 
2. Use the correlation coefficient (r) values returned to identify the set (S) of 
indices (i) corresponding to those spectral points with intensities that 
correlate to those of the driver peak with r > ! (defined correlation threshold) 
! 
S = i : ri > "{ } 
3. Save S as a putative structural set. 
4. Delete S from the variable set P 
! 
P "P # S  
5. Repeat steps 1 to 4 until no variables remain in P (i.e. all variables have been 
assigned to a putative structural set).  
 
 
All methods tested are summarised in Table 5.2. 
 
Proximity measure Method Linkage distance  
Euclidean 
Correlation – Pearson 
Correlation – Spearman 
Hierarchical Complete (farthest), single 
(nearest), average 
(UPGMA), weighted 
(WPGMA) 
Euclidean 
Correlation – Pearson 
K-means NA 
Pearson 
Spearman 
STOCSY NA 
 
Pearson STOCSY clustering NA 
Pearson CLASSY local clustering 
(Robinette et al., 2009) 
NA 
Table 5.2: Tested combinations of parameters and clustering or STOCSY based 
methods for structural versus non-structural assignment. 
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5.2.4 Performance statistics  
Performance in assigning inter-variable relationships as structural or non-structural 
was assessed through calculation of the sensitivity, specificity, positive predictive 
value (PPV) and AUC (area under ROC curve) statistics as described in Section 2.4.4. 
As introduced in this section, the PPV is defined as the proportion of positive results 
that are actually positive (Equation 5.1): 
 
! 
PPV = #TP#TP+#FP  
(5.1) 
where #TP and #FP are the number of correctly (true positive) and incorrectly (false 
positive) assigned structural elements respectively.  
One problem with the PPV however, is that it is, by definition, highly 
dependent on the prevalence of the condition under test (where prevalence = number 
of real positives / total population size) (Altman and Bland, 1994b). If, for example, 
the prevalence is 100% (i.e. there can be no false positives) then the PPV will also be 
100%, conversely though, at low prevalence (i.e. at a low numbers of positives in the 
whole population) even a very small error rate applied over a large population will 
produce a non-negligible number of false positives and thus deflate the PPV 
significantly. In this application the prevalence is extremely low (156/11225 or ~1.4 
%) and therefore even if the number of true positive values is similar between datasets 
any slight differences in the number of false positives will have a significant impact 
on the PPV. Thus, in addition to the PPV, the distance to optimum (DTO), a 
performance measure giving equal weighting to the TPR and FPR was also computed, 
as defined below (Equation 5.2). A range of DTO values are illustrated in Figure 5.3; 
the best possible method would have TPR and FPR values equal to one and zero 
respectively (and a point at the top left corner in the plot), for non-optimal methods 
the DTO value obtained could correspond to a range of possible TPR/FPR 
combinations which, when all possible combinations are plotted, form an arc about a 
centre of TPR = 1 and FPR = 0. 
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! 
DTO = 1"TPR( )2 + FPR2( )
1/ 2
 (5.2) 
where TPR (true positive rate) and FPR (false positive rate) are the proportions of 
positive instances among all positive or all negative results respectively, as defined in 
Section 2.4.4. 
 
 
Figure 5.3: Illustration of distance to optimum as a measure of method performance. 
Where TPR – true positive rate, and FPR – false positive rate. Any point along the 
blue, green, red or cyan lines represents a distance to optimum value of 0.1, 0.2, 0.5 
and 0.9 respectively. 
 Therefore through computation and comparison of TPR, FPR, PPV and 
distance-to-optimum results a more complete picture of method performance can be 
determined. 
5.2.5 Replication, testing and interpretation 
For each dataset a bootstrap analysis was employed to compare the performance of 
different methods. For each of 1000 bootstrap samples N samples were selected with 
replacement from the full sample set (N), clustering was performed and the resulting 
performance statistics calculated. Additionally the impact of sample size and number 
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of variables was investigated in the control dataset. For sample size a similar 
bootstrap analysis was performed in which, for each bootstrap sample, a total of S 
samples (S % {10, 20, 30, 40, 50, 100, 1050}) were selected with replacement from 
the full sample set, with the 250 variables as before. For investigation of the impact of 
number of variables a total of V variables (V % {150, 250, 350, 450, 550}) were 
selected, in each case 50 of which comprised the target metabolite variables and the 
remainder randomly sampled from the complementary peak picked set (n = 507). 
However, in the case of assessing differences in performance for different numbers of 
variables bootstrap resampling could not be used. This is because when sampling with 
replacement, any variables present multiple times in the set will obviously be more 
tightly clustered than non-identical variables. Thus the presence of identical variables 
skews the clustering results; since non-identical variables will be partitioned into 
separate clusters at a lower number of clusters than would be the case were identical 
variables not present. This effect gets more pronounced at higher numbers of 
variables (V) since a higher proportion of variables are selected from the limited 
complementary variable set multiple times. Therefore for the assessment of variable 
performance variables were sampled without replacement. In all cases 95% 
confidence intervals of each performance statistic were calculated and significance 
assessed based on the overlap of the resulting intervals for each condition being 
investigated.  
5.2.6 Impact of bagging 
As described in the introduction, bagging has been shown to improve the results of 
the K-means clustering of metabolites (Hageman et al., 2006). Therefore a bagging 
technique was also implemented for STOCSY, and hierarchical and K-means 
clustering methods. For preliminary investigation Pearson correlation distance was 
selected for both clustering methods and complete linkage for hierarchical clustering 
(optimal methods from non bagged results). The first step in bagging involves 
creating 1000 bootstrap samples, and for each, selecting N samples with replacement 
from the full sample set (of N samples). Subsequently for each resampling, cluster or 
STOCSY analysis was performed with the number of clusters or STOCSY correlation 
threshold selected as that which gave a false positive rate closest to 0.01 when the 
selected method was run on the full dataset. At this point the clustering or STOCSY 
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results were collected and inter-variable clustering recorded. Once completed for all 
1000 bootstrap samples, a final inter-variable clustering frequency matrix was 
generated giving the frequency of how often each variable was clustered with every 
other. Finally, the frequency matrix itself was clustered, and performance statistics 
calculated for this bagged result. Both K-means and hierarchical clustering were 
applied to cluster the final frequency matrix resulting from each initial method 
(STOCSY, hierarchical or K-means bagging). For clustering the frequency matrix, 
owing to the nature of the data, the Euclidean distance was selected as the proximity 
measure but as before, a variety of linkage measures for hierarchical clustering were 
applied and that chosen which resulted in the optimal performance across all numbers 
of possible clusters. 
5.3 Results 
5.3.1 Comparison of clustering methods for structural versus non-
structural assignment 
A variety of proximity measures, clustering methods and linkage distances (for 
hierarchical clustering) were investigated in terms of structural versus non-structural 
assignment, the PPV performance of which are shown in Figure 5.4. Across all 
datasets and for both K-means and hierarchical clustering methods, results generated 
from Euclidean proximity measures (square markers) performed poorly. In contrast, 
clustering based on both Pearson and Spearman correlation distances generally gave 
higher PPV results, with Pearson correlation typically out performing Spearman 
correlation, particularly at lower number of clusters. Similarly at low cluster numbers 
for hierarchical methods, results generated using complete linkage (green) typically 
gave the highest PPV levels, while in contrast, results generated with single linkage 
(red) yielded the lowest results, with levels approaching or below those generated for 
Euclidean distance methods.  
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Figure 5.4: Positive predictive value (PPV) performance at each number of clusters for each of the four datasets tested (A) controls, (B) 
caloric restriction, (C) ammonium chloride and (D) hydrazine. For each dataset, the proximity measure is indicated by marker type: ! – 
Euclidean, " – Pearson correlation, and ! – Spearman correlation; K-means clustering algorithm results are coloured mustard, and 
hierarchical clustering results by linkage method where: blue – average, green – complete, red – single and cyan – weighted. While for 
hierarchical clustering PPV increases monotonically with the number of clusters, for K-means PPV is highly variable, even for adjacent 
numbers of clusters. 
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In terms of the clustering algorithm itself, K-means with Pearson distance exhibited 
high PPV values, indeed some of the highest across all datasets at low cluster 
numbers. However, in contrast to hierarchical methods, for K-means clustering, PPV 
does not increase monotonically with the number of clusters, indeed, significant 
variation in performance is seen even between adjacent numbers of clusters. 
Additionally massive variability in results is exhibited when K-means clustering is 
repeated multiple times on the identical dataset (Figure 5.5). 
 
 
Figure 5.5: Mean (continuous line) and 95 % upper and lower confidence intervals 
(dashed lines) for PPV results at different number of clusters for K-means clustering 
using Pearson correlation distance on identical sample and variable subsets of the 
control – blue, caloric restriction – green, ammonium chloride – red and hydrazine – 
cyan datasets. 
Across all datasets one of the most striking observations is the poor 
performance of hierarchical clustering using single linkage methods. Although, 
particularly in the control dataset, performance for single linkage correlation methods 
does improve at higher number of clusters, at low number of clusters performance is 
significantly worse than the other linkage methods (Figure 5.4). Dendrograms 
obtained for each linkage method for hierarchical clustering on the control dataset 
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using the Pearson correlation proximity measure are shown in Figure 5.6, and can be 
seen to be quite different in shape (dendrograms for other datasets showed similar 
topology and thus are not shown). While the dendrogram produced by single linkage 
shows no large changes in level (i.e. few highly separated clusters), and thus implies 
that the data contains no group structure (Everitt, 1980), the remaining dendrograms 
clearly show larger changes in level and thus the presence of more clearly defined 
clusters.  
 
 
Figure 5.6: Dendrograms produced by applying (A) average, (B) complete, (C) single 
and (D) weighted linkage to the control dataset clustered using hierarchical clustering 
of Pearson correlation distances. 
The fact that, in general, the performance of single linkage improves at higher 
cluster numbers implies that the more closely related the variables or clusters, the 
better single linkage performs in grouping truly structural variables. 
 In contrast to analysing performance as related to the number of clusters, 
clustering methods can also be compared through ROC plot analysis and computation 
of the associated AUC statistic (Figure 5.7, Table 5.3). While conventionally the AUC 
statistic is computed over the full TPR/FPR range, since here we are most interested 
in performance at high specificity, the partial AUC statistic was also calculated for 
each method over FPR < 10 %. Again both the ROC plot and AUC values illustrate 
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the poor performance of Euclidean distance across all methods (although less obvious 
in the hydrazine dataset) and single linkage in hierarchical clustering. In terms of K-
means clustering, the high variability between results for different numbers of clusters 
results in depressed AUC statistics across all datasets.  
 
 
Figure 5.7: ROC plots, true positive rate (TPR) versus false positive rate (FPR), for 
method performance assessment for each of the four datasets tested (A) controls, (B) 
caloric restriction, (C) ammonium chloride and (D) hydrazine. For each dataset, the 
proximity measure is indicated by marker type: ! – Euclidean, " – Pearson 
correlation, and ! – Spearman correlation. K-means clustering algorithm results are 
coloured mustard, and hierarchical clustering results by linkage method: blue – 
average, green – complete, red – single and cyan – weighted. Generally, hierarchical 
clustering with Pearson correlation performs the best, while methods utilising 
Euclidean distance perform poorly. 
 108 
 Controls  Caloric restriction  Ammonium chloride  Hydrazine 
Method AUC Partial AUC  AUC Partial AUC  AUC Partial AUC  AUC Partial AUC 
            
STOCSY 0.9809 0.9167  0.9739 0.8775  0.9548 0.8283  0.8047 0.4764 
            
Hierarchical Euclidean average 0.6425 0.2935  0.6809 0.3267  0.6107 0.2663  0.7352 0.3624 
Hierarchical Euclidean complete 0.6578 0.3233  0.6899 0.3279  0.6046 0.3052  0.7213 0.3775 
Hierarchical Euclidean single 0.5939 0.2526  0.6182 0.2545  0.5981 0.2360  0.6396 0.3167 
Hierarchical Euclidean weighted 0.6404 0.3148  0.6789 0.3106  0.6141 0.2917  0.7343 0.3614 
            
Hierarchical Pearson average 0.9875 0.9187  0.9361 0.8774  0.9601 0.8520  0.7633 0.4664 
Hierarchical Pearson complete 0.9925 0.9388  0.9148 0.8749  0.9548 0.8833  0.8390 0.5719 
Hierarchical Pearson single 0.9655 0.8935  0.9280 0.7915  0.8897 0.6674  0.6843 0.3292 
Hierarchical Pearson weighted 0.9919 0.9203  0.9315 0.8874  0.8986 0.7861  0.7859 0.4682 
            
Hierarchical Spearman average 0.9988* 0.9863  0.9196 0.8136  0.9113 0.7691  0.7807 0.4371 
Hierarchical Spearman complete 0.9595 0.9277  0.9338 0.7998  0.8855 0.7174  0.7598 0.4558 
Hierarchical Spearman single 0.9666 0.8963  0.8859 0.7299  0.8773 0.7076  0.6545 0.3160 
Hierarchical Spearman weighted 0.9956 0.9620  0.9290 0.8110  0.8960 0.7390  0.7435 0.4872 
            
K-means Euclidean 0.6903 0.3708  0.7120 0.3830  0.6402 0.3368  0.7279 0.3756 
K-means Pearson 0.9521 0.7386  0.8699 0.8768  0.8866 0.8152  0.8204 0.4592 
Table 5.3: Full and partial (false positive rate, FPR < 0.1) AUC statistics for the STOCSY and clustering methods investigated across the 
four datasets. Cells marked with * have values significantly different from that of the STOCSY derived statistic (significance assessed by 
95% confidence intervals). With the exception of hierarchical clustering with Spearman distance and average linkage, no clustering 
protocol is significantly better than STOCSY at this significance level. 
 109 
Although in terms of AUC statistics no one method is statistically significantly 
better than any other, statistics across the datasets (and especially for the partial AUC 
results) are typically the highest for Pearson correlation proximity measure and 
complete linkage distance. Therefore, hierarchical clustering using Pearson 
correlation distances and complete linkage was selected as the optimum clustering 
method for the application of structural versus non-structural assignment, and all 
subsequent analysis was performed utilising this specific clustering routine.  
5.3.2 Clustering for structural assignment: comparison with 
STOCSY 
With the exception of the caloric restriction dataset, the AUC statistic values for 
hierarchical clustering with correlation proximity measure and complete linkage 
distance were found to typically exceed those of STOCSY, particularly at low false 
positive rates (Figure 5.8 Table 5.3). However, this increased performance was not 
statistically significant (by comparison of 95% confidence intervals on the AUC 
statistics). Despite this, similar to STOCSY, the high AUC values achieved across all 
datasets demonstrate a similarly high structural versus non-structural discriminatory 
power. 
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Figure 5.8: ROC plots, true positive rate (TPR) versus false positive rate (FPR), for 
performance comparison of STOCSY (black curve) and clustering (hierarchical, 
Pearson correlation proximity, complete linkage – green curve) for each of the four 
datasets tested (A) controls, (B) caloric restriction, (C) ammonium chloride and (D) 
hydrazine. There is no obvious improvement in structural versus non-structural 
assignment with this optimal method when compared to the basic STOCSY method. 
5.3.3 Clustering for the automated grouping of structural variables 
As well as comparing clustering performance results to STOCSY, results were also 
compared to methods that automatically group variables into unambiguous, putatively 
structural sets. These included the STOCSY clustering method, (similar to that used in 
Blaise et al., 2010 but using an imputed rather than set correlation threshold) and the 
method of local clustering utilised by Robinette et al., 2009 as part of CLASSY. Since 
for the STOCSY clustering method (as with STOCSY itself) a range of correlation 
thresholds can be imputed and clusters formed and statistics calculated for each, 
overall performance statistics were calculated over the full range of possible 
thresholds as before. Here, hierarchical clustering was found to perform statistically 
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significantly better than STOCSY clustering across most true positive rates (Figure 
5.9) and AUC statistics (Table 5.4) for all datasets. In contrast, since the local 
clustering method of Robinette et al., 2009 is threshold independent, and thus one set 
of performance statistics is generated for each dataset, performance to clustering was 
compared by selecting, for each dataset, that number of clusters for hierarchical 
clustering which produced an identical specificity to that found with local clustering. 
The local clustering method is very stringent, with high specificity across all datasets 
(Figure 5.9) and generally performance of clustering was not found to be significantly 
different at these low false positive rates (Table 5.5). The control data proved an 
exception to this, with (for the same specificity) a significantly higher TPR and 
significantly lower distance to optimum value that that obtained by local clustering, 
both indications of improved method performance. 
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Figure 5.9: ROC plots, true positive rate (TPR) versus false positive rate (FPR), for 
performance comparison of STOCSY clustering (black curve), clustering 
(hierarchical, Pearson correlation proximity, complete linkage – green curve) and the 
result of local clustering as described by Robinette et al., 2009 (red star) for each of 
the four datasets tested (A) controls, (B) caloric restriction, (C) ammonium chloride 
and (D) hydrazine. Here it can be seen that in general, clustering provides a distinct 
improvement in the partitioning of variables into structural sets when compared to 
STOCSY unambiguous clustering. 
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 Controls  Caloric restriction  Ammonium 
chloride 
 Hydrazine 
Method AUC* Partial 
AUC* 
 AUC* Partial 
AUC 
 AUC* Partial 
AUC* 
 AUC* Partial 
AUC* 
            
Clustering (Pearson, hierarchical, complete linkage) 0.9925 0.9388  0.9148 0.8749  0.9548 0.8833  0.8390 0.5719 
STOCSY clustering 0.8778 0.8625  0.8543 0.8225  0.8554 0.7391  0.7430 0.4053 
Table 5.4: AUC statistics across the four datasets comparing performance with hierarchical clustering to that of STOCSY clustering. 
With the exception of the partial AUC for the caloric restriction dataset, the values for clustering are statistically significantly higher (by 
comparison of 95% confidence intervals) than those for STOCSY clustering across all datasets tested (marked with *). 
 Sensitivity (TPR)  Specificity (1-FPR)  Positive predictive value  Distance to optimum 
Dataset 
Local 
clustering 
Clustering  Local 
clustering 
Clustering  Local 
clustering 
Clustering  Local 
clustering 
Clustering 
            
Control* 0.5064 0.6731  1 1  1 1  0.4936 0.3269 
Caloric restriction 0.6218 0.6154  0.9998 0.9998  0.9798 0.9796  0.3782 0.3846 
Ammonium chloride 0.5513 0.3910  0.9993 0.9993  0.9149 0.8841  0.4487 0.6090 
Hydrazine 0.3462 0.3526  0.9986 0.9986  0.7826 0.7857  0.6538 0.6474 
Table 5.5: Performance statistics across the four datasets for structural assignment using CLASSY local clustering and hierarchical 
clustering methods. With the exception of specificity (by which methods were compared) and PPV (equal to one in both cases), both TPR 
and distance to optimum were found to be statistically different (non-overlapping 95 % confidence intervals) between the two methods in 
the control dataset (marked with *). No other datasets were found to have statistically different performance values between the two 
methods.
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In summary, although hierarchical clustering did not perform statistically any 
differently to local clustering at the highly stringent specificities afforded by this 
method, it was shown to outperform STOCSY clustering across the complete 
specificity range.  
5.3.4 Selection of an appropriate number of clusters 
Since the clusters formed with hierarchical clustering are dependent on prior 
specification of the number of clusters into which the data should be partitioned, the 
practicality of using clustering for the formation of structurally related sets depends 
on two factors; firstly, whether there is an optimal number of clusters for the recovery 
of structural associations; and secondly, whether this can be generalised across 
datasets. In Figure 5.10 the performance in recovery of structural versus non-
structural associations for clustering is compared across different numbers of input 
clusters for the four datasets studied. Across all datasets, the specificity is strikingly 
similar, low at low numbers of clusters, but increasing rapidly to exceed 90 % when 
the number of clusters, K, is greater than around 10. Excluding the results for 
hydrazine for the moment, for the remaining datasets the true positive rates are also 
similar across different number of clusters. Although these similar specificity and 
sensitivity performance rates are reflected in comparable positive predictive values for 
the control and caloric restriction datasets, by comparison, the ammonium chloride 
PPV is markedly reduced at a moderate number of clusters. As introduced in Section 
5.2.2, this can be attributed to the inherent sensitivity of the PPV measure to small (in 
terms of rate), but numerically significant (because applied across a large population) 
differences in the FPR (1 – specificity) and thus the number of false positive 
classifications between datasets. In contrast, the distance to optimum measure is less 
sensitive to these changes, since it depends explicitly on rates rather than absolute 
numbers, and thus more comparable across these three datasets. In terms of hydrazine, 
even though the specificity is comparable to that of the other datasets, the TPR 
(sensitivity) across all number of clusters is significantly lower. However, owing to 
the relatively small true positive population compared to that of the true negative, and 
since the FPR for this dataset is comparatively low, this massive difference in TPR 
when compared to the other datasets is not strongly reflected in the positive predictive 
values, which in fact for the majority of K values exceed those of the ammonium 
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chloride dataset. Again, the distance to optimum values, (significantly greater than 
those for the other datasets) better reflect this comparatively low TPR.  
 
 
Figure 5.10: Sensitivity, specificity, positive predictive value (PPV) and distance to 
optimum (DTO) versus number of clusters for each of the four datasets; ! – control, 
" – caloric restriction, ! – ammonium chloride, and # – hydrazine. Although the 
PPV varies significantly between the datasets, specificity is similar across all datasets 
and numbers of clusters. With the exception of the hydrazine dataset, values for both 
sensitivity and DTO are relatively consistent across different numbers of clusters 
between the datasets. 
 The number of clusters required to attain key levels of each reported 
performance statistic for each dataset are given in Table 5.6. As judged by 
overlapping 95% confidence intervals, the number of clusters required to obtain a 
sensitivity = 1, specificity = 0.1 or 0.9 or PPV = 0.1 were not significantly different 
across all datasets. Particularly important perhaps is those results for specificity = 0.9, 
which indicates that for all the datasets tested, the FPR will be less than 10% for any 
number of clusters, K > 10. Since performance for the hydrazine dataset is unusual, it 
is perhaps also informative to compare significance across datasets with hydrazine 
results excluded. In this case, although the number of clusters to obtain key PPV 
levels vary significantly between datasets, the number of clusters required to achieve 
all distance to optimum values, and sensitivity = 0.1 and 0.5 are not significantly 
different. Furthermore, if the mean number of clusters for each distance to optimum 
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value of interest are computed across the datasets (still excluding hydrazine) and the 
corresponding sensitivity and specificity values obtained for each dataset at these 
values of K compared, the resulting TPR and FPR values are not statistically different 
(Table 5.7), and thus these can be used as a guide for structural assignment 
performance with the selected number of clusters. Here, as well as a range of distance 
to optimum values, that number of clusters yielding the minimum distance to 
optimum is also determined. By definition, this minimum value provides one measure 
of a potentially suitable number of clusters for the optimal recovery of structurally 
associated variables. Finally, even when the hydrazine dataset is clustered with these 
specified values of K, although the sensitivity is significantly lower than for the other 
datasets, the specificity is not significantly different between the datasets, thus 
although some true positive associations may be missed, importantly the number of 
false positives (or the chance of type I error, i.e. the chance of incorrectly classifying 
non-structural associations as structural) is not significantly increased. 
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 Sensitivity  Specificity  Positive predictive value  Distance to optimum 
Dataset 0.1* 0.5* 0.9 1†  0.1† 0.9† 1  0.1† 0.5 0.9 1  0.1* 0.5* 0.9* 1* Min* 
                    
Controls 234 178 49 1  1 9 142  9 27 65 142  49 177 234 250 19 
Caloric restriction 242 181 2 1  1 10 201  9 34 79 201  59 181 242 250 42 
Ammonium chloride 234 173 32 1  1 11 192  10 70 191 192  35 173 234 250 31 
Hydrazine 182 29 2 1  1 9 242  13 50 108 190  -  29 182 242 4 
                    
Mean 223 140 21 1  1 10 194  10 45 111 181  48 140 223 248 24 
Mean excluding hydrazine 237 177 28 1  1 10 178  9 44 112 178  48 177 237 250 31 
Table 5.6: Number of clusters (for hierarchical clustering with Pearson correlation proximity and complete linkage) required to attain 
specified performance statistics levels across the four datasets. Columns marked with a † have values not statistically different (by 95% 
confidence intervals) across all datasets and those marked with a * have values not statistically different across the datasets when 
hydrazine values are excluded. Empty cells indicate corresponding statistics were not obtained for at any number of clusters. Although 
there is significant difference in the number of clusters required for different positive predictive values, the number of clusters for all 
distance to optimum values tested is not statistically significantly different between datasets when hydrazine is excluded.  
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 Minimum DTO; K = 31  DTO = 0.1; K = 48  DTO = 0.3; K = 113  DTO = 0.5; K = 177 
Dataset TPR* FPR†  TPR* FPR†  TPR* FPR†  TPR* FPR† 
            
Controls 0.9231 0.0097  0.9231 0.0049  0.7949 0.0003  0.5192 0.0000 
Caloric restriction 0.8782 0.0151  0.8782 0.0054  0.7051 0.0005  0.5385 0.0001 
Ammonium chloride 0.9231 0.0260  0.7949 0.0135  0.6987 0.0042  0.5449 0.0013 
Hydrazine 0.5064 0.0189  0.4744 0.0112  0.3397 0.0005  0.1346 0.0001 
            
Mean 0.8077 0.0174  0.7676 0.0087  0.6346 0.0014  0.4343 0.0004 
Mean excluding hydrazine 0.9081 0.0169  0.8654 0.0079  0.7329 0.0017  0.5342 0.0005 
Table 5.7: TPR (sensitivity) and FPR (1-specificity) achieved for different distance to optimum (DTO) values (with number of clusters, 
K, determined from mean excluding hydrazine values taken from Table 5.6). Similarly, columns marked with a † have values not 
statistically significantly different across all datasets and those marked with a * have values not statistically significantly different across 
the datasets when hydrazine values are excluded. The relative consistency of the specificities and sensitivities achieved with these 
selected numbers of clusters is important, and indicates that clustering for the partitioning of variables into structurally related sets is 
sufficiently stable to be usefully applied to other datasets. 
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5.3.5 Impact of sample size and number of variables on clustering 
performance 
The effect of sample size (S) and number of variables (V) on the sensitivity and 
specificity obtained for structural assignment with hierarchical clustering on the 
control dataset is shown in Figure 5.11. In terms of sample size, the specificity for 
different sample sizes across different numbers of clusters is strikingly similar (Figure 
5.11 B), although with marginally smaller 95% confidence intervals as the number of 
samples increased. In contrast, although not statistically significant (by comparison of 
95% confidence intervals), across the board, the TPR decreases with decreasing 
sample size (Figure 5.11 A). It is worth noting though that this decrease becomes 
increasingly pronounced the more sample size is reduced, thus although for S = 10 the 
maximum percentage difference TPR to the full sample set can be as great as 35%, for 
the number of samples more typical in metabonomic studies (S = 40), and at a more 
optimal number of clusters (K = 31) the reduction compared to full dataset TPR is less 
than 6%. This is similarly reflected in the corresponding AUC statistics, where while 
the mean value for a sample size of 10 is 0.88, by S = 40 this has increased to 0.95, a 
similar discriminatory power to that obtained with the full number of samples (AUC = 
0.97). Finally the 95% confidence intervals achieved in the estimation of sensitivity 
and specificity are much greater for TPR than for TNR, this is simply owing to a vast 
difference between the positive and negative population sizes (n = 156 and n = 11069 
respectively). The decreasing confidence intervals observed with increasing sample 
sizes are indicative of more consistent structural versus non-structural assignment, 
although these differences could also reflect the fact that the larger the number of 
samples, the more similar each bootstrap resampling sample population is likely to be. 
 In terms of the effect on sensitivity and specificity of number of variables, 
again the specificity across absolute number of clusters is similar (Figure 5.11 D) 
while sensitivity, as would be expected, varies widely as a direct result of the number 
of clusters possible with different number of variables (Figure 5.11 C). However, 
perhaps a better comparison of performance between different numbers of variables 
can be attained when sensitivity and specificity are plotted versus the relative number 
of clusters (i.e. for each number of variables, sensitivity and specificity are plotted 
against the number of clusters as a proportion of the total number of variables). Here, 
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although there is more deviation between the specificity at different number of 
variables, particularly at low relative number of clusters (Figure 5.11 F), the 
sensitivity between different numbers of variables remain strikingly similar (Figure 
5.11 E). Indeed, with the exception of V = 150, there is no significant difference in 
sensitivity or specificity between different numbers of variables for any relative 
number of clusters.  
Finally, for the relative number of clusters equivalent to those attained for the 
range of distance to optimum values as tested across datasets in Table 5.6 (relative K 
= 0.124, 0.192, 0.452 and 0.708 for distance to optimum values corresponding to the 
minimum, 0.1, 0.3 and 0.5 respectively) sensitivity and specificity values for different 
number of variables, and different number of samples (although with potentially 
wider variation in sensitivity) were not found to be statistically significantly different 
to those obtained for the different datasets. Thus these relative number of clusters 
appear appropriate in the clustering of variables to attain sensitivity and specificities 
approximately equal to those described in Table 5.7 (0.9, 0.02; 0.86, 0.008; 0.73, 
0.002; 0.53, 0.005; sensitivity, specificity pairs for each relative number of clusters as 
before). 
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Figure 5.11: Impact of sample size (A – B) and number of variables (C – F) on 
sensitivity (left plots) and specificity (right plots). Each plot shows the mean (solid 
line) and 95 % confidence intervals (dashed lines) for each number of samples (S = 10 
– black, 20 – purple, 30 – blue, 40 – cyan, 50 – green, 100 – red, and 1043 – mustard) 
or variables (V = 150 – blue, 250 – cyan, 350 – green, 450 – red and 550 – mustard). 
While for A – D the performance statistics are plotted against the absolute number of 
clusters, for E and F they are plotted against the relative number of clusters, i.e. the 
proportion of clusters relative to the total number of variables. 
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5.3.6 Impact of bagging on clustering performance 
Bagging (bootstrap aggregation) was investigated to determine whether the accuracy 
of structural versus non-structural clustering could be improved. The AUC statistics 
for bagging applied to each of STOCSY, hierarchical and K-means clustering on the 
control dataset are presented in Table 5.8. Bagging did not provide any increase in 
performance for the STOCSY or hierarchical methods, and while bagged results for 
K-means clustering showed an increase in the AUC statistic, values still did not 
exceed those obtained for basic hierarchical clustering. 
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 Controls  Caloric restriction  Ammonium chloride  Hydrazine 
Method AUC 
Partial 
AUC 
 
AUC 
Partial 
AUC 
 
AUC 
Partial 
AUC 
 
AUC 
Partial 
AUC 
            
STOCSY 0.9809 0.9167  0.9739 0.8775  0.9548 0.8283  0.8047 0.4764 
Bagged STOCSY 0.9756 0.7291  0.9240 0.8524  0.8987 0.5760  0.7512 0.2311 
            
Hierarchical correlation complete 0.9925 0.9288  0.9148 0.8749  0.9548 0.8833  0.8390 0.5719 
Bagged Hierarchical correlation complete 0.9920 0.8911  0.9502 0.8776  0.9380 0.6497  0.8252 0.4020 
            
K-means correlation 0.9521 0.7386  0.9182 0.8664  0.8930 0.8227  0.8177 0.5293 
Bagged Hierarchical correlation complete 0.9919 0.9014  0.9840 0.8591  0.9408 0.7251  0.8189 0.5106 
Table 5.8: AUC statistics across the datasets comparing results generated for each method with and without bagging. In this case, 
bagging did not provide a statistically significant increase in performance for any dataset tested, indeed in the majority of cases the 
bagged AUC results are typically below those obtained for clustering of the original data. 
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5.4 Discussion 
In this chapter the performance of clustering based methods was investigated as 
relating to the successful discrimination between structural and non-structural 
assignment of variables in 1H NMR datasets. Through the comparison of performance 
statistics for a range of clustering methods across several biologically distinct 
datasets, hierarchical clustering of Pearson correlation derived distance matrices with 
complete linkage was the combination found to consistently outperform all other 
clustering approaches. 
 Although in direct comparison to 1D STOCSY (for the identification of 
unknowns), clustering was not found to perform significantly better than the well-
established STOCSY method, a similarly high structural versus non-structural 
discriminatory power was obtained. In contrast, when compared with methods for the 
unambiguous clustering of variables into putative structural sets (STOCSY clustering 
– similar to that used in Blaise et al., 2010, and local clustering – as used in CLASSY, 
(Robinette et al., 2009) , clustering was found to perform as well as (local clustering) 
or statistically significantly better than (STOCSY clustering) the alternative 
correlation based methods. Thus, in cases where the automatic clustering of variables 
is required the results presented here support clustering as the method of choice. 
Furthermore, in practical terms, relative to the number of variables to be clustered, a 
range of cluster numbers have been suggested for the optimal clustering of variables, 
each pertaining to an approximate sensitivity and specificity in terms of the structural 
relationship between variables. The ability to select an appropriate number of clusters 
to achieve an approximate specificity and/or sensitivity provides valuable flexibility. 
However, perhaps most useful is that of the number of clusters relating to the 
minimum distance to optimum, which calculated across a range of datasets is equal to 
12.4% of the total number of variables and yields a specificity greater than 98% and 
sensitivity greater than 87% (for all datasets excluding hydrazine, where sensitivity = 
50%, with the reasons for this being explicable). Although not derived from testing 
with different number of variables and samples, when this clustering cut-off was 
applied across datasets with a range of different sample sizes and numbers of 
variables, with the exception of those datasets with very low sample sizes (S < 40, 
where mean TPR = 78%) similarly high sensitivity and specificity values were 
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obtained. Thus, this suggests that for the majority of datasets a relative number of 
clusters equivalent to 12.4% of the total number of peak-picked variables is suitable to 
achieve high sensitivity and specificity in the clustering of structural variables. 
 Relating to clustering itself, the fact that Pearson correlation typically 
outperformed both Euclidean and Spearman correlation was no particular surprise, 
since this measure is well established across the board in methods assessing the 
relationship between variables (Cloarec et al., 2005a; Robinette et al., 2009; 
Weckwerth et al., 2004; Zhang et al., 2008). Although both hierarchical and K-means 
clustering have been applied to the clustering of variables or metabolites (Dumas et 
al., 2002; Ishihara et al., 2006; Ishihara et al., 2009; Robinette et al., 2009; Tikunov et 
al., 2005; Ursem et al., 2008) here, I conclude that hierarchical methods are more 
reliable. This is largely owing to the inherent nature of the clustering algorithm itself. 
In K-means clustering the data are split into the number of specified clusters in a 
single step and thus the clusters formed at each value of K are independent, and 
results between different sequential numbers of clusters can vary widely. In contrast, 
in hierarchical methods the relationship between all variables is predefined, and so 
changing the specified number of clusters simply further exposes the existing 
hierarchical structure. Since, for the clustering of variables into structural sets, the 
precise number of clusters for the optimal clustering of each dataset is not known, and 
therefore can only be estimated, it is desirable to select that clustering method where 
subtle differences in the number of clusters do not have such a significant impact on 
the relative structural versus non-structural performance. In contrast to the choice of 
proximity measure, there is less consensus in the literature as to which linkage method 
provides the best specification of clusters for hierarchical methods. Having said that, 
the poor performance of the single linkage measure in datasets containing a degree of 
noise has long been reported (Everitt, 1980). Here complete linkage was selected as 
performing optimally across a range of datasets, but for this measure especially it is 
worth noting the values at which clusters become linked (Figure 5.6). Since these 
dendrograms relate to correlation distance, the values correspond to 1 – r (correlation 
coefficient) and thus range from 0 (total positive correlation), though 1 (no 
correlation) to 2 (total negative correlation). As introduced in the previous chapter 
(Section 4.4.1) while high positive and negative correlations are generally significant, 
lower correlations (typically where | r | < 0.3) are frequently not. Thus in terms of 
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structural assignment, clusters formed at linkages exceeding 0.7 (1 – 0.3) are unlikely 
to be significant and indeed the higher the linkage distance the less likely they are to 
contain truly structurally related clusters. However, this only becomes a concern at 
very low numbers of clusters, and while for that number of clusters relating to the 
minimum distance to optimum the linkage value may approach 0.7, for significant 
negative correlations (i.e. linkages exceeding 1.3) the number of clusters would have 
be substantially less (K < 15), and therefore this is not typically a problem for the 
majority of datasets. Finally, although a bagging approach has been demonstrated to 
improve accuracy (by reducing the impact of noise) in the assessment of metabolic 
associations by K-means clustering (Hageman et al., 2006) here, even with the 
increased performance of K-means bagged results, classification accuracy did not 
exceed that of hierarchical clustering with complete linkage, and thus bagging was not 
proven to be of any advantage for this application. 
  When compared directly to STOCSY for the identification of putative 
structurally related peaks (for example, for metabolite identification), clustering was 
not found to offer any advantage in terms of structural versus non-structural 
classification. Although based purely on this non-significant result, clustering could 
equally well be applied to investigate the relationship of all variables to a variable of 
interest, and indeed may in theory be as accurate in highlighting putative structurally 
related peaks, clustering is unlikely to be applied for this task in practice. Not only is 
this owing to the well-established and proven performance of STOCSY, but also, 
STOCSY is perhaps better equipped to reveal more distant relationships between 
variables and can be computed quickly across the entire variable set without the prior 
need for peak-picking. Having said that, for the automatic grouping of the entire peak-
picked variable set into putative structurally related clusters, clustering has been 
shown to perform significantly better than a STOCSY clustering method. In recent 
years, the visualisation and investigation of inter-metabolite relationships on a whole 
dataset scale has become an increasingly popular approach, and commonly such 
approaches cluster putative structurally related peaks before extracting a 
representative value from each for subsequent analysis (Blaise et al., 2010; Robinette 
et al., 2009). Here, the first comparison has been provided between clustering and 
correlation based methods for the automated clustering of variables, and it was found 
that hierarchical clustering performed as well or better than the other methods tested 
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(including clustered STOCSY and local clustering) across a biologically diverse range 
of 1H NMR datasets. 
The basis for the difference in performance of clustering when compared to 
STOCSY methods can be determined through examination of the distribution of 
positive classifications between the target variables for the different methods, here at 
an arbitrarily selected specificity of 99% (Figure 5.12). The decreased performance 
when comparing STOCSY to STOCSY clustering can be explained by the inherent 
more rigorous grouping of variables into unambiguous sets, and thus deflation of the 
number of true positives. This can be seen in the lactate cluster for the control dataset 
(Figure 5.12 A and C) and the NMND cluster for ammonium chloride (Figure 5.12 B 
and D), where while STOCSY allows cluster membership to be indistinct (i.e. 
variables A and B, and variables A and C can be associated but variables B and C 
need not be), this is not the case in STOCSY clustering, where membership must be 
unambiguous.  Although both clustering and STOCSY methods are equally sensitive 
to significant peak overlap (for example, by comparison of the lactate cluster in the 
ammonium chloride dataset Figure 5.12 D and F), clustering constantly handles 
variability owing to peak shifting better than STOCSY (comparison of the citrate and 
NMND clusters for both methods and either dataset). Finally, the significantly lower 
sensitivity for the hydrazine dataset (Figure 5.12 H) can largely be attributed to the 
low intensity of many of the target metabolites (especially 2-OG, NMNA and 
NMND) in this dataset and many high non-structural correlations. 
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Figure 5.12: Plots showing the distribution of obtained (black shaded areas) and 
actual (red bounded areas) structural classifications at false positive rate = 0.01 for (A 
and B) basic STOCSY, (C and D) STOCSY clustering and (E – H) hierarchical 
clustering for datasets (A, C, E) control, (B, D, F) caloric restriction, (G) ammonium 
chloride and (H) hydrazine. Key: PAG, phenylacetylglycine; 2-OG, 2-oxogluterate; 
NMNA, N-methylnicotinic acid; NMND, N- methylnicotinamide. 
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When the effect of sample size on STOCSY performance was investigated 
(Couto Alves et al., 2009), while the sensitivity did not significantly alter between 
different numbers of samples, the specificity for any given threshold decreased 
significantly with decreasing sample sizes. Therefore it was concluded that the 
smaller the sample size, the higher the risk of spurious non-structural associations. 
Interestingly, the effect of sample size on clustering performance was completely the 
reverse, in that while specificity remained similar, a decrease in sample size was 
generally associated with a decrease in sensitivity (Section 5.3.5). While the merits of 
maintaining either sensitivity and specificity with respect to sample size can be 
argued, in terms of structural assignment, it is perhaps better to have more confidence 
in the groupings produced at the expense of missing some truly structural associations 
rather than the other way around.  
 In conclusion, while STOCSY remains the most appropriate method for the 
identification of putative structurally related peaks for assignment purposes, 
hierarchical clustering on correlation distances with complete linkage demonstrates 
the highest classification accuracy for the automated and grouping of putatively 
structurally related variables into unambiguous sets. Owing to the increasing 
popularity of approaches aiming to capture a complete picture of metabolic 
interactions based on the relationships between a reduced set of representative 
variables or descriptors, this is an important result providing a guide for researchers as 
to how best to recover sets representative of individual metabolites. 
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6 CONCLUSION 
Following conclusions specific to each results chapter, the following sections cover 
more general conclusions and the scope for future work. 
6.1 Statistical total correlation spectroscopy editing 
(STOCSY-E) 
In Chapter 3 the problem of strong signals from unwanted metabolites confounding 
chemometric analysis was addressed through a STOCSY-editing procedure in which 
signals from unwanted metabolites were first identified by STOCSY, then removed 
through down-scaling by virtue of their relative correlation to the STOCSY driver 
peak. Particularly relevant to toxicology datasets, which frequently contain multiple 
high intensity signals from the administered compound and its metabolites, this 
method has been shown not only to provide a quick means of identifying drug related 
peaks, but also though removal of the identified peaks and region reconstruction, to 
facilitate subsequent statistical analysis and enhance biomarker recovery. Although 
here applied to toxicological datasets, there are many occasions when peaks 
superfluous to the condition of interest are present in NMR metabonomic datasets. 
Thus STOCSY-E could be valuable, for example, in removing those resonances 
corresponding to alcohol or analgesics from human biofluid samples, or solvent or 
excipient signals as required prior to analysis.  
6.2 Iterative STOCSY (I-STOCSY) 
In analysis of metabonomic datasets the generation of a global map or network of 
variable-to-variable or metabolite-to-metabolite correlations is becoming an 
increasingly popular approach, however, the visualisation and interpretation of such 
complex relationships presents a continuing challenge. To provide a clear and directed 
data-driven approach for the elucidation and visualisation of such inter- and intra-
metabolite relationships, iterative-STOCSY was developed. In I-STOCSY, STOCSY 
is recursively performed, initially from a driver peak of interest, and subsequently 
from all peaks identified as correlating to the given driver above a certain pre-set 
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threshold. Furthermore, the grouping of any putatively structurally related variables 
allows the easy and intuitive exploration of both intra- and inter-node (and thus 
metabolite) relationships in the final fully interactive plot. When applied to the 
toxicological dataset presented in this thesis, I-STOCSY facilitated the efficient and 
effective recovery of both drug related metabolites and those endogenous metabolites 
previously identified as affected by treatment, alongside novel connections – therefore 
illustrating the ability of this method both to recover existing associations and to 
generate new hypotheses. 
6.3 Clustering 
Finally in Chapter 5 a range of clustering methods were investigated for the 
discrimination of structurally and non-structurally related variables. Here the 
optimally performing method was found to correspond to hierarchical clustering with 
complete linkage, with a distance matrix generated from calculation of correlation 
distances between variables. This method was compared to STOCSY based methods 
on two counts; and while clustering was not statistically significantly better than 1D 
STOCSY for the suggestion of putatively structurally related variables, for the 
unambiguous and automatic clustering of variables into putative structural sets 
clustering outperformed other methods tested. This result is particularly important 
since the reduction of the full variable set to a set where each is representative ideally 
of a single metabolite is becoming an increasingly popular approach in metabonomic 
data analysis for the investigation of global metabolic networks or correlation maps. 
6.4 General conclusions 
This thesis presents a range of correlation-based approaches for 1H NMR data 
analysis, with an emphasis on enhancing the interpretability of and information 
recovery from toxicological datasets through semi-automatic data-driven approaches. 
Correlation based approaches are well established in assessing the relationship 
between variables in metabonomic datasets, with strong correlations suggesting 
resonances resulting from the same metabolite and lower correlations alluding to 
biological or mechanistic associations. One critical parameter for many correlation-
based methods is the selection of an appropriate threshold, either for selection of 
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structurally related peaks, or as a cut-off for defining metabolite-to-metabolite 
associations. While from a previous study into structural versus non-structural 
discrimination by STOCSY a correlation threshold of r > 0.95 has been suggested for 
assigning resonances to the same metabolite with high confidence (Couto Alves et al., 
2009), for  non-structural associations thresholds in the literature range widely (from r 
> 0.5 to r > 0.8) and really depend on the dataset under study and the application 
required (Steuer et al., 2003, Clish et al., 2004). Both STOCSY-E and I-STOCSY 
utilise a correlation threshold to define putatively structurally related peaks and in 
both cases this was set to r > 0.95 (or in STOCSY-E the r2 equivalent of 0.9) as 
corresponding to that highly discriminatory value determined by Couto Alves et al., 
2009. This highly stringent threshold is ultimately suitable for I-STOCSY, where the 
primary goals of grouping such highly correlated peaks are a reduction in the number 
of nodes to minimise plotting complexity and suggestion of structurally related peaks 
for data interpretation. In STOCSY-E however, expert knowledge of peaks required 
for removal may mean a different threshold may be selected as more appropriate, 
especially in cases where a set of closely, but not necessarily structurally related peaks 
are required for removal. It is a similar case in the selection of the threshold in I-
STOCSY above which node-to-node non-structural associations are presented. Here, 
a user-defined threshold is desirable, since the strength of recovered associations are 
highly dataset and driver peak dependant and thus a tuneable threshold allows the 
optimal presentation of information for the required application and complexity of 
interactions. 
In contrast to many modelling and analysis methods, data-driven approaches do 
not rely on detailed knowledge of the underlying structure of the system under study. 
In terms of the analysis of metabonomic data this is highly desirable, since, as 
discussed in the introduction, metabonomics reflects a complex interweaving of 
whole organism and temporal metabolic effects, the structure of which is therefore not 
highly characterised. In this thesis there has therefore been a focus on the 
development of methods that aim to ease metabonomic analysis through the provision 
of transparent data-driven methods with the minimum of user input. Correlation-based 
methods provide intuitive insight into the associations between variables, however, 
their interpretation can be complicated by the sheer number of possible pair-wise 
correlations between variables, thus methods have also strived to reduce redundant 
information and simplify presentation of results. While STOCSY-E and the 
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investigation of clustering as a means of defining sets of putatively structurally related 
variables really provide a pre-analysis step, either in the removal of unwanted 
metabolite peaks or variable dimension reduction, I-STOCSY provides a means for 
the full investigation of metabolic relationships in a given metabonomic dataset.  
6.5 Scope for future work 
Considering future work as specifically relating to Chapters 3 to 5, there are a number 
of possible extensions with potential to further improve the interpretability of or 
information recovery from 1H NMR datasets.  
In Chapter 3 STOCSY-editing was developed and applied to several 
toxicological 1H NMR datasets of urine samples. Since 1H NMR spectra are typically 
complex, containing overlapping signals from many different compounds, signals 
arising from specific metabolites can sometimes be difficult to identify. With this in 
mind, when metabolites of interest contain an alternative spin-active X-nucleus (e.g. 
13C, 15N, 19F or 31P) heteronuclear STOCSY (HET-STOCSY), i.e. the correlation of 
1H and X-nucleus NMR signals recorded in parallel or series for the same dataset, has 
been applied with success for improved metabolite identification from various sets of 
1H spectra (Coen et al., 2007b; Keun et al., 2008; Wang et al., 2008). A similar tactic 
could be utilised in STOCSY-E, if unwanted compounds contained a spin-active 
nucleus other than 1H, heteronuclear correlations could be utilised to identify and 
remove corresponding metabolite peaks from 1H NMR spectra prior to subsequent 
analysis. 
STOCSY-E could also be investigated for the selective subtraction of glucose 
signals from plasma samples. In plasma spectra the region between 3.30 and 3.95 ppm 
is generally dominated by high intensity signals from glucose, which typically 
overwhelm resonances from all other metabolites in the area, thus making their 
identification incredibly difficult (Wevers et al., 1994). To apply STOCSY-E to this 
task several modifications to the method are likely to be necessary. Plasma samples, 
for example, contain high lipid and protein content, which results in a broad envelope 
of overlapping resonances and thus broad baseline changes. Therefore in this case, 
applying a 100Hz line broadening to the spectra to dissipate sharp low molecular 
weight metabolite signals and thus recreate the basic lipoprotein baseline could 
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potentially generate more representative baseline sections for use in the background 
replacement stage of STOCSY-E. 
In Chapter 4 iterative-STOCSY was applied to a full set of results including 
both pre- and post-dose time points following treatment with the model hepatotoxin 
galactosamine. I-STOCSY was shown to identify the consequences of treatment as 
previously identified alongside new connections, therefore both attesting validity and 
generating new biological hypotheses. While this approach elucidates the major 
metabolic consequences of treatment, equally interesting could be the investigation of 
associations for each treatment group or time point sample set and how these 
associations change between the subsets tested. This could be particularly interesting 
for the galactosamine dataset since galactosamine treatment results in a highly 
variable response, with some animals experiencing extreme toxicity and others 
appearing to suffer no adverse affect (Coen et al., 2009). Comparison of the metabolic 
associations present in different response groups therefore could help to further 
elucidate the underlying mechanisms behind these differential responses. 
Additionally, given the result from Chapter 5, that hierarchical clustering (with 
correlation distance measure) provides an improved discrimination between 
structurally and non-structurally related variables; this hierarchical method could be 
investigated in the production of putatively structurally related sets in I-STOCSY as 
an alternative to the STOCSY correlation-based method implemented.  
In terms of generating clusters of structural sets there is a wide scope for 
future work, both in the further investigation of the performance of this approach and 
in the application or development of data analysis tools utilising the resultant 
putatively structurally grouped results. As described in Chapter 5 (Section 5.1) a 
common method for reducing the complexity in calculation of metabolic correlation 
networks is the identification of putatively structurally related variable sets then to 
select a representative variable or measure from each set for subsequent correlation 
analysis. Here I have shown that hierarchical clustering (with correlation distance and 
complete linkage) provides an improved separation of variables into structural sets 
compared to other STOCSY based approaches, but the selection of the optimal 
measure by which each set should be subsequently represented would also be worth 
investigation. Additionally, in Chapter 5 datasets were selected as for (Couto Alves et 
al., 2009), to be representative of a range of physiological and pathological 
conditions. However, since all datasets were generated as part of the COMET project 
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and thus followed a set experimental design, it would be interesting to explore 
whether the obtained results generalise to samples from other biofluids and species. 
Additionally, here results have focussed on the identification of putative structural 
sets, but a further extension could be the investigation of the inter-relationship 
between the derived sets (putative metabolites) by systematically decreasing the 
number of clusters and observing the relationship between clusters as they merge. 
In terms of utilising the resultant set of variables (where ideally each is 
representative of a different metabolite), previously applied methods generally 
involve calculation of the correlations between all possible pairs and subsequent 
presentation of the resultant correlations in some way, for example, via a correlation 
map (Robinette et al., 2009) or a network of metabolic associations (Blaise et al., 
2010). An alternative approach, based on that which Google uses to rank web pages 
after a given word search, is that of Eigenfactor analysis (Bryan and Leise, 2006). 
Now established as a measure for assessing the impact or influence of scientific 
journals, in this context Eigenfactor analysis involves the calculation of a relative 
score for each journal based on the number of times its articles are visited if a reader 
were to follow a random chain of citations ad infinitum from an initially random 
starting point (Fersht, 2009). Eigenfactor analysis has subsequently been applied in 
biology, for example, for assessing the relative importance of species in co-
extinctions, and in the identification of regulatory modulators of a perturbed gene 
association network (Allesina and Pascual, 2009; Davis et al., 2010). In terms of the 
analysis of metabolic networks, a similar approach could be utilised to indentify 
important metabolites following a given metabolic perturbation by following inter-
metabolite correlations in a network of where each is representative of a unique 
metabolite (as determined, for example, by hierarchical clustering).  
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Statistical Total Correlation Spectroscopy Editing
of 1H NMR Spectra of Biofluids: Application to Drug
Metabolite Profile Identification and Enhanced
Information Recovery
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John C. Lindon, and Jeremy K. Nicholson*
Department of Biomolecular Medicine, Sir Alexander Fleming Building, Division of Surgery, Oncology, Reproductive
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Here we present a novel method for enhanced NMR
spectral information recovery, utilizing a statistical total
correlation spectroscopy editing (STOCSY-E) procedure
for the identification of drug metabolite peaks in biofluids
and for deconvolution of drug and endogenous metabolite
signals. Structurally correlated peaks from drug metabo-
lites and those from closely related drug metabolite
pathways are first identified using STOCSY. Subsequently,
this correlation information is utilized to scale the biofluid
1H NMR spectra across these identified regions, pro-
ducing a modified set of spectra in which drug me-
tabolite contributions are reduced and, thus, facilitat-
ing analysis by pattern recognition methods without
drug metabolite interferences. The application of STOC-
SY-E is illustrated with two exemplar 1H NMR spec-
troscopic data sets, posing various drug metabolic,
toxicological, and analytical challenges viz. 800 MHz
1H spectra of human urine (n) 21) collected over 10 h
following dosing with the antibiotic flucloxacillin and
600 MHz 1H NMR spectra of rat urine (n ) 27)
collected over 48 h following exposure to the renal
papillary toxin 2-bromoethanamine (BEA). STOCSY-E
efficiently identified and removed the major xenobiotic
metabolite peaks in both data sets, providing enhanced
visualization of endogenous changes via orthogonal to
projection filtered partial least-squares discriminant
analysis (OPLS-DA). OPLS-DA of the STOCSY-E spec-
tral data from the BEA-treated rats revealed the gut
bacterial-mammalian co-metabolite phenylacetylglycine
as a previously unidentified surrogate biomarker of
toxicity. STOCSY-E has a wide range of potential
applications in clinical, epidemiology, toxicology, and
nutritional studies where multiple xenobiotic metabolic
interferences may confound biological interpretation.
Additionally, this tool could prove useful for applica-
tions outside of metabolic analysis, for example, in
process chemistry for following chemical reactions and
equilibria and detecting impurities.
In the quest for the discovery and development of new
treatments for human disease and personalized healthcare, there
is strong pressure to identify novel biomarkers or signatures
specific to, for example, a certain mode of toxicity, disease state,
or treatment prognosis. Although much effort has been put into
the development of transcriptomic and proteomic platforms, a
major problem remains in relating gene-expression or protein level
changes to disease and pharmaceutically relevant end points.1 This
is largely owing to the huge metabolic complexity of “super
organisms” with diverse metabolically interacting symbiotic gut
microflora that are subject to strong environmental influences
(such as diet, drug therapy and lifestyle) which influence
metabolic phenotypes.2,3 In contrast to other “omics” platforms
metabonomics (defined as the quantitative measurement of the
multiparametric metabolic response of living systems to patho-
physiological stimuli or genetic modification)4 provides a systemic
and temporal metabolic description of the whole organism
response to a treatment and thus includes effects not only from
extended genomes but also from the impact of other environ-
mental factors. The metabonomic approach involves the spectro-
scopic analysis (with the majority of approaches utilizing nuclear
magnetic resonance spectrometry (NMR) or mass spectrometry
(MS)) of biological fluids and tissues coupled to statistical
interpretation of the complex spectral data sets produced. Meta-
bonomics is now recognized as a powerful tool in biomarker
discovery, not only in its own right, but also in providing a
connection between real world end points and data derived from
other “omics” platforms.5-9
One area where NMR-based metabonomic profiling has had
significant impact is in the field of toxicology (recently reviewed
by Coen et al.10). While early applications found that the metabolic
profiles revealed by NMR spectroscopy of biofluids gave insight
* To whom correspondence should be addressed. E-mail: j.nicholson@
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(3) Nicholson, J. K.; Holmes, E.; Lindon, J. C.; Wilson, I. D. Nat. Biotechnol.
2004, 22, 1268–1274.
(4) Nicholson, J. K.; Lindon, J. C.; Holmes, E. Xenobiotica 1999, 29, 1181–
1189.
(5) Kleno, T. G.; Kiehr, B.; Baunsgaard, D.; Sidelmann, U. G. Biomarkers 2004,
9, 116–138.
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into location, severity, and mechanisms of toxicity,11,12 major
advances in biomarker discovery came with the coupling of
spectroscopic data to chemometric methods. Metabolic profiling
can reveal global markers of metabolic dysfunction (for example
related to liver toxicity)13 and is sufficiently sensitive to indicate
the site of damage within an organ.14,15 Perhaps the most valuable
asset of metabonomics is in the elucidation of the mechanistic
action of toxins, not only in terms of drug metabolism but also in
revealing the endogenous consequences of toxin treatment. As
such, a wide range of toxins have now been investigated,
including, for example, the liver toxin hydrazine,16-18 the renal
papillary toxin 2-bromoethanamine hydrochloride,14,15,19,20 and the
bisphosphonates ibandronate and zoledronate.21 The aptitude of
metabonomics in both the detection and characterization of
toxicity has been demonstrated by the consortium for metabo-
nomic toxicology (COMET) project. In this project 147 toxins and
treatments were evaluated via 1H NMR spectroscopy of rat and
mouse urine, generating a large-scale metabolic database,
which was used to develop an expert predictive system for
assessing the toxicity of compounds with unknown modes of
action.7,22,23
In terms of identifying the endogenous metabolic conse-
quences of toxin administration, a complicating factor is the
presence of strong signals from the administered xenobiotic
compound and its metabolites. Although these drug-related
metabolites convey valuable information in their own right, it is
crucial that they are identified and removed from the spectra, so
any subsequent classification exercises recognize endogenous
patterns of toxicity and not signals specific to a particular
treatment.23 Unfortunately the identification of drug metabolite
spectral resonances is often both difficult and time-consuming
exercise. Furthermore, but the removal of drug metabolite
resonances from spectral data leads to the loss of (potentially
biologically interesting) information; if signals from drugs obscure
and overlap endogenous signals, these will also be removed when
the drug peaks are cut from the spectrum. In some cases (where
all drug related compounds present in the data set are known
and standard spectra have been prepared and acquired under
identical conditions), curve fitting (for example, using the method
LCModel)24 and subtraction can be an effective method of peak
removal. However, this method can be problematic, for example,
leading to the loss of a large amount of information in data sets
where multiple spectral regions are excluded.
The inherent correlations present in NMR spectral data have
been exploited in many data analysis methodologies.25-28 NMR
statistical total correlation spectroscopy (STOCSY) was originally
developed to aid the identification of potential biomarkers in NMR
metabonomic studies.29 Through calculation of the correlation
statistics between the intensities of all points in a set of spectra
and a driver set of values (for example, spectral intensities at a
particular resonance/point of interest), connectivities are gener-
ated highlighting resonances which covary in concentration
between samples. Since its development, STOCSY has been used
in many applications, including the extraction of biomarkers, the
derivation of novel pathway connectivity information, and as a
method of structural information recovery.30-32 In these studies,
high STOCSY correlations are typically seen for peaks arising from
the same molecule (structural correlations), while lower correla-
tion values can elucidate potential pathway or reaction intermedi-
ates. STOCSY has also been utilized in molecular epidemiology
studies to identify urinary drug metabolite signatures33 and as a
method to enhance information recovery from LC-NMR and
diffusion-edited NMR data sets.34,35
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Here we present STOCSY-E, a rapid means of drug metabolite
peak identification and editing, for enhanced endogenous informa-
tion recovery from complex NMR spectral data sets. In this
method, a correlation threshold is used to identify signals arising
from a chosen drug-related resonance to highly correlated
resonances, which are thus likely to arise from the same drug
metabolite. Subsequently, since the presence of unrelated overlap-
ping signals lowers the correlation values, these values are used
to scale the original spectral data and (following background
correction) to reconstruct potential endogenous peaks in drug
metabolite peak regions. In this way, this method eliminates the
need to identify and cut individual drug metabolite signals and
provides a useful tool for enhanced chemometric analysis. As well
as enhancing analysis of data from toxicology studies, this method
could be valuably applied to data from other areas, including for
example, epidemiology studies where drug use across the popula-
tion is extensive.33,36 Additionally, since this method results in
spectra where the contribution of a certain metabolite or metabo-
lites is reduced, it could be of value in any data set where any
unwanted metabolite (drug or otherwise) overwhelms the spectral
data.
EXPERIMENTAL SECTION
Flucloxacillin: A Model Antibiotic. The experimental details
have been published previously.37 In brief, urine samples were
collected from six healthy adult volunteers over 10 h after oral
dosing with 500 mg of flucloxacillin (total number of samples n
) 26). On collection samples were immediately frozen and stored
at -40 °C before being thawed and vortex-mixed prior to
preparation for NMR. A volume of 300 µL of urine was added to
300 µL of phosphate buffer (0.2 M, pH 7.4) containing 1 mM
sodium 3-(trimethylsilyl) propionate-2,2,3,3-d4 (TSP), 3 mM
sodium azide, and 20% (v/v) D2O. Samples were then vortex-
mixed and centrifuged at 16 000g for 10 min, and 550 µL of
the resulting supernatant was placed in an NMR tube for
analysis.
One-dimensional (1D) 1H NMR spectra were acquired using
a Bruker Avance II NMR spectrometer (Bruker Biospin,
Rheinstetten, Germany) operating at a 1H frequency of 800.32
MHz. A standard solvent suppressed 1D pulse sequence
(recycle delay-90°-t1-90°-tm-90°-acquisition) was used with an
acquisition time of 3.36 s and a t1 of 3 µs. Presaturation of the
water signal was applied during the recycle-delay of 2 s and
the mixing time (tm) of 100 ms. For each sample, 64 scans and
8 dummy scans were collected into 64k data-points with a
spectral width of 12.2 ppm. An exponential line broadening
function of 0.3 Hz and automatic zero-filling of a factor of 2
was applied to each FID prior to Fourier transformation.
Spectra were manually phased and baseline corrected using
TOPSPIN (version 2.0.1, Bruker BioSpin) and referenced to
the TSP resonance (δ1H ) 0.00).
Data were imported into the MATLAB computing environment
(R2007a, The MathWorks, Inc., MA) using Metaspectra 4.0 (in-
house MATLAB routine written by Dr. O. Cloarec) with spectra
reconfigured to a common part per million scale by cubic spline
interpolation to 11 000 data points (δH ) -1 to 10) resulting in a
final spectral resolution of 0.8 Hz/pt. Of the 26 samples, 5 were
rejected from subsequent analysis owing to the presence of
significant water suppression artifacts (as in Keun et al.).37
2-Bromoethanamine: A Model Renal Papillary Toxin.
Twenty seven male 6-7 week old SD rats (Crl:CD(SD) IGS BR,
Charles River, Wilmington, MA) were housed in metabolism cages
with a 12 h light and 12 h dark cycle, and water and standard
food were made available ad libitum throughout the study. A
predose urine collection was made for all rats 24 h prior to dosing.
On day 0, rats were administered an intraperitoneal (ip) injection
of vehicle (0.9% saline, n ) 9) or 250 mg/kg 2-bromoethanamine
hydrobromide (n ) 18). Urine was collected at 0-2, 2-4, 4-8,
8-24, and 24-48 h after dosing and stored at -70 °C until
analysis.
Samples were prepared for NMR as for the flucloxacillin study
and similarly 1D 1H NMR spectra obtained using a Bruker
Avance NMR spectrometer operating at 600 MHz for 1H, with
solvent suppression using the standard 1D-NOSEY-based pulse
sequence. For each sample, 64 scans and 8 dummy scans were
collected into 64k data-points with recycle-delay ) 4 s, tm )
100 ms, and a spectral width of 20 ppm. Prior to Fourier
transformation, an exponential line broadening function of 0.3
Hz and automatic zero-filling of a factor of 2 was applied to
each FID. Spectra were manually phased, baseline corrected,
and referenced to the TSP resonance (δH ) 0.00) using
NMRproc (in house software developed by Drs. T. Ebbels and
H. Keun). Similarly to the flucloxacillin data, data were
imported into MATLAB using Metaspectra 4.0 with the spectra
reconfigured to a common part per million scale by cubic spline
interpolation to 22 000 data points (δH ) -1 to 10).
The NMR spectral data were aligned38 prior to running the
STOCSY editing algorithm, and the alignment was individually
optimized in regions displaying significant chemical shift variation.
Subsequently, probabilistic quotient area normalization was ap-
plied using the method described by Dieterle et al.39
ALGORITHM
A summary of the process of STOCSY-E for the identification
and removal of drug metabolite peaks is shown in Algorithm 1.
The process of STOCSY-E can be split into two key stages:
the identification of signals resulting from drug related compounds
(step 1) followed by the selective scaling and background
correction across the regions identified (step 2).
Driving STOCSY from a particular peak returns a set of
correlation coefficients that vary in strength across the spectrum.
As mentioned previously, while highly correlated points are likely
to be structural (signals resulting from the same molecule), points
with lower correlations may highlight metabolic relationships, i.e.,
the temporal metabolism of the administered toxin or changes in
endogenous metabolites as a result of the toxic insult. An
important step in the STOCSY-E algorithm is the exclusive
identification of drug metabolite peaks from STOCSY analysis.(36) Dumas, M. E.; Maibaum, E.; Teague, C.; Ueshima, H.; Zhou, B.; Lindon,
J. C.; Nicholson, J.; Stamler, J.; Elliott, P.; Chan, Q.; Holmes, E. Anal. Chem.
2006, 78, 2199–2208.
(37) Keun, H. C.; Athersuch, T. J.; Beckonert, O.; Wang, Y.; Saric, J.; Shockcor,
J. P.; Lindon, J. C.; Wilson, I. D.; Holmes, E.; Nicholson, J. K. Anal. Chem.
2008, 80, 1073–1079.
(38) Veselkov, K. A.; Lindon, J. C.; Ebbels, T. M.; Crockford, D.; Volynkin, V. V.;
Holmes, E.; Davies, D. B.; Nicholson, J. K. Anal. Chem. 2009, 81, 56–66.
(39) Dieterle, F.; Ross, A.; Schlotterbeck, G.; Senn, H. Anal. Chem. 2006, 78,
4281–4290.
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This is achieved through selecting only those data points which
correlate with the drug driver peak with an r2 value greater than
a set threshold θ (Algorithm 1, step 1.3). The selection of an
appropriate θ value depends both on the data set and on the
aim of the research. Here, θ ) 0.9 was selected from thorough
analysis of the data sets under study to purely identify only
structural resonances. This value of 0.9 is also consistent with
recently published research, in which it was shown that a
STOCSY correlation threshold of r > 0.95 (corresponding to
an r2 close to 0.9) was required to assign resonances as
resulting from the same metabolite with high probability in a
variety of data sets.40
Following the identification of drug related peaks, STOCSY
assisted scaling was used to reduce the influence of each drug
metabolite in the spectral data to the overall variation between
control and treated classes, using the equation in step 2.1. A key
property of this equation is that the scaled value (xsc) approaches
0 as r approaches 1 and vice versa. Although potentially any
equation having this property could be used to scale the
spectral data, it was found that for this application, this equation
gave good results for spectral interpretability. Here, the use of
r2 rather than r emphasizes high correlations more than
moderate correlations, again beneficial for the STOCSY-E
method.
The scaling step produces spectra where drug signals are
reduced; however, both in terms of data interpretation and pattern
recognition, the use of the unmodified scaled data in subsequent
analysis is suboptimal. First, where signal intensity approaches
background noise level (at the edge of and occasionally within
drug peak regions), decreased correlation coefficients result in
either no (if r2 < θ) or reduced scaling compared to bordering
regions and thus the production of spurious peaks. These peaks
create misleading signals in the STOCSY-edited spectra, not
only for peak identification but also potentially in terms of
pattern recognition. Additionally, across the scaled regions,
since r rarely has a value of 1 and since at each index point all
samples are scaled by the same coefficient, some small amount
of signal frequently remains after scaling and this continues
to be picked up as important when pattern recognition methods
are applied. Background correction is thus a crucial part of
the algorithm, since it allows the correction of spurious peaks
and randomization of any correlations that remain owing to
the scaling method, while importantly, leaving any endogenous
signal present across the scaled regions.
(40) Couto Alves, A.; Rantalainen, M.; Holmes, E.; Nicholson, J. K.; Ebbels,
T. M. D. Anal. Chem. 2009, 81, 2075–2084.
Algorithm 1. STOCSY-E Algorithm
Let x ) [x1. . .xn] denote intensity values of the real spectrum at each ppm.
step 1.1 Select a peak corresponding to a drug metabolite.
step 1.2 Run STOCSY on the original spectral data driven from the selected peak.
step 1.3 Use the correlation coefficient (r) values returned by STOCSY to identify the set (D) of indices (i) corresponding to those spectral
data points with intensities that correlate to those of the drug driver peak with r2 > θ [θ optimized for the study in question
(see text below)].
D ) {i:ri
2 > θ}
step 1.4 For each sample spectrum, extend D at either end of each identified region to include spectral data points until the signal intensity
reaches a local minimum. This new set D′ corresponds to putative drug related compound (DRC) peak regions.
step 2.1 For each sample spectrum x, generate a STOCSY edited spectrum xsc by scaling the original data only in the drug metabolite peak
regions D′ using
xsci ) {xi(1 - ri2) i ∈ D'xi i ∉ D' }
step 2.2 For each sample generate a drug metabolite spectral profile xdrug calculated as
xdrug ) x - xsc
step 2.3 Identify regions in the scaled data within D′ which fall below the limit of detection as defined by
B ) {i:i ∈ D', xsci < x¯baseline + 3snoise}
where x¯baseline and snoise are estimates of the local baseline and noise, respectively (see text below).
step 2.4 Replace signal intensities over B to yield the final edited spectra xfinal such that
xfinali ) {∼N(x¯baseline, snoise2) i ∈ Bxsci i ∉ B}
where ∼N(x¯baseline, snoise2 ) denotes sampling from a normal distribution with mean x¯baseline and variance snoise2 .
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The background correction method is based on the theory that
where endogenous signal is present in a drug region, the data
points will correlate less strongly with the drug metabolite driver
peak, and therefore after scaling, peaks will remain in the resultant
spectra. At this point, peaks in the scaled spectra could be either
owing to true endogenous signal or spurious peaks (as discussed
above). However, since true drug signal will correlate more
strongly to the driver peak than endogenous signal, the drug
signal will be scaled to a greater degree producing smaller peaks
in the scaled spectra. Thus, signal intensity across the scaled
regions can be used in determining whether points should be
replaced or remain in the final spectrum; this is achieved in step
2.3. The right-hand side of the formula represents the limit of
detection, the minimum signal that can be distinguished from the
background spectral noise.41 At this step, anything in the scaled
data greater than the limit of detection remains in the spectra as
valid signal, while anything less is replaced. To deal with the
problem of spurious peak production in areas adjoining scaled
regions, data scaling and background correction continues either
side of each identified drug peak region until the signal intensity
for each sample reaches a local minimum.
Throughout the algorithm, the standard deviation of the noise
(snoise) is calculated from intensity levels for all samples at a
chemical shift known to be devoid of signals. However, the
local baseline levels may vary across the spectrum owing to
the presence and overlap of many small signals (chemical
noise) or to instrumental artifacts. Therefore, the mean baseline
level (x¯baseline) is estimated separately for each drug replacement
section. For each drug region and each sample, the baseline
is estimated as the minimum intensity value across an extended
area (0.02 ppm either side of each drug region), then the mean
is subsequently calculated across all samples. Since each
extended region covers multiple peaks, it is reasonable to
assume that the minimum level is an accurate estimation of
the baseline level for that specific region.
It is crucial that the replacement background intensities be
randomly distributed to ensure that no patterns are present which
could subsequently be picked up as important discriminators by
pattern recognition tools. For pattern recognition, as long as the
intensities are randomly distributed and signals in the STOCSY-
edited spectra remain above the level of noise, the actual values
of replaced regions are unimportant. However, from a visual point
of view and ease of spectral interpretation, it is important that the
replaced sections resemble typical spectral baselines to provide
optimal visualization of signals remaining above the limit of
detection. The background regions identified in step 2.3 were thus
replaced with sections generated from a normal distribution with
mean and variance as given in step 2.4.
RESULTS
Running STOCSY on the urinary 1H NMR spectroscopic data
from a known resonance of the parent flucloxacillin compound
clearly highlights all additional parent drug resonances in the
spectrum (Figure 1A). Only these structurally correlated reso-
nances have correlation values above the selected cutoff (r2 > 0.9)
and thus are successfully selectively identified as drug me-
tabolite peaks in the next step of STOCSY-E (Figure 1B). The
resonances identified here agree with previously published flu-
cloxacillin assignments in the literature.42
Figure 1C shows the spectra produced following drug peak
identification and rescaling as compared to the original spectral
data. Although scaling successfully reduces the contribution of
drug peaks in the spectra, as discussed in the Algorithm section,
it can also lead to the production of spurious peaks, which can
be seen both at the edge and occasionally within drug metabolite
peak regions (Figure 2A). Furthermore, these spurious peaks are
picked up as important discriminators between groups, for
example, when predose and 2 h postdose flucloxacillin-treated
samples are compared using orthogonal to projection filtered
partial least-squares discriminant analysis (OPLS-DA) (Figure
2B).43,44 This result is similar to when OPLS-DA is run on the
original data (Figure 2C,D). The final background correction step
is critical in removing these signals and, therefore, the contribution
of these spurious drug related signals in the discrimination
between the control and treated samples (Figure 2E,F).
Running STOCSY-E on this data set illustrates the quick and
effective identification of the parent flucloxacillin resonances in the
spectrum. Additionally in OPLS-DA, the resultant final spectra (with
contributions from parent drug resonances removed) would provide
clearer observation of the endogenous resonances important in
discriminating between data sampled at different time-points and thus,
a more easily interpretable model for characterizing the biochemical
effect of treatment. However, the number of samples in each group
for this data set was small (n) 4), thus the OPLS-DA model quality
was low and (as for the original data) no endogenous changes were
identified between the time-points investigated. Therefore, a more
comprehensive spectral data set, representing administration of the
renal papillary toxin, 2-bromoethanamine (BEA), allowed further
testing of the STOCSY-edited scaling method and the generation of
more robust discriminant models.
BEA treatment results in many BEA-related metabolites ap-
pearing in the urine, with the largest contributions from aziridine
(AZ), 2-oxazolidone (OX), and 5-hydroxy-2-oxazolidone (HOX).20,45
AZ is the cyclic intermediate formed from BEA through elimina-
tion of HBr, while OX is formed from the reaction of BEA with
endogenous bicarbonate followed by a cyclization reaction in
which HBr is eliminated. HOX is subsequently formed from the
hydroxylation of OX. BEA and its metabolites appear sequentially
in the urine spectra (collected at 0-2, 2-4, 4-8, 8-24, and 24-48
h postdosing with BEA) with BEA and AZ appearing in the early
time-point spectra and OX and HOX appearing at later time-points,
reflecting the metabolic time-course.
Because of the time-course of BEA metabolism, it was neces-
sary to drive STOCSY-E from one resonance relating to each of
the four major metabolites (BEA, OX, HOX, and AZ). Again, a
correlation cutoff of r2 > 0.9 identified the resonances relating
to the four compounds (Figure 3A) and resultant drug peak
eliminated edited spectra were produced for each sample, in this
case, using the editing method to remove peaks from all four
compounds simultaneously (Figure 3B). Driving STOCSY-E
(41) Long, G. L.; Winefordner, J. D. Anal. Chem. 1983, 55, 712A–724A.
(42) Everett, J. R.; Jennings, K.; Woodnutt, G. J. Pharm. Pharmacol. 1985, 37,
869–873.
(43) Trygg, J. J. Chemom. 2002, 16, 283–293.
(44) Trygg, J.; Wold, S. J. Chemom. 2003, 17, 53–64.
(45) Anthony, M. L.; Holmes, E.; McDowell, P. C.; Gray, T. J.; Blackmore, M.;
Nicholson, J. K. Chem. Res. Toxicol. 1995, 8, 1046–1053.
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from different resonances relating to each of BEA, OX, and HOX
(AZ only has one resonance) did not significantly affect the correla-
tion coefficients and thus the results of the algorithm in terms of
drug metabolite peaks identified and final STOCSY edited spectra.
In addition, the higher number of samples available at each time-
point for this data set allowed the generation of robust OPLS-DA
models for both the original and the newly generated STOCSY-edited
data comparing control (n) 8) and dosed (n) 17) samples at each
time-point. The results of which are shown for the 8 h time-point
(representing urine collection from 4-8 h) (Figure 4). The statistical
parameter Q2Yhat calculated for each model represents the pre-
dicted proportion of variance in the data following 7-fold cross-
validation, thus providing a measure of model robustness.44 The
similar Q2Yhat values obtained for the OPLS-DAmodels for original
and STOCSY-edited data (0.776 and 0.771, respectively) indicate
no significant loss of model quality for models generated from
the edited spectral data.
At this time-point in the edited data, resonances of HOX and OX
(the main xenobiotic-derived resonances present in the 8 h urinary
data) were no longer picked up in discriminatory analysis, allowing
clearer observation of the major known endogenous changes
between the control and treated animals (glutaric acid, 2-oxoglutarate,
creatinine, and hippurate).20 However, in addition to these previously
identified metabolites, a new significant peak at 3.68 ppm was also
picked up in the STOCSY-edited data, which was not seen in the
analysis of the original data (Figure 5A,B). This peak is present in
control samples, but it overlaps significantly with the OX triplet at
3.67 ppm (Figure 5C) and is therefore only resolved in the final
spectra following removal of the drugmetabolite resonances, scaling,
and background correction (Figure 5D).
On the basis of interpeak correlations using STOCSY and
assignments in the literature, this peak has been identified as
arising from the gut bacterial-mammalian cometabolite pheny-
lacetylglycine (PAG) (Figure 5E).46 By examination of changes
in the original NMR spectra, levels of this metabolite are seen to
decrease in the urine of treated animals, confirming the result of
OPLS-DA on the STOCSY-edited data.
DISCUSSION AND CONCLUSIONS
The STOCSY-Emethod has been shown to be effective at quickly
identifying drug metabolite peaks and also at providing enhanced
endogenous information recovery from spectral regions containing
drug metabolite resonances through the selective scaling and
background correction of the original spectra. Thus, this method
represents a useful semiautomatic tool to aid drug metabolite peak
identification and subsequent data analysis of the associated toxic
consequences on the endogenous metabolic profile.
For this application (the selective identification and removal
of only structural correlations, i.e., resonances resulting from the
same molecule), selecting only those resonances that correlate
(46) Li, J. V.; Wang, Y.; Saric, J.; Nicholson, J. K.; Dirnhofer, S.; Singer, B. H.;
Tanner, M.; Wittlin, S.; Holmes, E.; Utzinger, J. J. Proteome Res. 2008, 7,
3948–3956.
Figure 1. Results of the STOCSY-E algorithm run on the flucloxacillin data. (A) STOCSY on the 1H NMR data driven from the peak at δ1H )
5.53 (a known flucloxacillin resonance) highlighting correlations to all flucloxacillin resonances (a-e). The correlation coefficient (r) is superimposed
onto the covariance at each data point using the color scheme indicated, and the enlarged section shows that the correct peaks are picked out
by STOCSY. (B) Peaks identified as drug related metabolites through their correlation to the STOCSY driver peak with r2 > 0.9. (C) Original
(blue) and scaled (green) spectral data prior to background correction (after step 2.1).
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with each driver (a known drug peak) with a cutoff r2 > 0.9 proved
appropriate. In this case (for proof of principle) the principal
drug-related metabolites were known a priori; however, even
if drug resonances were unknown prior to dosing, in the
majority of cases, comparison of pre- and postdose spectra
would yield putative drug candidates that could then be
investigated by application of the STOCSY-E algorithm. The
correlation coefficients obtained through STOCSY are obvi-
ously dependent on the choice of the driver peak. In theory
therefore, correlation coefficients resulting from STOCSY
driven from different peaks of the same compound may be
affected by peak overlap and baseline fluctuations, and this
could affect the results of STOCSY-E in a way similar to the
effects caused by misalignment (discussed in detail below).
However, despite some serious peak overlap in the data, the
correlation values and thus overall results were not significantly
affected when STOCSY-E was driven from different drug peaks
for both the flucloxacillin and bromoethanamine data sets.
Although r2 > 0.9 was found to be an appropriate cutoff value
for both data sets investigated (and agrees with related
literature),40 it is certainly possible that for different data sets
and depending on the specific goal of performing STOCSY-E,
Figure 2. Flucloxacillin administration study: (A) scaled spectral data (at step 2.1, before the background correction step) colored by time-point
with superimposed representative original sample (cyan) illustrating where drug metabolite peaks have been removed; (B) median scaled spectrum
colored by correlation to the discriminant variable (correlation coefficient) generated through an OPLS-DA model between 0 and 2 h; (C) original
spectral data colored by time-point; (D) Median original spectrum colored by correlation to the discriminant variable as in B but from OPLS-DA
run on the original data; (E) spectral data, original, blue; scaled, green; final STOCSY-edited (scaled and background corrected), red; and (F)
median final STOCSY-E spectrum colored by correlation to the discriminant variable as in part B but from OPLS-DA run on the final data.
Figure 3. BEA administration study: (A) mean drug metabolite spectral profiles (xjdrug) for each of the major BEA drug metabolites (generated
from running STOCSY from one peak corresponding to each) and (B) results of STOCSY-editing for all samples across all time-points, original
spectra, blue; final STOCSY-edited spectra, red.
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a different value may be more appropriate. One approach to
select an appropriate cutoff value could be the iterative process
of running the algorithm with different cutoff values and
selecting the value generating the most reasonable resultant
drug metabolite spectral profiles with respect to the structure
of the compound. Additionally (even if the drug metabolite is
unknown), running the extracted putative drug metabolite
spectral profiles against NMR spectral databases (such as the
Figure 4. OPLS-DA coefficient loadings from the BEA administration study. Each loadings plot is the covariance across the chemical shift scale
colored by the correlation coefficient (scale shown) comparing the control and dosed 8 h urine samples for (A) the original spectral data (Q2Yhat )
0.776); (B) the final STOCSY-edited spectra (Q2Yhat ) 0.771). Key: C, creatinine; H, hippurate; 2-OG, 2-oxoglutarate; GTA, glutaric acid.
Figure 5. (A and B) OPLS-DA coefficient loadings from the BEA administration study. Each loadings plot is the covariance across the chemical
shift scale colored by correlation coefficient (scale shown) comparing control and dosed 8 h urine samples for (A) the original spectral data and
(B) the STOCSY-edited spectra; (C) original spectral data colored by time-point (predose, black; 0-2 h, red; 2-4 h, pink; 4-8 h, green; 8-24
h, cyan; 24-48 h, blue); (D) original spectral data, blue; and final STOCSY-edited spectra, green (arrow indicates newly discriminatory peak).
(E) Peak identification; STOCSY plot driven from the identified peak (*). Similarly to parts A and B, this plot is the covariance across the chemical
shift scale colored by the correlation coefficient (scale the same as shown for parts A and B). Key: P, phenylacetylglycine (PAG).
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Biological Magnetic Resonance Data Bank (BMRB)47 or the
Human Metabolome Database48), in an approach analogous
to that utilized by the Bru¨schweiler laboratory,49 could prove
useful in the identification of endogenous resonances. This
information could then be used to update the cutoff value so
as not to include resonances relating to endogenous molecules.
The challenge remains that it may be the case that (for biological
reasons) an endogenous peak correlates highly to the driver drug
peak. This has serious implications: not only would this produce a
false positive peak in the identified drug metabolite spectral profiles,
but also this peak would be scaled and removed from the edited
spectra and thus lost from any subsequent analysis. It is worth noting
that a major endogenous consequence of treatment with BEA results
in marked increases in urinary glutaric acid. However, this metabolite
is not picked up as a drugmetabolite, despite following a time course
similar to OX, possibly owing to subtle time scale differences and
interanimal variation in response to the treatment. It is therefore
perhaps unlikely that an endogenous metabolite would correlate
wholly with a parent drug metabolite, and so, with selection of a
stringent enough cutoff this should not prove to be a problem. On
the other hand, owing, for example, to peak overlap, it is possible
that certain drug metabolites resonances may fall below the set
correlation cutoff and thus remain in the final edited spectra.
However, even if these resonances were picked up as important (for
example in discriminant analysis of pre- and postdose samples), it is
likely that in the subsequent process of metabolite identification they
would be identified as drug related and thus disregarded.
This method could also be used to elucidate subtle metabolic
pathway connections, for example, from STOCSY-E derived connec-
tivities between a drug metabolite and toxic metabolic products or
metabolites produced in detoxification processes. In this case, the
selection of an appropriate cutoff is more complicated since different
drug metabolites correlate with different degrees to the drug driver
peak. If this were required, the approach suggested above of
systematically decreasing/increasing the cutoff could be employed
to optimize selection of an appropriate cutoff value.
In terms of data preprocessing for STOCSY-E, specifically
normalization, the important factor to consider is that any
normalization procedure preserves both the structural and non-
structural correlations between spectral points. Although total area
normalization is most common in metabolic analysis, it has been
shown that this method can introduce correlation artifacts,50 which
may affect the results of STOCSY-E. Therefore, probabilistic
quotient normalization was applied, although other normalization
methods could be equally suitable.
Understandably, since STOCSY relies on the multicolinearity of
variables in a set of spectra, it is important that peaks across the
spectrum are well aligned. Any peak shifting will directly change the
order of sample intensities, affecting the apparent multicolinearity
and thus potentially significantly impacting the correlation coefficient
at affected points. In STOCSY-E, the presence of shifted peaks has
several implications: first, true drugmetabolite peaks may be missed
if shifting results in correlation coefficients falling below the cutoff.
Second, even if correlation coefficient levels remained above the
cutoff, they may still be reduced compared to their true value (i.e.,
if peaks were properly aligned). This may mean such peaks are
significantly less scaled than they should be, and thus the remaining
signal maymeet the criteria for remaining in the STOCSY-E spectrum
as “endogenous” signal.
Finally, this method has shown to be effective in the recovery of
novel information, for example, in the identification of the PAG peak
in the BEA data set. PAG is a microbial-mammalian co-metabolite
and has previously been identified as a surrogate biomarker of
phospholipidosis when present in urine at high levels.51,52 In this
case however, the alteration in PAG levels are more subtle and
decrease following BEA treatment, thus these changes are more
likely to indicate minor disruptions to gut microbial activities rather
than overt phospholipidosis.53 It is worth noting that the intensity
values of any resonances remaining in scaled regions are modified
from their original values; thus, if novel peaks are resolved in the
regions where drug peaks are removed, it is necessary (as for all
biomarkers identified in chemometric models) to go back to the
original data to identify whether these changes are indeed valid.
In conclusion, this semiautomatic algorithm provides a rapid
method for the identification of potential spectral drug metabolite
resonances. Additionally the removal of these drug related peaks,
together with reconstruction of the surrounding regions, facilitates
improved statistical analysis and ultimately enhanced biomarker
recovery and discovery. As such, STOCSY-E assisted scaling could
provide a valuable tool in the analysis of any NMR spectral data set
containing resonances resulting from a set of interfering metabolites.
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 154 
A.2 STOCSY-E MATLAB code 
function[XSE cor out]=STOCSYE(X,ppm,peak,cutoff,all,noise,extra,mode) 
% 
% Runs STOCSY editing algorithm 
% 
% X = (mxn) original spectral data matrix (m samples, n variables) 
% ppm = (1xn) ppm scale 
% peak = (struct OR 1xp) either structure if peak saved using right click  
%        on plot) OR a vector of peak indices (vector form if multiple 
%        peaks) 
% cutoff = (1x1 OR 1xp) correlation threshold if scalar will use across all  
%          peaks, otherwise can input vector if a different cutoff for each  
%          peak is required (optional, default = 0.9) 
% all = (string) if 'all' will include pos and neg correlations else if 
%       'pos' will use positive correlations only (optional, default = 
%       'pos') 
% noise = (1x2) start and stop ppm values of noise region (optional,  
%         default = between 9.5:10ppm) 
% extra : defines region around each drug peak to find local baseline  
%         (optional, default is 0.02ppm either side of each region to scale) 
% mode = (string) if 'bysam' calculates region to scale and replace 
%        separately for each sample, if 'bymean' calculates region from 
%        mean spectrum and uses for all samples (optional, default = 
%        'bysam') 
% 
% XSE = (mxn) scaled and background corrected stocsy edited data 
% cor = (p+1,n) squared correlation vectors for each peak, and 
%       cor(p+1,:) = max of all.^2 
% out = (struct) saved running parameters (optional) 
%       .peak .cutoff .all .noise .extra .mode .XD (edited peaks) 
%  
% Example run: 
% peaks=[[6010 7968 7869 8986]; % for multiple peaks 
% [XSE]=STOCSYE(X,ppm,peaks); 
% 
% CJS 070409 
% 140210 adapted from STOCSYE_v17 optimised and tidyed up  
  
% initial set up define global variables and undefined input arguments 
  
if(nargin<8); mode=[]; end 
if(nargin<7); extra=[]; end 
if(nargin<6); noise=[]; end 
if(nargin<5); all=[]; end 
if(nargin<4); cutoff=[]; end 
  
if(isempty(mode)) 
    mode='bysam'; 
end 
  
ppmInc=median(diff(ppm)); % find increments of ppm scale 
if(isempty(extra)) 
    extra=round(0.02/ppmInc); % extra default (0.02 ppm each side) 
    disp('extra set to default 0.02ppm each side of region') 
end 
  
if(isempty(noise)) 
    noise=[9.5 10]; 
    disp('noise region to default 9.5:10ppm') 
end 
[chuck,ppmmin]=min(abs(ppm-noise(1))); [chuck,ppmmax]=min(abs(ppm-noise(2))); 
noise=ppmmin:ppmmax; 
  
if(isempty(all)) 
    all='pos'; 
    disp('all set to pos i.e. only returns positive correlations') 
end 
  
if(isempty(cutoff)) 
    cutoff=0.9; 
    disp('cutoff set to default 0.9') 
end 
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ppmcut=find(diff(ppm)>ppmInc*1.5)'; % identify regions where data cut (i.e. water 
removed) 
if(isstruct(peak)); peak=peak.DataIndex; end % converts peak from struct to index 
[sam,var]=size(X); 
XSE=X; XD=zeros(size(X)); 
if(strcmp('bymean',mode)); Xm=mean(X); end 
  
% generate correlation 
cor=zeros(length(peak),var); 
for p=1:1:length(peak) 
    cor(p,:)=stocsyCS(X,peak(p)); 
end 
  
if(strcmp('pos',all)); cor(cor<0)=0; end % delete negs if only interested in pos 
cor2=max(abs(cor),[],1).^2; % find max correlation squared (for data scaling) 
     
% find indices to scale (indices with correlation>cutoff) 
if(length(cutoff)==1); cutoff=repmat(cutoff,length(peak),1); end 
cutoff=repmat(cutoff,1,var); 
[chuck,remove]=find(cor.^2>cutoff); 
  
% generate matrix of start and stop indices for each region (each region=row) 
ax=1; ay=1; rem_list(ay,ax)=remove(1); 
for j=2:1:length(remove) 
    if(remove(j)-remove(j-1)>10); % emalgamates if less than 10 between two peaks 
        rem_list(ay,2)=remove(j-1); 
        ay=ay+1; 
        rem_list(ay,1)=remove(j); 
    end 
end 
rem_list(ay,2)=remove(end); 
  
  
% for every drug region (defined by a pair in rem_list) 
for p=1:size(rem_list,1) 
     
    % define region +/-extra each side of peak for background estimation 
    start=rem_list(p,1)-extra; 
    stop=rem_list(p,2)+extra; 
    if(start<1); start=1; end 
    if(stop>length(ppm)); stop=length(ppm); end 
    
    % check doesn't span a cut region 
    cutmatstart=repmat(ppmcut,1,rem_list(p,1)-start+1); 
    cutmatstop=repmat(ppmcut,1,stop-rem_list(p,2)+1); 
    checkstart=cutmatstart-repmat(start:1:rem_list(p,1),length(ppmcut),1); 
    if(any(checkstart==0,2)==1); start=ppmcut(any(checkstart==0,2)+1); end 
    checkstop=cutmatstop-repmat(rem_list(p,2):1:stop,length(ppmcut),1); 
    if(any(checkstop==0,2)==1); start=ppmcut(any(checkstop==0,2)); end     
     
    % LOD=mean(local baseline)+3*std(noise) 
    min_baseline=min(X(:,start:stop),[],2); 
    std_noise=mean(std(X(:,noise),[],1)); 
    LOD=mean(min_baseline)+3*std_noise; 
     
    if(strcmp('bymean',mode)); 
        differ=diff(Xm); 
        from=rem_list(p,1)-find(fliplr(differ(1:rem_list(p,1)-1))<0,1,'first')+1; 
        to=rem_list(p,2)+find(differ(rem_list(p,2)+1:end)>0,1,'first'); 
    end 
  
    % do scaling and background correction 
    for t=1:1:size(XSE,1) % for each sample 
         
        if(strcmp('bysam',mode) % find local minima either side of region 
            differ=diff(X(t,:)); 
            from=rem_list(p,1)-find(fliplr(differ(1:rem_list(p,1)-1))<0,1,'first')+1; 
            to=rem_list(p,2)+find(differ(rem_list(p,2)+1:end)>0,1,'first'); 
        end 
         
        % scale data 
        tempdata=X(t,from:to).*(1-cor2(from:to)); 
         
        XD(t,from:to)=X(t,from:to)-tempdata; 
         
        % background correct if signal<LOD 
        inds=find(tempdata<LOD); 
        tempdata(inds)=repmat(abs(min_baseline(t)),... 
            1,length(inds))+std_noise*randn(1,length(inds)); 
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        XSE(t,from:to)=tempdata; 
    end 
end 
  
if(nargout>1) 
    cor=[cor.^2;cor2]; 
end 
  
if(nargout>2) 
    out.peak=peak; 
    out.cutoff=cutoff; 
    out.all=all; 
    out.noise=[ppmmin ppmmax]; 
    out.extra=extra; 
    out.mode=mode; 
    out.XD=XD; 
end 
A.3 STOCSY-E users guide 
MATLAB code required: 
STOCSYE.m  
stocsyCS.m 
 
A detailed description of all input and output arguments is given in the STOCSYE 
help: 
>> help STOCSYE 
 
Basic run: 
 
>> XSE = STOCSYE(X,ppm,peak); 
 
Where XSE is the set of STOCSY-edited spectra returned from scaling the original 
dataset, X, based on correlations to the peak index/indices included in peak (where 
peak can either correspond to a saved datatip structure or a single or set of index 
value/s corresponding to a peak from each metabolite required for removal). 
 
If no other input arguments are included STOCSY editing is run with the following 
default parameters: 
cutoff = 0.9 
all = ‘pos’ 
noise = between 9.5 and 10ppm 
extra = 0.02 ppm either side of each region to be scaled 
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mode = ‘bysam’ 
 
Optional input arguments: 
 
Additionally, depending on the dataset and required application, the explicit 
specification of one or more running parameters may improve performance. These are 
described below: 
 
>> XSE = STOCSYE(X,ppm,peak,cutoff,pos,noise,extra,mode); 
 
cutoff = correlation threshold. Indices correlating to peak with a correlation 
coefficient (r) r2  > cutoff will be scaled and background corrected if signal intensity 
(I) I < LOD (limit of detection). If 0.9 is unsuitable (owing, for example, to reduction 
in correlation values caused by peak overlap) different correlation cutoff values may 
be more suitable. Plotting correlation to each peak prior to running STOCSYE may be 
useful in finding a suitable cutoff: 
>> cor = stocsyCS(X,peak); 
>> figure; plot(ppm,cor.^2) 
 
If running STOCSYE from multiple peaks, different cutoff values may be entered for 
each peak (e.g. if two driver peaks are specified then cutoff=[0.9 0.8]) 
 
all = ‘pos’ uses positive correlations to peaks in ‘peak’ only (i.e. use for scaling 
structural correlations) while ‘all’ includes negative correlations (i.e. will scale any 
correlation with r2 > cutoff). 
 
noise = start and stop ppm values of spectral region including only noise (for 
background correction). 
 
extra = defines the number of indices each side of each region which are used to 
identify where the background should be replaced and to generate the replacement. 
Basically it is important that extra is sufficiently large that the region peak+/- extra 
includes a section in between peaks for local background estimation. The default 
value should be sufficient for most datasets. 
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mode = defines how the sections to scale and replace are defined. ‘bysam’ (default) 
specifies that data scaling and background correction continues either side of each 
identified drug peak region until the signal intensity for each sample reaches a local 
minimum. However, in some cases (for example in regions of peak shifting) this may 
result in peaks not being scaled for some samples (if their peak apex falls outside the 
original r2 > cutoff region). In this case ‘bymean’ may produce better results, in this 
mode, data scaling and background correction for each sample continues either side of 
each identified drug peak region until the signal intensity of the mean spectrum 
reaches a local minimum. 
 
Additional output arguments: 
 
>> [XSE cor out] = STOCSYE(X,ppm,peak); 
 
cor = matrix of r2  values. Each row corresponds to the correlation across the spectrum 
for each input peak, and the final row is the maximum correlation across all peaks at 
each point. 
 
out = structure containing values of the running parameters (peak, cutoff, all, noise, 
extra, mode) and a matrix of the edited peaks for each sample. 
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APPENDIX B: I-STOCSY 
B.1 I-STOCSY MATLAB code 
I-STOCSY 
function[out]=ISTOCSY(X,ppm,in) 
% Fully automated iterative STOCSY. Iterates  multiple rounds of STOCSY 
% initially from a given driver peak of interest, but in subsequent rounds 
% from all peaks correlating above a certain threshold to driver/s in the 
% previous round. Highly correlating (putatively structural) peaks are 
% grouped together and the results automatically plotted in the 
% ISTOCSY_Iplot interactive plot (showing node-to-node associations 
% alongside the corresponding spectral data) 
% 
% X = (mxn) original spectral data matrix (m samples, n variables) 
% ppm = (1xn) ppm scale 
% in = (struct) running parameters, including fields (driver is the only 
%      required field for all others if not included default values will be  
%      used (as described below) 
%      .driver = (struct OR 1xp) initial driver peak, either structure (if  
%                peak saved as datatip point) OR scalar of peak index 
%      .peakInds = (1xp) peak picked indices, if not included peak list  
%                  generated through detection at zero crossings of a 
%                  smoothed spectral derivative calculated using a Savitzky 
%                  -Golay third order polynomial filter of the mean spectrum 
%                  (code written by Kirill Veselkov see findPeaksKV.m) 
%      .ISTOCSY_cutoff = (1x1) correlation threshold above which 
%                        (|r|>ISTOCSY_cutoff) associations are presented 
%                        (default = 0.8) 
%      .struct_cutoff = (1x1) for each set of newly identified peaks at  
%                       each round, groups those which correlate with 
%                       absolute value > struct_cutoff (default = 0.95) 
%      .Nrounds = (1x1) number of rounds of iteration to run (default=10) 
%      .name = (str) save ISTOCSY results and interactive plot as this 
%      .plot_method = (str) colour scale by which to colour peaks in the 
%                     interactive plot, if 'all' colours on scale from -1  
%                     to 1, else colours on scale from min to max correlation 
% 
% out.allInRound=addAll(1:nrounds+1,1); 
% out = (struc) output results with fields 
%       .in = (struct) running parameters (see above) 
%       .results = (kx2) matrix of results which peaks detected in each  
%                  round, columns correspond to  
%                  round | index of representative peak 
%       .sets = (kxu) 'structural' or highly related sets, each row  
%               contains the indices of highly related peaks (represented  
%               by one node in the interactive plot) 
%       .connections = (kxu) node connectivities; for each row, the first  
%                     number corresponds to the driver node, and subsequent 
%                     values to those connected nodes (where all numbers  
%                     relate to row indices in the results matrix) 
%       .correlates = (kxu) corresponding correlations for each connection 
%       .peaksplot = (kxn) plotting peaks information, each row corresponds 
%                    to a row in connections, and all peaks from the same  
%                    structural set have the same index 
%       .allpeaksplot = (1xn) all peaks identified 
%       .roundpeaksplot = (Nroundsxn) peaks identified in each round 
%       .plot_xy = (kx2) x and y locations for each node in the interactive 
%                  plot 
% 
% 110510 CJS 
  
  
% 1. set up defaults and peaks vector 
  
% STOCSYI_cutoff = 0.8 
if(~isfield(in,'ISTOCSY_cutoff')); in.ISTOCSY_cutoff=0.8; end 
  
% number of rounds = 5 
if(~isfield(in,'Nrounds')); in.Nrounds=10; end 
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% driver is not in structure (as saved by data tip) 
if(isstruct(in.driver)); in.driver=in.driver.DataIndex; end 
driver=in.driver; 
  
% run peakpicking and check driver is part of picked peaks 
if(~isfield(in,'peakInds')); [in.peakinds in.allpeaks] = 
findPeaksKV(mean(X),ppm,'real'); end 
if(in.allpeaks(driver)~=driver) % add driver to peaks if not present already 
    in.allpeaks(driver)=driver; 
    in.peakInds=[in.peakInds driver]; 
end 
peaks=zeros(size(ppm)); peaks(in.peakInds)=in.peakInds; 
  
% save named by date 
if(~isfield(in,'name')); in.name=date; end 
  
% plot method = 'all' plots coloured from [-1,1] 
if(~isfield(in,'plot_method')); in.plot_method='all'; end 
  
% define how structural peaks to be assigned 
% default is propSame with 2/3 peaks same for diff members same set OR 
% threshold = 0.95 if absolute method specified 
if(~isfield(in,'struct_cutoff')) 
    in.struct_cutoff=0.95; 
end 
  
save(sprintf('%s',in.name),'in'); 
  
% 2. initialise variables 
results=zeros(length(in.peakInds),2); 
results(1,:)=[0 driver]; 
sets=zeros(length(in.peakInds)); sets(1,1)=driver; inds.S=2; 
connects=zeros(length(in.peakInds)); 
correlates=zeros(length(in.peakInds)); 
round=1; 
inds.start=1; inds.stop=1; indS=inds.S; 
addAll=zeros(length(in.peakInds),3); 
  
% 3. run iterative STOCSY until Nrounds reached or no new peaks identified 
while(round<=in.Nrounds) 
     
    addAll(round,:)=[inds.stop+1 inds.start inds.stop]; 
     
    [results connects correlates inds sets]=eachRound(X,sets,... 
        in.ISTOCSY_cutoff,peaks,connects,correlates,results,... 
        in.struct_cutoff,inds,round); 
     
    if(indS==inds.S-1); break; end 
     
    indS=inds.S; 
    round=round+1; 
end 
  
if(all(results(inds.start,:)==0)) % if ended because no new peaks 
    inds.stop=inds.start-2; 
else % if round exceeded Nrounds tidy last round so connections link back to preceding 
peak 
    for i=inds.start:inds.stop 
        [row,~]=find(connects==i); 
        connects(i,1:length(row))=row; 
        correlates(i,1:length(row))=correlates(connects==i); 
    end 
    addAll(max(results(:,1))+1,:)=[inds.stop+1 inds.start inds.stop]; 
end 
  
% add row to connects and correlates - connect to all peaks 
results(inds.stop+1,1)=round-1; 
for i=1:max(results(:,1))+1 
    connects(addAll(i,1),1:addAll(i,3)-addAll(i,2)+1)=addAll(i,2):addAll(i,3); 
    temp=unique(sets(addAll(i,2):addAll(i,3),:)); 
    sets(addAll(i,1),1:length(temp))=temp; 
end 
  
results=results(1:inds.stop+1,:); 
connects=connects(1:inds.stop+1,:); 
correlates=correlates(1:inds.stop+1,:); 
sets=sets(1:inds.stop+1,:); 
  
% 4. determine the y axis values 
 161 
round=results(:,1)+1; 
n=zeros(1,max(round)); 
k=zeros(size(round)); 
b=1; 
for p=1:1:max(round) 
    n(p)=length(round(round==p)); 
    k(b:n(p)+b-1)=n(p); 
    l(b:n(p)+b-1)=1:1:n(p); 
    b=b+n(p); 
end 
plot_at=(max(n)-1)./(k+1); 
plot_at=plot_at.*l'+1; 
plot_at(addAll(1:max(round),1))=max(plot_at(addAll(1:max(round),1))); 
  
plot_xy =[results(:,1) plot_at]; 
  
% adapt peaks and define peaksplot and allpeaksplot 
peaksplot=zeros(inds.stop+1,length(ppm)); allpeaksplot=zeros(1,length(ppm)); 
for i=1:inds.stop+1 
    temp=sets(i,:);temp(temp==0)=[]; 
    peaksplot(i,ismember(in.allpeaks, temp))=1;  
    allpeaksplot(ismember(in.allpeaks, temp))=sets(i,1); 
end 
  
% all peaks found in each round 
nrounds=max(results(:,1)); 
roundpeaksplot=zeros(nrounds,length(ppm)); 
for i=1:nrounds 
    temp=results(results(:,1)==i,2); 
    
roundpeaksplot(i,ismember(allpeaksplot,temp))=allpeaksplot(ismember(allpeaksplot,temp)
); 
end 
  
out=in; 
out.results=results; 
out.sets=sets; 
out.connections=connects; 
out.correlations=correlates; 
out.plot_xy=plot_xy; 
out.peaksplot=peaksplot; 
out.allpeaksplot=allpeaksplot; % all peaks identified 
out.roundpeaksplot=roundpeaksplot; % peaks identified in each round 
out.allInRound=addAll(1:nrounds+1,1); 
  
save(sprintf('%s',in.name),'out'); 
  
% 5. plot results 
  
% interactive plot 
ISTOCSY_Iplot(out,X,ppm,in.plot_method); 
saveas(gcf,sprintf('%s.fig',in.name)); close 
  
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
function[results connects correlates inds sets]=eachRound(X,sets,... 
    cutoff,peaks,connects,correlates,results,strThr,inds,round) 
% function generates connectivities from incoming peaks (identified at 
% previous round) with |r|>cutoff 
% 
% peajs with correlations |r|>0.95 are grouped as structural and represented  
% by a single peak from the group - but STOCSY is run from each member then  
% all unique peaks identified connect to single representative peak 
  
inds.S=inds.S+1; 
  
for k=inds.start:inds.stop % all new peaks IDd in previous round 
     
    peakout=[]; peakcors=[]; 
  
    run=sets(k,:); run(run==0)=[]; % each row == set of peaks r^2>0.9 
  
    % now for each set of structural peaks identify correlations>cutoff 
    for i=1:length(run) 
  
        % correlations to all peak apexes EXCEPT those in group 
        if (i==1) 
            peakstemp=peaks; peakstemp(run)=[]; 
            peaksIDd=unique(peakstemp(peakstemp~=0)); 
        end 
 162 
  
        % run STOCSY 
        cor=stocsyCS(X(:,peaksIDd),X(:,run(i))); 
  
        % select peaks r2>cutoff (pos and neg) 
        peaksIDd2=peaksIDd(abs(cor)>=cutoff); 
  
        % continue to next peak if empty 
        if(isempty(peaksIDd2)); continue; end 
  
        corrs=cor(abs(cor)>=cutoff); 
         
        % want unique list from ALL peaks in highly connected group 
        tf=ismember(peaksIDd2,peakout); 
        peakout=[peakout peaksIDd2(tf==0)]; 
        peakcors=[peakcors corrs(tf==0)]; 
        cor=[]; 
  
    end 
  
    % if have already run peak - find in sets then save connectivities and 
    % maximum correlation value 
    tf=ismember(peakout,sets); 
  
    old=peakout(tf==1); oldcor=peakcors(tf==1); tcon=zeros(size(old)); 
    for j=1:length(old) 
        [tcon(j) col]=find(sets==old(j)); 
    end 
    [tcon m]=unique(tcon); 
    tcor=oldcor(m); 
  
    % add new peak indices to sets output 
    peakout(tf==1)=[]; peakcors(tf==1)=[]; 
     
    con1=[]; con2=[]; 
    if(~isempty(peakout)) 
        con1=inds.S; 
        [sets inds results 
cor]=addSets(X,peakout,peakcors,sets,strThr,inds,results,round); 
        con2=inds.S-1; 
    end 
     
    % save connectivities and correlations 
    tcon=[tcon con1:con2]; tcor=[tcor cor]; 
    connects(k,1:length(tcon))=tcon; 
    correlates(k,1:length(tcor))=tcor; 
     
end 
  
results(inds.stop+1,1)=round-1; 
inds.start=inds.stop+2; 
inds.stop=inds.S-1; 
  
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
function[sets inds results 
cor]=addSets(X,peakout,peakcors,sets,strThr,inds,results,round) 
% for each set of newly identified peaks, identify those peaks which 
% correlate with r^2>0.9 and save into 'sets' variable and into results 
  
i=1; 
while(~isempty(peakout)) 
     
    % identify structural correlations within driver peak list 
    structCor=stocsyCS(X(:,peakout),X(:,peakout(1))); 
    sInds=find(structCor>=strThr); 
    cor(i)=mean(peakcors(sInds)); 
    run=peakout(sInds); 
     
    % save in sets matrix 
    sets(inds.S,1:length(run))=run;  
     
    % save in results for previous round 
    results(inds.S,:)=[round run(1)]; inds.S=inds.S+1; 
     
    % delete structural correlations from driver peak list 
    peakout(sInds)=[]; peakcors(sInds)=[]; 
    i=i+1; 
end 
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I-STOCSY interactive plot 
function out = ISTOCSY_Iplot(in,X,ppm,method) 
% interactive STOCSYI plotting plots results of ISTOCSY.m 
%  
% in = (struct) results from ISTOCSY.m, with required fields: 
%      .plot_xy (kx2) x and y location of each node 
%      .connections = (kxu) node connectivities; for each row, the first  
%                     number corresponds to the driver node, and subsequent 
%                     values to those connected nodes (where all numbers  
%                     relate to row indices in the results matrix) 
%      .correlates = (kxu) corresponding correlations for each connection 
%      .peaksplot = (kxn) plotting peaks information, each row corresponds 
%                   to a row in connections, and all peaks from the same  
%                   structural set have the same index 
%      .sets = (kxu) 'structural' or highly related sets, each row  
%              contains the indices of highly related peaks (represented  
%              by one node in the interactive plot) 
% X = (mxn) spectral data 
% ppm = (1xn) ppm scale 
% method = (str) colour scale by which to colour peaks in the interactive  
%          plot, if 'all' colours on scale from -1 to 1, else colours on  
%          scale from min to max correlation 
% 
% out = (struct) imputed and generated arguments (output if required) 
% 280410 CJS 
  
% Check for call-back invocation 
if (nargin == 1 && ~isempty(gcbo)) 
   [~,f] = gcbo; 
   doclickCS(f, in); 
   return 
end 
  
if(nargin<4); method='all'; end 
  
gx=in.plot_xy(:,1); 
gy=in.plot_xy(:,2); 
gconnect=in.connections; 
peaks=in.peaksplot; 
correlates=in.correlations; 
maxR=find(all(gconnect==0)==1,1,'first'); % max number of connections at any one level 
  
% determine colours for correlations 
corcolour=correlates; 
  
figure; Color=get(gcf,'Colormap'); close 
if(strcmp('all',method)) 
    mincol=-1; 
    maxcol=1; 
else 
    mincol=min(correlates(correlates~=0)); 
    maxcol=max(correlates(correlates~=0)); 
end 
caxisval=[mincol maxcol]; 
  
inc=(maxcol-mincol)/size(Color,1); 
inc=mincol:inc:maxcol; 
  
for i=1:size(Color,1) 
    corcolour(correlates>=inc(i)&correlates<=inc(i+1))=i; 
end 
corcolour(correlates==0)=0; 
  
in.corcolour=corcolour; 
in.color=Color; 
in.caxisval=caxisval; 
  
corr.col=Color; 
corr.cor=corcolour; 
corr.all=in.allInRound; 
  
% set up colour matrices 
n=length(gx);  
if(size(X,1)>1); 
    maxX=max(X); 
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else 
    maxX=X; 
end 
maxmaxX=repmat(0,size(maxX)); 
gpeaks=repmat(maxX,n,1); 
gpeaks(peaks==0)=NaN; 
  
% set colormap to jet minus yellow for rest of plotting.... 
figure;colormap(hsv(min([maxR 50])));col=get(gcf,'Colormap'); close; 
data.gconnect=gconnect; data.col=col(randperm(size(col,1)),:); 
  
% Create initial plot with all groups - if click within each plotted area 
% calls back to doclickCS function.... 
figure; set(gcf,'Color',[1 1 1],'Userdata',data); 
subplot(2,1,1); hold on 
for j=1:n 
   ftxt = sprintf('STOCSYI_plotI_v2607(%d)', j); 
   plot(gx(j),gy(j),'ko','UserData',j,  'ButtonDownFcn',ftxt); 
end 
set(gca,'Box','off','YColor',[1 1 1],'XColor',[1 1 1],'UserData',n); 
title('Interactive Iterative STOCSY Plot', 'fontweight','bold'); 
  
subplot(2,1,2); hold on 
plot(ppm,X,'Color',[0.8 0.8 0.8]); hold all; 
for k=1:n 
    plot(ppm,gpeaks(k,:),'k-','UserData',k) 
     
    ftxt2 = sprintf('STOCSYI_plotI_v2607(%d)', k); 
    sets=in.sets(k,:); sets(sets==0)=[]; 
    plot(ppm(sets),maxmaxX(sets),'k*','Userdata',k,'ButtonDownFcn',ftxt2); 
end 
set(gca,'YColor',[1 1 1],'Box','off','Xdir','reverse','UserData',corr); 
caxis(caxisval); 
colorbar 
  
  
% Color peaks corresponding to initial driver 
doclickCS(gcf,1); 
hold off 
  
if(nargout==1) 
    out=in; 
end 
  
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
function doclickCS(hfig,grp) 
  
%DOCLICK Processes a click on group grp 
  
% Get info from graph 
data = get(hfig,'UserData'); 
gconnect=data.gconnect; 
gcol=data.col; 
%ax = get(hfig, 'CurrentAxes'); 
ax=get(hfig,'Children'); topax=ax(3); botax=ax(2); 
ngroups = get(topax, 'UserData'); 
corr = get(botax,'UserData'); 
corcol=corr.col; 
corcor=corr.cor; 
corall=corr.all; 
  
% Loop over all points, adjusting colors  
connect=gconnect(grp,:); connect(connect==0)=[]; 
if(~isempty(connect)); 
    Col=repmat(gcol,ceil(length(connect)/size(gcol,1)),1); 
    a=1; 
end 
  
for j=1:ngroups      
   h = findobj(topax, 'UserData',j, 'Marker','o'); 
   h1= findobj(botax,'UserData',j,'Type','Line'); 
    
   if (isempty(h)), continue; end 
   if (j == grp) 
      clr = 'k'; 
      clr2=clr; 
   elseif(ismember(j,gconnect(grp,:))) 
      clr = Col(a,:); a=a+1;  
      if(all(corcor(grp,:)==0)) 
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          clr2=clr; 
      else 
          clr2=corcol(corcor(grp,gconnect(grp,:)==j),:);   
      end 
           
   else 
      clr = repmat(0.8,1,3); 
      clr2 = clr; 
       
   end 
   set(h, 'Color', clr,'MarkerFaceColor',clr); 
   set(h1(1),'Color',clr);   
   set(h1(2),'Color',clr2);  
    
end 
  
h=zeros(length(corall),2); 
for i=1:length(corall) 
    h(i,:) = findobj(botax,'UserData',corall(i),'Type','Line'); 
end 
h=h(:); 
set(h,'Visible','off') 
B.2 I-STOCSY users guide 
MATLAB code required: 
ISTOCSY.m 
ISTOCSY_Iplot.m 
findPeaksKV.m (if peak picking required) 
 
A detailed description of input (required and optional) and output arguments is 
provided in the ISTOCSY help: 
>> help ISTOCSY 
 
To run ISTOCSY 
>> out = ISTOCSY(X,ppm,in); 
 
This automatically generates the interactive plot of iterated STOCSY results, showing 
node-to-node associations alongside the corresponding spectral data. The output 
variable out is a structure containing all the running parameters, ISTOCSY node-to-
node association information and the information required to generate the interactive 
plot. 
 
In terms of input parameters X is the original spectral data, and ppm the 
corresponding ppm scale. The final input argument ‘in’ is a structure with fields as 
described below. Where fields are required they are indicated by a * otherwise default 
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values are given in the description relating to each. 
 
.driver* = ISTOCSY initial driver peak, this can either correspond to a saved datatip 
structure or directly to an index value of a peak from the metabolite of interest. 
 
.peakInds = peak picked indices, if not included this will be generated using code 
written by Kirill Veselkov, which generates list of peak apex indices through 
detection at zero crossings of a smoothed spectral derivative calculated using a 
Savitzky-Golay third order polynomial filter of the mean spectrum. 
 
.ISTOCSY_cutoff = correlation threshold above which peaks-to-peak associations are 
saved and presented (default = 0.8). 
 
.struct_cutoff = correlation threshold for partitioning detected peak indices into 
putative structural sets (default = 0.95). 
 
.Nrounds = maximum number of ISTOCSY rounds to be run (default = 10). Although 
it should be noted that even if this number has not been exceeded, as soon as no new 
peaks are detected ISTOCSY will be terminated. 
 
.name = name by which to save the output and resultant interactive plot (default = 
date). 
 
.plot_method = colour scale by which to colour the peaks in the ISTOCSY plot, peaks 
are coloured by strength of correlation, either on scale of -1 to 1 (‘all’, default) or 
from the minimum to the maximum correlation values obtained (if plot_method is not 
‘all’). 
